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Abstract 
 
Estrogens the female sex hormones have numerous biological actions. Estradiol is the 
most abundant estrogen in women before menopause. It influences the development, 
maturation and function of the female reproductive tract. It also plays a role in 
mammary cancer. Accordingly determinations of estradiol level in body fluids assist 
in the evaluation of ovarian function and diagnosis for malignancies. Estriol is the 
primary estrogen in pregnant women and secreted from the fetoplacental unit. 
Measurement of estriol in maternal body fluids is the basis of fetoplacental 
monitoring test.  
Concentration of estrogens in body fluids is determined by immunoassay. Accuracy 
of this measurement depends on the availability of a specific antibody. As estrogens 
are not antigenic, their derivatives (haptens) are coupled with a carrier and this 
hapten-protein conjugate is used to generate antibodies. Specificity of the generated 
antibody largely depends on the structure of hapten. Therefore the synthesis of a 
hapten with a right structure is crucial for the accurate measurement of a steroid. We 
have synthesised new haptens for estradiol and estriol by adding an alkyl or alkoxy 
side chain at the C-7 of estrane skeleton. The side chains carry a terminal amino 
group, which can be used for conjugation with a carrier molecule. 
Estrogens and their biosynthetic precursor androgens both exist as fatty acid esters. 
They are known to act as hormone storage but their physiological role is not 
completely known yet. Our collaborator is studying their effect in cardiovascular 
diseases. We synthesised fatty acid ester derivatives of several steroids in high yield 
by a very rapid procedure (in 1 min) under microwave irradiation in an ionic liquid 
(IL). An expedient regioselective hydrolysis at C-3 of estradiol diesters is also 
reported. 
8-Isoestrogens are compounds of pharmaceutical interests, their synthesis, structure, 
conformation and biological activity studies are ongoing. 7-Hydroxy-8-isoestradiol 
and 7-alkyl ether of it were synthesised as well. 
 5 
During this study we have developed a selective O-debenzylation method. A mild 
route for selective removal of benzylic protection on phenol in presence of benzyl 
protected alcohol was explored. 
 6 
Abbreviations 
 
Ac acetyl 
Bn benzyl 
Bz benzoyl 
BSA bovine serum albumin 
CAL candida antartica lipase 
CETP cholesteryl ester transfer protein 
CME carboxymethylether 
 CRL candida rugosa lipase 
CYP cytochrome P450 
DCM dicloromethane 
DDQ 2,3-dichloro-5,6-dicyanobenzoquinone 
DHEA dehydroepiandrosterone 
DIPA diisopropylamine 
 DMAP 4-(N,N-dimethylamino)pyridine 
 DMF N,N-dimethylformamide 
DMSO dimethylsulfoxide 
E1 estrone  
E2 estradiol 
E3 estriol 
EI electron impact 
ESI electrospray ionisation 
FAE fatty acid ester 
FITS-6 perfluorohexyl-phenyliodoniumtrifluoromethanesulfonate 
HDL high density lipoprotein 
HSD hydroxysteroid dehydrogenase  
IL ionic liquid 
NaHMDS sodium hexamethyldisilazide 
 KHMDS potassium hexamethyldisilazide 
 LAH lithium aluminium hydride 
 7 
LCAT lecithin:cholesterol acyltransferase 
 LDA lithium diisopropylamide 
LDL low density lipoprotein 
LIHMDS lithium sodium hexamethyldisilazide 
 m-CPBA m-chloroperbenzoic acid 
MOM methoxymethyl 
MW microwave  
NOESY nuclear Overhause effect spectroscopy 
PCC pyridinium chlorochromate 
Pg protecting group 
PTC phase transfer catalyst 
 Py pyridine 
RIA radioimmunoassay 
rt room temperature 
SH steroid hormone 
TBAF tetra-n-butylammonium fluroide 
TBDMS tert-butyldimethylsilyl 
THP tetrahydropyranyl 
TIPS triisopropylsilyl 
p-TsOH p-toluene sulfonic acid 
VLDL Very low density lipoprotein 
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1. INTRODUCTION 
 
Estrogens comprise a group of steroid hormones responsible for female sexual 
characteristics. In the female body, there are three main types of estrogens produced - 
estradiol, estrone and estriol (Figure 1). Estradiol (E2) is the main estrogen in 
premenopausal women and ovaries are the main formation sites. Estrone (E1) is less 
active than estradiol, it is the predominant estrogen after menopause. Estriol (E3) is an 
important estrogen for pregnant women. It is the most abundant estrogen during 
pregnancy, when the fetoplacental unit produces large amount of estriol.1  
Estrogens are measured by for example, immunoassay, GC-MS, LC-MS, LC-MS-
MS, HPLC-MS-MS. Immunoassays are most widely used for sensitivity and low cost. 
More specific and accurate assays of these analytes are still needed in the analysis of 
estrogen in physiological sample. 
 
HO
O
H
H
H
HO
OH
H
H
H
HO
OH
OH
H
H
H
Estrone 1 Estradiol 2 Estriol 3  
Figure 1. Structure of estrogens 
Biosynthesis pathways of estrogens are shown in Scheme 1. Estrogens are 
synthesized from cholesterol. Cholesterol is converted to androgens, the precursors of 
estrogens, either via the Δ5 pathway (pregnenolone pathway) or Δ4 pathway 
(progesterone pathway). In humans, Δ5 is the preferred pathway. This involves 
formation of the 17α-hydroxy-pregnenolone followed by dehydroepiandrosterone 
(DHEA). DHEA is converted to androstenedione by the action of 3β-hydroxysteroid 
dehydrogenase (3β-HSD). Androstenedione is then converted to estrone by aromatase 
(CYP19). Estrone is subsequently converted to estradiol. 17β-hydroxysteroid 
dehydrogenase (17β-HSD) is responsible for the interconversion of estrone and 
estradiol. In postmenopausal women, estrone is mainly produced from plasma 
androstenedione. Conversion of testosterone to estradiol is important in males but in 
 9 
females this route has little importance due to low level of testosterone. Estriol is 
produced by the metabolism of estrone and estradiol. During pregnancy, it is 
produced from an androgen precursor by the fetoplacental unit. Pregnenolone is 
converted to the sulfate conjugate in the fetus. DHEA sulfate is formed from 
pregnenolonesulfate via 17α-hydroxy-pregnenolonesulfate. DHEAsulfate is 
hydroxylated at 16 position. Then 16α−DHEAsulfate is transported to the placenta, 
hydrolysed and converted to estriol via 16α−hydroxyandrostenedione. During 
pregnancy this route is more important than E3 from E2 and E1. Measurements of E3 
in serum, plasma and urine provide information on maternal and fetal well-being. 
Often low levels of E3 is associated with high risk pregnancy. 
 10 
HO
O
HO
O
HO
H
H
H
HO
O
HO
cholesterol
O
O
O
O
HO
H
H
H
DHEA
Pregnenolone Progesterone
17-Hydroxy-pregennolone 17-Hydroxy-progesterone
O
HO3SO
O
HO
HO3SO
O
HO3SO
O
OH
O
O
HO3SO
DHEAsulfate
16α-Hydroxy-DHEAsulfate 16α-Hydroxy-androstenedione
OH
Pregnenolonesulfate
17α-Hydroxy-pregnenolonesulfate
O
O
Androstenedione
O
OH
Testosterone
HO
O
E1
HO
OH
E2
HO
OH
OH
E3
EstrogensAndrogens  
Scheme 1. Biosynthesis of estrogens1,2  
Estrogens have several physiological actions. The main action of estrogens is the 
development of female sex organs and secondary sexual characteristics. They have 
effects on other organs, too.3 They may act as a cardioprotective agent by vasodilation 
action. By increasing lipoprotein receptor in liver they decrease the LDL (low density 
lipoprotein) level in circulation. Estrogens reduce the risk of colon cancer, maintain 
 11 
bone density and decrease the risk of osteoporosis. In addition, they influence the 
central nervous system, estrogen-deficient women have a higher risk of Alzheimer’s 
disease.  
Estrogens play a significant role in the development and progression of several 
cancers. Breast cancer risk is associated with a prolonged exposure to estrogen and a 
great majority of breast cancers are estrogen receptor positive.4-6 There is an 
association between estrogen and risk of endometrial cancers.4 Estrogen metabolites 
(see Scheme 2) have both stimulatory and inhibitory effects on the growth of various 
tumors. 4-Hydroxyestrogens can be transformed to estrogen-3,4-quinone, which 
affects DNA and causes cancer. On the other hand 2-methoxyestradiol has an 
anticarcinogenic effect.7,8 
Estradiol and its precursor androgens also occur as fatty acid ester derivative in 
human. They act as hormone storage. Physiological roles of these fatty acid esters are 
presently under study. 
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HO
O
E1
HO
OH
E2
HO
OH
OH
E3
HO
O
OH
HO
O
OH
HO
OH
OH
OH
HO
O
HO
HO
OH
HO
HO
O
MeO
HO
OH
MeO
4-HydroxyE1
16α−HydroxyE1
2-HydroxyE1
2-MethoxyE1 2-MethoxyE2
2-HydroxyE2
4-HydroxyE2
 
Scheme 2. Metabolism of estrogens (partial)9  
A lot of research has been devoted to study the effect of chemical modification of 
natural estrogens. Compounds with preferable properties were produced which can be 
applied for diagnostic and therapeutic purposes. Use of natural estrogen for hormonal 
therapy often suffers from significant limitations due to the unwanted side effects. It 
was found that some modified estrogenic steroids retain the useful properties of 
naturally occurring hormone whereas unwanted side effects decrease. The ring B, C 
and D of estrane skeleton (Figure 2), have been mostly modified. In ring D the 
substituent were introduced at C-16 and C-17. In ring C most of the modifications 
 13 
were done at C-11 position. Ring B was modified at C-6 and C-7. We have reviewed 
thoroughly the modification of estrane skeleton by alkyl substitution.10 At the same 
time an overview of synthesis of C-7 substituted estradiol was published by a 
Japanese and Portuguese group.11 
A B
C D1
2
3
4 5 6
7
8
910
11
12
17
18
16
1514
13
 
Figure 2. Estrane skeleton 
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2. LITERATURE REVIEW 
 
In this thesis work modification of estrane skeleton at C-7, C-8 and C-17 was studied. 
In connection to our own work the modifications of estrogens by substituting at C-7 
and stereochemical modification at C-8 are reviewed in the following subchapters. 
Immunoassay and the required modification of E2 and E3 for immunoassay are also 
briefly discussed here. This chapter also reviews the occurrence, synthesis and 
biological effects of steroid fatty acid esters. 
 
2.1 C-7 substituted estrogen 
 
C-7 substituted estra-1,3,5(10)trienes are a class of compounds of considerable 
pharmaceutical interest. They have been widely used for diagnostic as well as 
therapeutic purposes. C-7 substituted estradiol has higher affinity to estrogen receptor 
than the original estradiol. They also act as antagonists in estrogen responsive tissues. 
Due to their antiestrogenic properties, this class of compounds is used for treatment of 
estrogen positive breast cancer, e.g. ICI 164,384,12,13 ICI 182,78014-16 (structures 
shown in Figure 3). C-7 substituted radioactive derivatives are potential receptor-
based agents for imaging of estrogen positive breast cancer.17-19  
HO
OH
R
ICI 182,780    R = (CH2)9SO(CH2)3CF2CF3
ICI 164,384    R = (CH2)10CON(n-C4H9)CH3  
Figure 3. The structures of ICI 182,780 and ICI 164,384. 
In this sub chapter, I will discuss the following three main strategies for the synthesis 
of 7-substituted compounds. 
• The introduction of the C-7 substituent to derivatives of another steroidal 
series. 
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• The addition of the C-7 substituent to an estrogen derivative, in which the C-7 
position has been activated. 
• The hydroxylation at C-7 of the estrane skeleton. 
 
2.1.1 Synthesis of C-7 alkyl substituted estrogen by converting other steroids to 
estrogen 
 
Conventional synthesis of C-7 derivatives of estrogens from other steroidal series is 
based on the Cu(I) catalyzed 1,6-conjugate addition of properly functionalized 
organometallic reagent to steroidal 4,6-dien-3-ones, and subsequent aromatization of 
the ring A.  
Wieland and Anner synthesized 7-methyl estrone (7a) by addition of methyl 
magnesium bromide to the dienone 4a. The addition product was converted to 7-
methyl estrone in several steps. The C-19 methyl group was lost in the final 
aromatization step (Scheme 3).20 Later French et al. carried out several experiments 
on 6-dehydrotestosterone derivative (4b) for optimization of reaction conditions to get 
better diastereoselectivity and yield for addition of 4-pentenyl magnesium bromide 
(Scheme 3). They found that four equivalents of Grignard reagent in 1:1 THF/ether 
gave the best results.21  
 
O O R2
HO RO R
4a, R1 =
4b, R1 = OAc
5a, R1 =              R2 = Me 57.5%
5b, R1 = OAc, R2 = (CH2)3CHCH2 56%
a
b c
R1
R1
R1
O O
R1
O O
6a, R1 = R2 = Me 54%
6b, R1 = OAc, R2 = (CH2)3CHCH2  50%
O O 7a, R1 = =O R2 = Me 68%
7b, R1 = OH R2 = (CH2)3CHCH2 50%  
Scheme 3. Reagents and conditions (a) (i) MeMgBr, Cu(I), (ii) separation of 
α and β isomer; (b) DDQ; (c) Li, Ph-Ph, PhCH2Ph. 
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Bucourt et al. obtained 17β-acetoxy-19nor-androsta-4,6-dien-3-one (8) from 19-
nortestosterone and used the former as the precursor of 7- substituted estradiol. Again 
the reaction involved the 1,6-addition of a Grignard reagent.22 This method has been 
used for the preparation of several 7α-substituted estradiols.19,23-25 A limited number 
of functional groups can be directly introduced due to use of Grignard reagent. Mostly 
the hydroxy protected alkanol chain was added and then functional modification was 
done on the hydroxy group. Thus Bowler et al. synthesized several antiestrogens, 
including ICI 164,384.25 
Use of 19-nortestosterone instead of 6-dehydrotestosterone facilitates the 
aromatization of ring A. In the latter case aromatization is achieved in two steps - 
dehydrogenation with 2,3-dichloro-5,6-dicyanobenzoquinone (DDQ) followed by 
reductive aromatization. Due to absence of the 19-methyl group, this conversion is 
achieved in one step under mild conditions for 19-nortestosterone (Scheme 4). 
However the diastereoselectivity decreased due to absence of 19β-methyl group.  
 
O
OR1
O
OR1
(CH2)nOTBDMS
OPg
(CH2)nOAcHO
a
c
8 9
11, 68%
O
OR1
(CH2)nOAc
b
10, 91%
R1 = OAc, n = 3, 46%
R1 = H, n = 9, 37%
R1 = OAc, n = 11, 32%
 
Scheme 4. Reagents and conditions (a) (i) (CH2)nOTBDMSMgBr, Cu(I), (ii) 
separation of α and β isomer; (b) (i) H+, H2O, (ii) Ac2O/Py; (c) CuBr2, LiBr, CH3CN 
reflux. 
An allyl group can be introduced at C-7 by reaction with allyltrimethylsilane. When 
the reaction was carried out in the presence of tetra-n-butylammonium fluoride 
(TBAF) catalyst both 1,6-addition (13, major) and 1,2-addition (14) products were 
obtained. The mentioned reaction was also reported with TiCl4 catalyst. This reaction 
is temperature dependent. While the reaction at -78 oC mainly gives the desired 7α-
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allyl compound (15), at -15 oC the major product is the 6β,6´β-dimer (17). No 1,2-
addition product nor 7β-allyl product was formed.26 Nickisch and Laurent obtained 
the 7α-allyl product (18) when employing allyltrimethylstannane and aluminium 
chloride (Scheme 5).27  
 
O
OPg
O
OPg OPg
+
Me3SiO
O
OPg
O
OPg
O
PgO
O
OPg
+
O
OPg
O
OPg
++
a
12 14, 23%, Pg = Ac
15, 35-40%, Pg = Ac 16, 3-4%. Pg = Ac
17, 36%, Pg = Ac 15, 14%, Pg = Ac 16, 6%, Pg = Ac
b
O
OH
c
d
18, 35%, Pg = TBDMS
13, 15% α   Pg = Ac  
      17% β
 
Scheme 5. Reagents and conditions (a) allyltrimethylsilane, TBAF, HMPA, DMF; (b) 
allyltrimethylsilane, TiCl4, DCM, -78 oC; (c) allyltrimethylsilane, TiCl4, -15 oC, 
DCM; (d) allyltributylstannane, AlCl3. 
Although an ethenyl group can be added to the dienone directly, the subsequent 
aromatization step is problematic. Therefore 7-ethenyl estradiol (24) was accessed via 
a nitrile derivative.28 A nitrile group can be introduced stereoselectively at 7α position 
in high yield by hydrocyanation with diethylaluminum cyanide.29,30 After ring A 
aromatization, modification of the nitrile group gave the desired ethenyl substituted 
product (Scheme 6). 
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O
OAc
O
OAc
CN HO
OAc
CN
HO
OAc
CHO HO
OAc
CHCHBr2 HO
OAc
H
HO
OH
H
+
a b c
d e
12 19, 74%, 20, 60%
21, 60% 22, 62 % 23, 20%
24, 60%  
Scheme 6. Reagents and conditions (a) Et2AlCN, THF-toluene, 1 h, aq. NaOH; (b) 
CuBr2, LiBr, CH3CN, rt, 30 min; (c) DIBAL-H, toluene, 3 h, MeOH-HCl; (d) CBr4, 
PPh3, CH2Cl2, 0 oC; (e) n-BuLi, -78 oC to rt, H2O, 4 h. 
In general the addition reaction of organometallic reagent to dienone is not 
stereoselective, producing mixtures of 7α and 7β products. Subsequent separation of 
the stereoisomers is required. Additionally generation of dienone and ring A 
aromatization steps make this methodology lengthy and inefficient.  
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2.1.2 Direct addition of substituent to C-7 of estrane skeleton 
 
By activating the C-7 position, a substituent can be added directly to the estrane 
skeleton. For this purpose either equilin is employed as starting material or benzylic 
C-6 of E1 or E2 is oxidised to the keto function. 
In 1991, Künzer et al. prepared 7α–hydroxymethyl estradiol starting from equilin. 
The C7-C8 double bond of 25 was hydroxymethylated by treatment with dimethyl 
aluminium chloride and paraformaldehyde, resulting in two homoallylic alcohols (26 
and 27). Both were hydrogenated over Pd/C to give an 8α analogue of 7α substituted 
estradiol (28). Birch reduction of the C-8-C-9 unsaturated alcohol gave 7α substituted 
estradiol (29) (Scheme 7).31 
 
MeO
OTBDMs
MeO
OTBDMs
CH2OH MeO
OTBDMs
CH2OH
+
MeO
OTBDMs
CH2OH MeO
OTBDMs
CH2OH
H
a
b
25 26, 65% 27, 12%
29, 5% 28, 56% from 26
      45% from 27
c c
 
Scheme 7. Reagents and conditions (a) Al(CH3)2Cl, (HCHO)n, -10 oC /-5 oC; (b) NH3, 
Li, THF, -50 oC ; (c) H2/Pd, rt. 
In another approach, protected 6-oxo-estradiol (30) was converted into the 
corresponding phenyl-thioenolether (31) and then oxidised to the sulfone (32). This 
vinyl sulfone (32) was utilised as a Michael acceptor in reaction with lithium organyls 
to prepare 7-substituted estradiol derivatives. The sulfone group was removed by 
reductive elimination. In this method, alkyllithiums show poor stereoselectivity, 
methyllithium shows almost no stereoselectivity, as the bulk of the substituent 
increases more β- selectivity is observed. Alkenyllithium showed good α selectivity 
with good yield. Using this methodology ICI 164,384 (39) was synthesised (Scheme 
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8).32 In contrast to Bowler’s reported synthesis, here the amide group was added 
directly. 
 
MeO
OAc
O
MeO
OAc
SPh
MeO
OAc
SO2Ph
MeO
OH
SO2Ph
R
MeO
OH
a b
c, d
MeO
OH
R R
30 31 32, 86% overall from 30 to 32
35a), R = Me 91%
35((b), R = n-C4H9 81%
36(a), R = Me 87%
36(b), R = n-C4H9 84%
36(c), R = t-C4H9  90%
MeO
OH
SO2Ph
R
+
33(a), R = Me 51%
33(b), R = n-C4H9 16%
33(c), R = t-C4H9  0%
33 (d), R = CC(CH2)8CON(n-Bu)Me 57%
34(a), R = Me 32%
34(b), R = n-C4H9 77%
34(c), R = t-C4H9  75%
34 (d), R = CC(CH2)8CON(n-Bu)Me 0%
f f
e
MeO
OH
R
for 33(d)
37, R = (CH2)10CON(n-Bu)Me 
80%
MeO
OH
R
38, R = (CH2)10CON(n-Bu)Me 
93%
HO
OH
R
39, R = (CH2)10CON(n-Bu)Me 
65%
f g
SO2Ph
 
Scheme 8. Reagents and conditions (a) TiCl4, THF, 0 oC, PhSH, Et3N, rt; (b) AcOH, 
NaBO3.4H2O, rt; (c) RLi, THF, -78 oC/-10 oC; (d) KOH, MeOH; (e) Pd/C, H2, 22 oC 
(f) MeOH, 3% Na(Hg), Na2HPO4, 0 oC; (g) NaSCH3, DMF, 130 oC. 
After α-bromination of 6-oxo-estradiol the resulting 7-bromo compound (40) can be 
methylated at C-7 by reacting with methyl iodide and zinc (Scheme 9).33 
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MeO
OAc
O
30
MeO
OAc
O
Br MeO
OAc
O
CH3
40 41
a b
 
Scheme 9. Reagents and conditions (a) Br2; (b) CH3I, Zn, DMSO. 
Tedesco et al. directly alkylated the 6-oxo-estradiol derivative and thus eliminated the 
sulfone introduction steps. In this method the enolate formed by deprotonation of the 
α-position of keto group with t-BuOK, reacts with alkyl iodide to yield the 7-
substituted product. Deoxygenation of alkylated ketone (43) with BF3.Et2O/Et3SiH 
gives the 7-substituted estradiol derivative (44) (Scheme 10). This reaction generally 
gives a mixture of 7α (major) and 7β substituted products, but β to α conversion can 
be done by base catalysed epimerization.34  
 
MeO
THP
MeO
OTHP
O O
R
MeO
OH
R
42 43 (a)  R = Me 78 %
   = Et 65 % (after epimerisation)
   = (CH2)10COCH3C4H9 78%
44, 95% for R= Me
a
MeO
OTHP
O
R
+
b
43(b)
Pg1 = Me
Pg2 = THP c
 
Scheme 10. Reagents and conditions (a) t-BuOK, RI; (b) NaOMe, MeOH, reflux; (c) 
BF3.Et2O, Et3SiH. 
Using this methodology many 7-substituted estrones and estradiols were 
synthesised.35-38 Synthesised compounds and yields (%) are listed in Table 1. Keto 
functionality at C-6 can be introduced by oxidation with chromium based oxidising 
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agents. For this purpose chromic acid,39 pyridinium chlorochromate (PCC)40-42 and 
chromiumoxide/3,5-dimethylpyrazole43 have been used. The most widely used 
method is hydroxylation at C-6 with LIDAKOR/B(OMe)3/H2O2 followed by 
oxidation of hydroxyl group to keto group.44 After alkylation the keto functionality in 
C-6 was removed by reduction with BF3/Et3SiH or catalytic hydrogenation. A number 
of functional groups can be incorporated through the introduced chain. Further 
functional modification of the introduced chain can give access to a wide range of 7-
substituted compounds. Re and 99mTc containing estradiol complexes have also been 
synthesised.45,46  
 
Table 1. Protecting groups and yields (%) of the reaction 
R1O
O
R2
R1O
O
R2
t-BuOK/ R3I
R3
 
 
Protecting group R3 Yield (%)  
R1 = THP, R2 = 
OTHPH  
 
(CH2)4CHCH2 47%35 
53%45 
R1 = Me, R2 = TBS Allyl 77% 
(after 
epimerization)47 
R1 = THP, R2 = 
O
O  
(CH2)4CN 
(CH2)5CN 
(CH2)6CN 
(CH2)10CON(CH3)C4H9 
40%  
43% 
38% 
49%48 
R1 = MOM, R2 = 
OMOMH  
(CH2)6OBn 65%37 
R1 = THP, R2 = 
OTHPH  
(CH2)6CN 62%38 
R1 = t-Bu, R2 = 
Ot-BuH  
(CH2)10CON(CH3)Boc 67%36 
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The 7β isomer predominated when Kanbe et al. introduced an allyl chain using 
KHMDS as the deprotonating agent.47 Selectively 7β-substituted compounds can be 
prepared from the 7α−isomer. Reduction of the keto functionality to hydroxy (46), 
subsequent dehydration and hydrogenation of the resulting 6,7-double bond over Pd/C 
leads to the 7β−isomer (48) (Scheme 11).49 
 
MeO
OO
(CH2)4CN MeO
OO
(CH2)4CN
O
MeO
O
(CH2)4CN
MeO
O
(CH2)4CN
45 46, 98%
47, 32%
48
a b
c
OH
Scheme 11. Reagents and conditions (a) NaBH4, Et2O/MeOH; (b) p-TsOH, benzene, 
heat; (c) Pd/C, H2, MeOH. 
Adamczyk et al. encountered a problem of O-alkylation versus C-alkylation when 
trying to alkylate 3,17β-bis(2-trimethylsilyl)-ethoxymethylestra-1,3,5(10)-trien-6-one 
(49) with 5-bromo-1-pentene in the presence of NaHMDS as base (Scheme 12). 
Attempts to use other bases (e.g. LDA, LiHMDS, KHMDS) did not solve the 
problem.50 
 
SEMO
OSEM
SEMO
OSEM
O O
a
SEMO
OSEM
O
+
49 50, 21% 51, 42%  
Scheme 12. Reagents and conditions (a) NaHMDS, HMPA, 5-bromo-1-pentene, 
THF. 
Success in the alkylation depends on the length and functionality of the alkyl chain. 
Seimbille et al. failed to substitute 16-epiestriol by this methodology.19 Insertion of 
ethyl chain carrying an electron withdrawing group gives poor results. In these cases 
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the synthesis can best be accomplished by Michael addition of the enolate to the 
group to be introduced under phase transfer conditions.51 The main product of this 
reaction is a 7α-substituted compound (53) along with some dialkylated (54) product 
(Scheme 13).  
 
MeO
OO
O
MeO
OO
O
CN MeO
OO
O
CN
+
2
52 53, 47% 54, 11%
a
 
Scheme 13. Reagents and conditions (a) acrylonitrile, [PhCH2N(CH3)3]OH, dioxane, 
water. 
Reaction of the silyl enol ether (56) with perfluorohexyl-
phenyliodoniumtrifluoromethanesulfonate (FITS-6) produces the 7-perfluoroalkyl 
estradiol derivative (57) with high diastereoselectivity (α:β = 10:1). Trifluoromethyl 
group may be introduced by reaction of 58 with trifluoromethyl-benzothiophenium 
triflate under UV irradiation (Scheme 14). The same reaction under thermal condition 
gives a poorer yield.52  
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AcO
OAc
O
AcO
OAc
OTBDMS
AcO
OAc
O
C6F13
AcO
OAc
O
CF3
55 56, 92% 57, α 67 %
       β 9.4%
58, α 52%
      β 39%
a b
c
 
Scheme 14. Reagents and conditions (a) t-butyldimethylsilyltriflate, 2,6-lutidine, 
CH2Cl2; (b) FITS-6, 2,6-lutidine, CH2Cl2; (c) Trifluoromethyl-benzothiophenium 
triflate, DMF, hν. 
Srivastava et al. have prepared pyrrolidine and morpholine substituted estradiol 
derivatives under Mannich reaction conditions (Scheme 15). The substitution 
occupied the β-position.53 
 
MeO
OAc
O
30
MeO
OAc
O
R
R = N .HCl
ON .HCl
59
60 R=
a
70%
59%
 
Scheme 15. Reagents and conditions (a) aq. HCHO, pyrrolidine or morpholine, HCl.  
Using the 6-oxo group as an auxiliary 7α-mercapto derivatives of estradiol have also 
been synthesized. After α-bromination of the ketone, the resulting bromoketone (62) 
reacted with sodium or potassium salt of arylmarcaptan to produce 63. Removal of 
the ketone functionality afforded the 7α-mercaptoestradiol derivative (64) (Scheme 
16).54,55  
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MeO
OMe
O
MeO
OMe
O
Br MeO
OMe
O
SAr
MeO
OMe
SAr
a b
61 62, 90% 63, 90%
64, 82%
c
 
Scheme 16. Reagents and conditions (a) Br2, CH2Cl2; (b) ArSH, base; (c) Et3SiH, 
BF3Et2O. 
 
2.1.3 Synthesis of 7-hydroxyestrone and estradiol 
 
The introduction of a C-7 oxygen function to the estrane skeleton is accomplished 
using 6-dehydroestrone or 6-dehydroestradiol. Oxidation of the 6-7-double bond with 
peracid leads to the 6α,7α-oxido compound (66). Reduction of this epoxide with 
lithium aluminium hydride (LAH) followed by acid hydrolysis gave 7α-
hydroxyestrone (Scheme 17).56-59 
 
PgO
OO
PgO
OO
O
PgO
OO
a b
OH
65 66, 100% (crude) 67, 51%  
Scheme 17. Reagents and conditions (a) peracid; (b) LAH, THF, reflux. 
Wintersteiner et al. had converted 6-dehydroestradiol to 6β-hydroxy-7α-
bromoestradiol-3,17-diacetate (69). This on treatment with anhydrous base was 
converted to 6β,7β-oxidoestradiol diacetate (70). Reduction of the epoxide with 
lithium aluminium hydride (LAH) yields 7β hydroxy estradiol (71) (Scheme 18).60 
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AcO
OAc
AcO
OAc
OH
Br AcO
OAc
HO
OH
OH
68 69, 62% 70, 98%
71, 57%
a b
c
O
 
Scheme 18. Reagents and conditions (a) 0.5 N perchloric acid, N-bromoacetamide, 
dioxane; (b) t-BuOK, t-BuOH, rt ; (c) LAH, THF, reflux. 
Synthesis of 7-hydroxyestradiol from equilin or dihydroequilin involves the addition 
of hydroxyl groups at C-7 and C-8. Hydroxyl groups are added by hydroxylation with 
OsO4. The 7-8-glycol (73) is converted to the 7-keto derivative (74) by pyrolysis. 
Reduction of corresponding enol acetate (75) produces the 7β-hydroxy derivative (76) 
(Scheme 19).58,61 
 
AcO
O
HO
O
OH
OH
HO
O
O
AcO
O
OAc HO
O
OH
a b
72 73 74
7675
c d
 
Scheme 19. Reagents and conditions (a) (i) OsO4 (ii) aq. Na2SO3; (b) high vacuum 
distillation; (c) NaOAc, Ac2O; (d) (i) Pd/C, glacial acetic acid; (ii) KOH, MeOH. 
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Estrone and estradiol can be converted into 7α-hydroxy derivatives by 
microorganisms. For example Aspergillus carneus converts estrone to 7α−hydroxy 
estradiol along with 7α−hydroxy estrone. Hydroxylation with microorganism 
furnished a mixture of many products and thus the isolation procedure is 
complicated.62 
In contrast to estradiol, there are very few reports on the 7-substitution of estriol. No 
direct addition of alkyl chain to 6-oxo derivative of estriol has been reported. 
Substitution of 16-epiestriol was attempted by this methodology but was not 
successful.19 7-Substituted estriol is synthesized by substituting steroidal 4,6-dienone 
at the C-7 and then converting it in several steps to estriol.63,64  
 
2.2 Studies on 8-isoestrogens  
 
8-Isoanalogue of estrogens and their derivatives have many therapeutic uses. Lower 
hormonal activity than their natural analogue in combination with other properties 
such as cholesterol-lowering ability, ovulation-inhibiting activity, etc., make them 
potentially valuable for the preparation of steroidal drugs and contraceptives. 
Korkhov et al. studied different 8-isoestradiol derivatives and tested their 
effectiveness as contraceptives. They found that 7α-methyl-8-isoestradiol is quite 
promising.65 3-Methoxy-8-isoestradiol possesses cholesterol-lowering activity in 
combination with low estrogenic activity, which made them potentially useful for the 
treatment of atherosclerosis.66 For better understanding of biological activity several 
studies on structure and biological activities of different 8-isoestrogen derivatives 
have been carried out.67 Several articles were published on the crystal structure of 8α-
analogue of estradiol derivatives by Shavva’s group.68,69 They also studied the 
conformational mobility of 7α−methyl-8α−estradiol derivative in solution.70  
8-Isoestrogens are synthesized by catalytic hydrogenation of the corresponding estra-
1,3,5(10)8,14-pentaene compound. The estra-1,3,5(10)8,14-pentaene compounds are 
synthesized in several steps starting from the tetralone derivative.71 Total synthesis of 
4-methyl-8-isoestradiol (82) is shown in Scheme 20.66 
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78, 62.4 % 79, 67.4%
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Scheme 20. Reagents and conditions (a) (i) vinyl magnesium bromide, THF; (ii) 2-
methylcyclopentan-1-3-dione, TritonB, t-BuOH, reflux; (b) KU-2 resin (acid form), 
methanol, rt; (c) (i) LAH, THF, reflux; (ii) Ac2O, Py, rt; (d) Raney Ni, H2 (80- 100 
atm), benzene, 40-65 oC; (e) NaOH, benzene, methanol, reflux. 
Marshall David J. patented a procedure for synthesis of 8-isoestrone (85) by reduction 
of equilenin or equilin with K/liq NH3 at -33 oC (Scheme 21).72 
 
HO HO
O
H H
H
OMe
OMe
HO
b
94%
b yield not mentioned
O
O
HO
O
HO
O
a
c
83 84 85
86 87  
Scheme 21. Reagents and conditions (a) trimethylorthoformate, Conc. H2SO4, MeOH; 
(b) (i) K/liq.NH3, -33 oC (ii) HCl, 40-50 oC; (c) (CH2OH)2, p-TSOH, benzene, reflux. 
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2.3 Immunoassay 
 
The levels of estrogens in body fluids are measured by immunoassay. This method is 
rapid and highly sensitive. For biological sample analysis this method predominates. 
In this diagnostic assay antibodies are used to identify and quantify estrogens. The 
basic reaction can be represented in a simplified form e.g. for estradiol 
estradiol + antibody  antibody-bound estradiol  
Amount of estradiol in the sample is obtained by measuring amount of antibody-
bound estradiol.73 Therefore for accurate measurement an antibody with good 
specificity and high affinity is required. Estrogens cannot generate antibody on their 
own but when attached to a macromolecule can elicit immunogenic responses. 
Generally, estrogens are coupled with a protein through a chemical bridge via amide 
linkage. In most of the cases estrogens are derivatised to a compound containing a 
carboxylic acid group and then the carboxylic acid group is employed to form an 
amide linkage with the amino group of a protein. Generally bovine serum albumin 
(BSA) is used as it is available in fairly pure form and contains a large number of 
lysine residues available for amide linkage. Diazotization and then formation of an 
estrogen-azo-protein conjugate has also been reported.74,75  
Since all estrogens and their metabolites have similar structures, obtaining an 
antibody specific for only one particular substance is difficult. Cross reactivity is 
often encountered. Lack of highly specific antibody is one of the major problems with 
the estrogen immunoassay. Success of generation of a specific antibody depends on 
the position of the steroid skeleton through which the protein is coupled and the 
length and nature of chemical bridge. For good specificity, the length of the chemical 
bridge should be four to six carbon atoms.76 A site away from functional groups and a 
position that is not changed by metabolism, is most favorable as a protein attachment 
site. The C-7 position of the estrogen skeleton meets both fundamental requirements 
for a better attachment site for protein.76 
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Haptens* of estradiol and estriol reported so far are shown in table 2. When the hapten 
prepared through derivatisation of a functional group at C-3, C-16, and C-17, the 
resultant antibody shows low specificity. Antibodies raised against estradiol 17β-
succinyl-BSA (89) and estriol 16,17-disuccinyl-BSA (91) cannot distinguish different 
estrogens. The antibody for estradiol 17β- succinyl-BSA (89) cross reacts with 
estrone and estriol77 Antibody against estriol-16,17-disuccinyl-BSA (91) shows high 
cross reactivity with estrone and estradiol.78 D-ring glucuronosides also cross react 
extensively. The antisera obtained with 3-O-carboxymethyl-estriol (90)-BSA 
conjugate show better specificity to ring D. It does not cross react with estrone and 
estradiol but cross reacts with 2-methoxyestriol, 6α-hydroxyestriol and 16-
epiestriol.79 The positions in ring A and ring B other than functional groups are also 
not suitable for conjugation. E2-15-craboxymethyl (95)-BSA antisera shows cross 
reaction with estriol.80 4-Azobenzoyl-estriol (93) antibodies cross react with 
estradiol.81 E3-3-sulfate and 3-glucuronosides.82 To obtain better specificity 
conjugation was made through ring-B and ring-C remote from functional groups. The 
haptens containing chemical bridge at C-11 (94), C-6 (96, 97, 98, 99, 100, 101) and 
C-7 (102, 103, 104) were synthesized. When conjugation is made through C-6 cross 
reaction with other estrogens is reduced, but with C-6 metabolites increase. The 
antibodies against 6-O-carboxymethyloxime-estriol-BSA showed marked cross 
reaction with the estriol metabolites, 6-ketoestriol and 6α-hydroxyestriol.77 As a 
double bond at the chemical bridge cannot rotate freely, mixtures of syn and anti 
isomer may form. Single bond derivatives have been prepared, but E2-6CME (97)- 
antibody also exhibits very high cross reactivity to 6-oxo estradiol. They cross react 
with estrone too.83 There are two patents on hapten 102 and 104 which have not been 
published in scientific journals. No specificity data are available for 10284 and 104 is 
used for total estriol immunoassay.  
                                                
* A hapten is a small molecule, which can elicit an immune response only when 
attached to a large carrier such as a protein.  
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Table 2. Reported haptens of estradiol and estriol 
Site of coupling Estradiol Hapten Estriol Hapten 
 Functional groups OH
HO2CH2CO  
88 
HO
OCO(CH2)2CO2H
 
89 
OH
OH
HO2CH2CO  
90 
HO
OCO(CH2)2CO2H
OCO(CH2)2CO2H
 
91 
C-4 OH
HO
N N
CO2H  
92 
OH
HO
N N
CO2H
OH
 
93 
 
C-11 
 
HO
OH
HO2C(H2C)2OCO
 
9485 
 
C-15 
HO
OH
SCH2CO2H  
95 
 
C-6 
HO
OH
NHCOCH2CO2H  
9686 
OH
OH
HO
NOCH2CO2H  
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Site of coupling Estradiol Hapten Estriol Hapten 
HO
OH
OCH2CO2H  
9783 
HO
OH
OCO(CH2)2CO2H  
9887 
HO
OH
NH2  
9988 
10086 
OH
OH
HO
NHCOCH2OCH2CO2H   
10184 
C-7 
HO
OH
OCO(CH2)2CO2H  
10287 
HO
OH
NHCOCH2CO2H  
10389 
OH
OH
HO S(CH2)2CO2H  
10490 
 
2.4 Fatty acid esters of steroids 
 
Fatty acid esters (FAE) of steroid hormones (SH) occur naturally in the human body. 
When the hydroxyl group is protected as an ester they are metabolically stable. They 
act as a hormone reservoir and can release the active hormone to the target tissues as 
required by the action of esterase. Both androgens and estrogens exist in the form of 
fatty acid esters.91,92  
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Estradiol fatty acid esters (E2-FAE) are the most potent mammalian estrogens.93 They 
occur in blood and different tissues. Janocko et al. first found that E2-FAE circulates 
naturally in human blood. Before this discovery estradiol esters were used as synthetic 
drugs but it was not known that they occurred endogenously. They detected it as a 
family of E2-FAE by HPLC and RIA (radioimmunoassay), but individual esters were 
not identified and also not quantified.94 Later from the same laboratory E2-FAE was 
measured by GC/MS in blood, adipose tissues, muscle and cyst fluid.95 
In blood, E2-FAE circulate in very low amounts; they are detectable but not 
accurately quantifiable.95 Vihma et al. measured the distribution of E2-FAE in plasma 
lipoprotein during late pregnancy when serum concentration of both free E2 and E2-
FAE is high. E2-FAE obtained from serum and lipoproteins were saponified, purified 
and then quantified by time-resolved fluoroimmunoassay. They showed that during 
late pregnancy, 75% of the E2-FAE in the blood are associated with lipoprotein. The 
majority of these are associated with high density lipoprotein (HDL) (54 %) and LDL 
(28 %).96 Studies have shown that E2 FAE in blood can protect lipoproteins against 
oxidation97 and take part in the reverse cholesterol transport mechanism as well.98 
These findings indicate that these compounds may reduce the risk of cardiovascular 
diseases. In blood, E2-FAE are synthesized by the action of LCAT 
(lecithin:cholesterol acyltransferase) associated with HDL then transferred to LDL by 
CETP (cholesteryl ester transfer protein).97,99  
They are most abundant in the adipose tissue.95 The E2-FAE/ free E2 ratio varies in 
different hormonal states. Both in serum and adipose tissue, the E2-FAE/ free E2 ratio 
is lowest in pregnant women. The ratio increases from pregnant to premenopausal 
women and is highest in postmenopausal women. High concentration of E2 and E2-
FAE in the adipose tissue in postmenopausal women compared to serum indicates 
that adipose tissue act as a production and storage site of E2-FAE. It is not clear yet if 
the E2-FAE have any independent physiological role in this tissue.100  
E2-FAE are present in breast cyst fluid also. Their concentration is much lower than 
that of free E2.95 In vitro studies showed that E2-FAE are synthesized in breast tumor, 
51% of which are saturated esters. The synthesized E2-FAE were mainly composed 
of arachidonate, linoleate, oleate, linolinate, palmitoleate, stearate and palmitate. E2-
oleate is the most prevalent ester (30%). Concentration and composition is not related 
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to the estrogen receptor or progesterone receptor content.101 Mills et al. found that E2-
FAE can stimulate the growth of mammary tumors in the rat and suggest E2-FAE 
may be a risk factor for breast cancer.102,103  
Ovarian follicular fluid of gonadotropin-stimulated women contains a mixture of 
different E2-FAE, comprising predominantly of unsaturated FAE. E2-linoleate is the 
most abundant ester comprising 43%. Other saturated and unsaturated esters are: 
palmitate (20%), arachidonate (19%), oleate (14%), and stearate (4%).104 In ovarian 
follicular fluid also, E2 esterification is induced with LCAT.105 Since estradiol has 
action on ovaries, it is expected that E2-FAE may also have an important role in the 
female reproductive system. 
Belanger et al. found dehydroepiandrosterone fatty acid esters (DHEA-FAE) in the 
adrenals.106 In humans, the concentration of DHEA-FAE in the adrenal gland is three 
times higher than that of free DHEA.106 DHEA-FAE are also found in blood and most 
of the DHEA-FAE in blood are bound to the lipoprotein fraction. In vitro studies 
showed that in blood DHEA-FAE are synthesized by LCAT and mostly unsaturated 
fatty acid esters are formed. Unlike E2-FAE, DHEA-FAE are transported from HDL 
to LDL and Low density lipoprotein (VLDL) by a CETP independent mechanism.107 
Together with our collaborator we found that in ex vivo system DHEA-FAE improves 
the vasodialatory effect of HDL.108 In vitro studies show that DHEA-FAE is formed 
in the ZR-75-1 breast cancer cells and they may act as a prehormone for other 
steroids.109,110 
ZR-75-1 breast cancer cells are the formation site of 5α-androstane-3β,17β-diol 
diesters also.111 
Testosterone esters occur in the fat and testes of male rat.112 In the rat, testosterone is 
esterified in brain and it may play an important role in the development of the rat 
brain.113 
All these studies suggest that SH-FAE participate in important biological processes. 
Their biological actions are currently under active study. Studies on synthesis and 
metabolism of SH-FAE in lipoprotein and adipose tissues are reviewed by Vihma et 
al.114 A better understanding of their physiological role may be therapeutically 
helpful. 
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SH-FAE are generally prepared by reacting the steroid with corresponding acyl 
chloride or acid anhydride in dry pyridine (Py). This process suffers from 
sluggishness and often results in low yield.115 For E2, while the major product was 
E2-3,17-diester, also E2-3-ester, E2-17-ester and unreacted estradiol were detected. 
To prepare E2-17-FAE this mixture was isolated and then hydrolyzed with NaHCO3 
to remove the ester function at C-3.115 Enzymatic preparations of SH-FAE are also 
reported. Bruttomesso et al. synthesized FAE of DHEA (105) with lipase catalyst. 
Lipases from Candida rugosa (CRL) esterified DHEA at 30 oC. Increase in 
temperature did not improve the yield. For long-chain unsaturated acids, yield 
decreased when temperature was increased (Scheme 22).116 
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Scheme 22. Reagents and conditions (a) acyl chloride or acid anhydride, dry Py 
(conventional method) (b) fatty acid, CRL, toluene, 72 h (enzymatic method). 
Using CRL, FAE of E2 was also prepared by reacting E2 with a fatty acid. While 
under solvent free condition estradiol-3,17-diester was obtained, when the reaction is 
carried out in toluene 17-OH was esterified selectively. Estradiol-17-ester is also 
obtained by selective enzymatic alcoholysis of estradiol-3,17-diester. Alcoholysis of 
estradiol-3,17-diester with lipase obtained from Candida antartica (CAL) afforded 
estradiol-17-ester.117 All of these enzymatic synthetic processes take several days to 
produce target material (Scheme 23). 
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Scheme 23. Reagents and conditions (a) fatty acid, CRL, 55 oC, 72 h; (b) CAL, 
alcohol, 55 oC, 72 h; (c) fatty acid, CRL, toluene, 55 oC, 72 h. 
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3. AIMS OF STUDY 
 
1. Synthesis of new estrogen haptens. 
Our objective was to synthesise estradiol and estriol haptens by adding an alkyl or 
alkoxy side chain at C-7, terminating with an amino group. Though immunoassay is 
widely used for steroid hormone analysis of biological samples, scarcity of a specific 
antibody is the limiting factor of immunoassay. This drawback can be addressed by 
synthesizing a new hapten which can generate a more specific antibody. So far, 
linking of estrogens hapten with protein is achieved by converting the steroid into a 
steroid derivative containing a CO2H group. It is not essential that the linking bridge 
always contains a terminal CO2H group. The linking bridge may also posseses a 
terminal NH2 group that can link with some carrier molecule that has a carboxyl 
residue.  
 
2. Synthesis of fatty acid esters of steroids under microwave irradiation in ionic liquid 
Our aim was to find a synthetic procedure of fatty acid esters of steroids where we 
could follow the green chemistry principle. The methodology should be fast and high 
yielding and applicable for synthesis of labeled steroid fatty acid esters also. Our 
objective was to develop an efficient methodology with the assistance of ionic liquid 
and microwave irradiation.  
Our target molecules, the synthesized fatty acid esters of estrogens and androgens are 
mostly new molecules in the chemical literature and their biological effect in human 
body is studied by our collaborator. 
 
3. Synthesis of 8-isoestradiol derivatives  
Synthesis of 7-hydroxy-8-isoestradiol and 7-alkyl ether of it, starting from equilin.  
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4. RESULTS AND DISCUSSION 
 
4.1 Synthesis of estriol 
 
Estriol (3) was synthesized starting from estrone (1). Several methods were 
investigated for stereoselective hydroxylation at C-16 (Scheme 24). α-Hydroxy 
ketones are generally prepared by oxidation of enolates or enol derivatives of the 
ketone. Transition metal peroxide reagents such as MoO5.py.DMPU (MoOPD) and 
MoO5.py.HMPA (MoOPH) are known for preparing α-hydroxy ketones from ketones 
containing α-methylene group.118 MoOPD was chosen because of lower toxicity and 
was prepared from MoO3 by a literature method. MoO3 was first converted to 
MoO5.DMPU.H2O by reacting with H2O2 and DMPU. Then treatment of 
MoO5.DMPU.H2O with pyridine furnished MoO5·DMPU·Py (MoOPD).119 The 
phenolic OH of 1 was protected as tert-butyldimethylsilyl (TBDMS) ether (109) with 
imidazole/TBDMSCl in DMF by literature method.120 The enolate generated by 
treatment of 109 with LDA was subjected to oxidation with MoOPD but no 
hydroxylation occurred. To check whether enolate was formed with lithium 
diisopropylamide (LDA), a similar reaction was carried out with D2O instead of 
MoOPD. The resultant product was analyzed by 1H NMR spectroscopy. Absence of 
the characteristic peak of H-16 (dd at 2.49 ppm) in nmr spectra indicates that 
deuteriation occurs at C-16, which proves that there was no problem in formation of 
enolate with LDA.  
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Scheme 24. Reagents and conditions (a) (i) H2O2, 40 oC, (ii) DMPU, 10 oC; (b) Py, 
THF, 0 oC; (c) imidazole, TBDMSCl, DMF, rt; (d) LDA, THF, -78 oC, MoOPD, -23 
oC; (e) Ac2O, NaOAc; (f) proline, nitrosobenzene, DMF, 0 oC; (g) isopropenyl 
acetate, H+, reflux; (h) (i) PhI(OCOCF3)2 (ii) aq. Na2S2O3 and aq. NaHCO3 solution; 
(i) m-CPBA, DCM, aq. NaHCO3, rt; (j) LAH, diethylether, reflux; (k) reverse 
addition of LAH, diethylether, reflux; (l) H+, NaBH4; 
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Aminoxylation followed by cleavage of the N-O bond with CuSO4 in methanol is 
another means of synthesizing α-hydroxy ketone.121 Our attempt to aminoxylate 3-
acetoxyestrone (111) with nitrosobenzene under proline catalysis failed, no reaction 
occurred.  
In another approach, estrone (1) was converted to the enolacetate 114 (78% yield) by 
treatment with isopropenyl acetate under acid catalysis. Among p-TsOH, polymer 
bound p-TsOH and H2SO4 the best yield was obtained with concentrated H2SO4. 
Longer reaction times and higher temperature cause a blackening of reaction mixture 
and detoriation of yield.  
When 114 was tested for conversion to 16-hydroxy derivative (115) by treatment with 
iodobenzene bis(trifluoroacetate), followed by hydrolysis, no reaction occurred.122 
Oxidation of 114 with m-chloroperbenzoic acid (m-CPBA) gave 16α,17α−epoxy-
estra-1,3,5(10)triene-3,17β -diol diacetate (116) in 94% yield. Since the enolacetate 
(114) is acid sensitive, epoxidation was carried out in a biphasic system in 
dicloromethane (DCM)-aq. NaHCO3 solution.123 The compound 116 is not stable on 
flash column therefore without further purification crude 116 was subjected to 
reduction with LAH. Addition of the epoxide solution to LAH suspension (normal 
addition) results in many products. Inverse addition of LAH i.e. addition of LAH 
suspension to the epoxide solution reduces the number of side products. But this 
method also produced two inseparable isomers. Rearrangement of 116 with acid and 
subsequent reduction with sodium borohydride controlling the pH 5- 6.5 produced 
estriol (3) in 74% yield. Estriol was characterized by 1D and 2D NMR. 
Stereochemical assignments of C-16 and C-17 were inferred by Nuclear Overhause 
effect spectroscopy (NOESY). NOE between H-16 and CH3-18 and absence of NOE 
between H-17 and CH3-18 provided the evidence of 16α−ΟΗ, 17β−ΟΗ 
stereochemistry.  
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4.2 Protection of hydroxyl groups of estradiol and estriol 
 
The hydroxyl groups of steroids need to be protected with a protecting group that can 
withstand the subsequent reaction conditions. Tetrahydropyranyl (THP) protecting 
group is mostly used, but a THP protection gives rise to two diastereomers. Therefore 
in compounds containing more than one hydroxyl group like estradiol and particularly 
in estriol THP protection gives a complicated mixture of products. 
Estradiol (2) was protected as acetate (123) and benzotae (125) ester in high yield by 
treatment with Py/Ac2O 124 and Py/BzCl respectively (Scheme 26). Both of them were 
suitable for C-6 oxidation with Cr (VI) oxidizing agent, but acetate protection need to 
be changed before the following alkylation step. See page 45. 
Best results were obtained with tert-butyl ether protection. Protection of 2 as the di-
tert-butyl ether (127) was accomplished by passing isobutylene gas through a mixture 
of Amberlyst H-15 resin and 2 in DCM. NMR data of 127 is reported before36 but we 
found the multiplicities of the aromatic protons are different from that of literature. 
We found a side product (128) was also formed by substitution at C-2 (Scheme 26). 
Although the yield of 127 was lower than that of ester protection (123, 125), tert-
butyl ether protection was compatible throughout all the subsequent reaction 
conditions. Deprotection was also achieved easily, no additional steps were required 
for removal of the tert-butyl group as it was cleaved during reductive elimination of 
6-oxo group. 
Protection of estriol (3) was more challenging. All of our attempts to protect estriol as 
triisopropyl silyl (TIPS) ether resulted in partially protected estriol only. Protection of 
3 under routine conditions (TIPSCl, imidazole, DMF) gives diprotected estriol in 93% 
yield.  Maybe the steric hindrance of 17-OH prevents the introduction of bulky TIPS 
group. Reaction conditions known for protection of hindered alcohol e.g Py, TIPSCl, 
AgNO3 125 and NaH, TIPSOTf 126 were also tried, but none of them gave triprotected 
estriol (117).  
Attempted protection of 3 as tert-butyl ether with isobutylene gas under the catalysis 
of Amberlyst H–15 left a major part of estriol unreacted, the desired tri-tert-butyl 
ether of estriol (118) being obtained only in 16% yield (Scheme 25). Some partially 
protected estriol (119, 120) and a byproduct (121) were also isolated. The low 
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solubility of estriol in dichloromethane causes such poor results. Ionic liquids (IL) are 
known for their solubilising capacity and Shi et al. showed that neutral ILs can 
catalyze the formation tert-butyl ether of primary alcohol (not mentioning other 
alcohols).127 We tried tert-butanol and [bmim]BF4 for protection of estriol as tert-
butyl ether. Better dissolution of estriol in tert -butanol/[bmim]BF4 was expected. Shi 
et al. conducted the reaction at in autoclave at 130 oC but did not mention pressure. 
We carried out the reaction under microwave irradiation in a closed vial at 130 oC, but 
the reaction nevertheless failed.  
Finally full protection of estriol as tri-(methoxymethyl) ether (122) in 86% yield was 
accomplished by reaction of 3 with methoxymethyl chloride (MOMCl) and 
diisopropylethylamine (DIPEA) (Scheme 25). 1H NMR spectra of 122 was 
reported,128 where two OCH2O peaks were reported as multiplet. We found those as 
ABq and doublet. 
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Scheme 25. Reagents and conditions (a) imidazole, TIPSCl, DMF, rt; (b) Py, TIPSCl, 
AgNO3, rt; (c) NaH, TIPSOTf, THF, rt; (d) isobutylene, Amberlyst-15, DCM, rt; (e) 
t-BuOH, [bmim]BF4, MW, 130 oC, 100 W, 70 min; (f) diisopropylethylamine, 
MOMCl, THF. 
 
4.3 Oxidation at C-6 of estradiol and estriol 
 
The next step after protection of hydroxy groups is the selective oxidation at C-6 of 
the estrane skeleton. A range of reagents was explored for oxidation at C-6. Oxidation 
with CuSO4.5H2O/K2S2O8, in refluxing CH3CN-H2O was not selective. 3,17-estradiol 
diacetate (123) resulted in a mixture of many inseparable products. Oxidation of 125 
under same conditions provided only 7% of 6-oxo-estradioldibenzoate (126), and a 
mixture of other products (Scheme 26).  
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CrO3 and PCC oxidised steroids to 6-keto derivatives but yields were low. Chromium 
(VI) oxide/3,5-dimethylpyrazole produced the 6-oxoestradiol derivatives in 22-28% 
yield depending on starting compound (Scheme 26).43  
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Scheme 26. Reagents and conditions (a) Ac2O, Py; (b) CrO3, CH2Cl2, 3,5-
dimethylpyrazole, -25 oC; (c) CuSO4. 5H2O/ K2S2O8, CH3CN, reflux; (d) Py, BzCl, rt; 
(e) isobutylene, Amberlyst-15, CH2Cl2; (f) i. DIPEA, BuLi, t-BuOK, -78 oC ii. 
B(OMe)3, 0 oC iii. H2O2, rt (g) PCC, CH2Cl2, Py, rt. 
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Estriol was protected as triacetate (131) with Py/Ac2O. Oxidation of estriol triacetate 
(131) with PCC in refluxing benzene gives a 26% yield of 6-oxo-estrioltriacetate 
(132) (Scheme 27). Agglomeration of reagent causes poor yield and often results were 
not reproducible. PCC was mixed with Celite to avoid agglomeration but still the 
yield of 6-oxo derivative was low. Addition of molecular sieves (3Å) in the reaction 
mixture did not improve the yield either. Formation of large amounts of waste and 
therefore the tedious and difficult work up procedure is another problem of using 
chromium based oxidising reagents. 
Attempted oxidation of 131 through UV irradiation in acetone/water/FeCl3 failed. 
This methodology was reported for C-6 oxidation of tetralin129 but for estriol 
triacetate resulted in a mixture of very polar compounds. TLC of the crude product 
showed many inseparable spots near the base line and no 6-oxo-estrioltriacetate was 
formed. 
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Scheme 27. Reagents and conditions (a) PCC, benzene, reflux; (b) FeCl3, water, 
acetone, UV; (c) CrO3, CH2Cl2, 3,5-dimethylpyrazole, -20 oC to -30 oC; (d) i. DIPA, 
BuLi, t-BuOK, THF, -78 oC ii. B(OMe)3, 0 oC iii. H2O2, rt; (e) DMSO, oxalyl 
chloride, DMF, -55 oC. 
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6-oxo derivatives were best obtained by hydroxylation at C-6 followed by oxidation. 
The compound 127 was deprotonated under superbase conditions (1:1 potassium tert-
butoxide and lithium diisopropylamide) in dry THF, and then the anion was trapped 
with trimethyl borate, followed by oxidation with H2O2 to afford 6-hydroxy-estradiol-
di-tert-butyl ether (130) (Scheme 26). After addition of H2O2 a sticky white lump was 
formed. The mixture was stirred for 2 h with mechanical stirrer but the lump was not 
broken. Yield of 130 was only 51%. Probably the lump formation reduced the yield. 
This assumption was verified during synthesis of 6-hydroxy-estriol-tri-tert-butyl ether 
(133) by hydroxylation of 122 using same methodology (Scheme 27). Again after 
addition of H2O2 a sticky precipitate was formed and 133 was obtained in 49% yield 
only. Only 4.4% unreacted 122 was recovered. The reaction was repeated and this 
time after addition of H2O2 the mixture was stirred vigorously with mechanical stirrer 
for one day. The precipitate was disappeared and yield of 133 was raised to 76% 
(Scheme 27). 
Subsequent oxidation of 130 with PCC furnishes 6-oxo-estradiol-di-tert-butyl ether 
(129). As the tert-butyl group is sensitive to acidic conditions, pyridine was added to 
keep the medium basic during oxidation. The presence of MOM protecting group 
made 133 incompatible for oxidation with PCC. 133 was oxidised by Swern oxidation 
(oxalyl chloride, DMSO) to yield 134 in 95% yield. 
 
4.4 Alkylation at C-7 
 
t-BuOK was employed to deprotonate 6-oxo steroids for alkylation at C-7. When 
solid t-BuOK was suspended in THF and the solution of steroid (e.g. 125, 129, 134) 
added to it the mixture was not homogeneous and no reaction took place after 
addition of the alkylating agent. When reaction of 125 with bromo butyro nitrile 
failed, more active alkylating agents such as iodobutyronitrile and allylbromide were 
tested, but none of the reactions was successful, no reaction happened (Scheme 28). 
Iodobutyronitrile did not react with 133 either under the same conditions (Scheme 
30).  
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Scheme 28. Reagents and conditions (a) i. t-BuOK (solid), THF ii. Br(CH2)3CN; (b) t-
BuOK (solid), THF ii. I(CH2)3CN; (c) t-BuOK (solid), THF ii. allyl bromide. 
One experiment was carried out with Boc-protected 3-iodopropylamine (139). 
Compound 139 was synthesised starting from 3-aminopropanol (137) (Scheme 29). 
The amino group was protected as tert- butyl carbamate by reacting 137 with (Boc)2O 
with ZrCl4 catalyst.130 Iodination of 138 with I2, imidazole and triphenyl phosphine in 
dry CH2Cl2 gives a 70% yield of 138.131 NMR data of 139 was same as that of 
reported. A Problem of 3-iodopropylamine is that it is not stable and has to be 
prepared freshly prior to use. 
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Scheme 29. Reagents and conditions (a) (Boc)2O, ZrCl4, acetonitrile; (b) I2, 
imidazole, PPh3, DCM. 
Reaction of 134 with 139 in presence of t-BuOK (solid) also failed. In another 
approach the side chain was tried to introduce by a Michael addition reaction. To a 
solution of 134 and benzyl trimethylammonium hydroxide in dioxane and water was 
added acrylonitrile as Michael acceptor.51 No addition product was obtained even 
after 18 h stirring. Only starting compounds were there (Scheme 30). 
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Scheme 30. Reagents and conditions (a) acrylonitrile, [PhCH2N(CH3)3]OH, dioxane, 
water, rt; (b) t-BuOK (solid), I(CH2)3CN, THF; (c) t-BuOK (solid), 139. 
When all of our attempts to introduce the side chain by deprotonating C-7 with solid 
t-BuOK failed, commercially available potassium tert-butoxide solution in THF (1M) 
was used for alkylation. For this purpose bromovaleronitrile (143) was converted to 
iodopentane nitrile (144) by refluxing with NaI in good yield.132  
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Scheme 31. Reagents and conditions (a) NaI, acetone, reflux; (b) t-BuOK (1M 
solution in THF). 
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Reaction of 129 with 144 in presence of potassium tert-butoxide solution furnished 
two monosubstituted compounds 145, 146 and the disubstituted compound 147 
(Scheme 31). The compound 145 was the major product. When the reaction mixture 
was stirred for longer time (overnight at rt) the α/β ratio increases but overall yield of 
monoalkylated compound decreases. Yield and product ratio of the reaction under 
different conditions are summarized in Table 3. The reaction was carried out under 
microwave irradiation also. As the reagent (t-BuOK) of the reaction and the 
intermediate enolate are ionic, they were expected to absorb microwave energy (MW) 
with high efficiency and in turn react more efficiently. After addition of solution the 
mixture was irradiated with MW to convert 129 to the corresponding enolate then 
cooled down to -78 oC and after addition of 144 again irradiated. During the reaction 
the reaction tube was cooled continuously with a microwave transparent cooling 
liquid. So the reaction temperature although subjected to MW irradiation, did not 
increase. However MW irradiation did not improve the yield. One reaction under MW 
irradiation was carried out at 0 oC to check if there is any noticeable MW effect at 
relatively higher temperature. In this reaction the α/β ratio decreased. 
Table 3. Effects of reaction conditions on yield and α/β ratio 
Reagents and conditions Yield (%) α/β 
t-BuOK, 0 oC 45 min, -78 oC, 144, 0 oC, 2 hr, rt, overnight 32 1.9 
t-BuOK, 0 oC 45 min, -78 oC, 144, 0 oC, 2 hr, 50 1.7 
t-BuOK, 0 oC 45 min, MW,  -78 oC, 144, 0 oC, 2 hr, 37 1.3 
t-BuOK, 0 oC 45 min, MW, 144, 0 oC, MW 2 hr, 30 0.25 
 
After alkylation at C-7, the removal of 6-oxo group and reduction of nitrile to primary 
amine were planned to be done in one step. Catalytic hydrogenation of 145 on Pd-
C36or 20% Pd(OH)2/C133 was not successful, no reaction occurred, but as a test 
reaction when tetralone was hydrogenated over Pd-C, all the tetralone was reduced to 
tetralin. Maybe other functional groups present in 145 were disturbing hydrogenation. 
An equimolar mixture of aluminium chloride and LAH is effective in conversion of 
alkyl aryl ketone to the corresponding hydrocarbon134 and reduction of the nitrile 
group to primary amine.135 145 was subjected to reduction with LAH/AlCl3.. NMR of 
the crude product shows that the ketone was reduced to alcohol not to the 
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hydrocarbon. Nitrile group was not present anymore, may be reduced to amine and 
the protecting group at C-3 was cleaved. The product was very polar so its 
purification was attempted by reverse phase chromatography, but purification 
provided four compounds each in very low yield and products could not be identified.  
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Scheme 32. Reagents and conditions (a) Pd/C- H2; (b) Pd(OH)2/C- H2; (c) LAH/AlCl3; 
(d) NH2NH2/ KOH; (e) NaBH4/CoCl2; (f) LiAlH4, ether, rt; (g) NaBH4, MeOH, rt; (h) 
Et3SiH, BF3.Et2O, CH2Cl2, rt. 
When the simultaneous removal of oxo group and reduction of nitrile did not work we 
tried to reduce the ketone to alcohol as well as the nitrile group to primary amine. 
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NaBH4 in combination with CoCl2 can reduce nitrile to primary amine.136,137 
Therefore NaBH4/CoCl2 was employed to convert 145 to 148 but the reaction resulted 
in many products. TLC of the crude product showed many inseparable spots. 
Reduction with LAH furnishes 148, product was too polar so purification by 
chromatography was difficult.138 The amine group was making the compound very 
polar and it was stuck on silica gel. Then we tried to reduce first the keto functionality 
only. Reduction of 145 with NaBH4 furnished 149 in 60% yield. When 149 was 
subjected to hydrogenation under 3 bar hydrogen over Pd(OH)2/C at 60 oC expected 
product 150 was not obtained. The nitrile group may reduced but hydrogenolysis at 
C-6 did not occur. Then we decided to remove the oxo functionality before reducing 
the nitrile. Attempt of removal of the 6-oxo group by Wolff-Kishner reduction 
(NH2NH2/KOH) did not give the desired product (147). A complicated mixture of 
many products was obtained. Reductive elimination of 6-oxo group was achieved 
with Et3SiH/BF3.Et2O. This treatment also caused the removal of tert-butyl protecting 
groups resulting in 151. Now the only reducible group present is the nitrile group and 
a clean reduction was expected. The compound 151 was subjected to H2 over 20% 
Pd(OH)2/C, but no reaction took place. Finally reduction of 151 with LAH gave the 
desired product 152. NMR shows that nitrile group was reduced. No M+ peak was 
observed in EI-MS, although an M-15 peak was seen. However the ESI-MS shows an 
M+1 peak. 
In 151 one of the H-6’s appears at 2.90 ppm as double doublet Jgem = -17.25 Hz and 
J6,7 = 5.5 Hz. Coupling constant H-6-H-7 is 5.5 Hz indicates this is an ax-eq coupling. 
Another H-6 does not couple with H-7 i.e dihedral angle is very small, so they are 
both in equatorial position. Therefore it is evident that H-7 has β configuration and 
the side chain has α configuration. 
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Scheme 33. Reagents and conditions (a) KOt-Bu (1M solution in THF), 144; (b) 
Et3SiH, BF3.Et2O, CH2Cl2, rt; (c) Conc. HCl, MeOH, reflux; (d) Et3SiH, BF3.Et2O, 
CH2Cl2, rt (e) [bmim]BF4, Et3SiH, BF3.Et2O, CH2Cl2, rt. 
Alkyl side chain at C-7 of estriol was introduced by same methodology. 
Deprotonation of 133 with t-BuOK solution followed by alkylation with 5-
iodopentanenitrile (144) gave 153, a mixture of α and β epimer (α:β = 84:16). Unlike 
7-substituted estradiol derivative these isomers were not separable by flash column 
chromatography. The mixture was refluxed with NaOMe in methanol, after 3 days 
α/β ratio was 94:6. Doubly substituted compound 154 was obtained in 17% yield and 
30% of unreacted starting ketone (134) was recovered (Scheme 33). 
When 153 was treated with Et3SiH/BF3.Et2O to remove the 6-oxo group a mixture of 
unexpected products was obtained which could not be identified. So MOM-protection 
was first removed. Refluxing 153 in methanol in presence of conc. HCl quickly 
removed the MOM group without affecting nitrile group. Treatment of 155 with 
Et3SiH/BF3.Et2O yielded 157 but the reaction was slow and yield was low (50%). 
Even after 3 days reaction 11% of unreacted 156 was recovered. Again low solubility 
of 156 in DCM was the problem. To overcome this problem in another reaction 
[bmim]BF4 was employed as cosolvent and 156 was completely soluble in the 
medium, Et3SiH/BF3.Et2O was added and the mixture was stirred at room 
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temperature. No unreacted 156 was detected after 1 day, but yield of 157 dropped 
drastically. After flash chromatography only 17% of 157 was isolated (Scheme 33). 
 
4.5 Hydroxylation and etherification at C-7 
 
For synthesis of alkoxy substituted estradiol derivative 2 was first protected as 
triisopropyl silyl ether. The reason behind choosing the TIPS ether was that it could 
be cleaved by F- ion, while alkyl ether remains unaffected. Therefore it would be easy 
to remove silyl protection from the final product, which contains an alkyl ether 
linkage at C-7. Silyl protection was installed smoothly but this protection was not 
compatible with the subsequent hydroxylation conditions. When attempting to 
hydroxylate 158 a mixture of products was obtained none of which is the desired 
hydroxylated derivative (159) (Scheme 34).  
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TIPSO
OTIPS
TIPSO
OTIPS
OH
a b
2 158, 83% 159  
Scheme 34. Reagents and conditions (a) imidazole, TIPSCl, DMF, rt; (b) DIPA, 
BuLi, t-BuOK, -78 oC ii. B(OMe)3, 0 oC iii. H2O2, rt. 
Dehydration of 130 in DMSO at 170 oC gave 160 and 161. In ionic liquid, under 
microwave irradiation dehydration occurs at much quicker rate, but both of the 
protecting groups were cleaved, 162 was formed at 100 oC in 10 min. Lowering of 
temperature or reaction time did not help to keep the protecting groups intact. At 
lower temperature no reaction happens at all. Shorter irradiation time results in 
incomplete reaction.   
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Scheme 35. Reagents and conditions (a) DMSO, 170 oC; (b) [bmim]Cl, MW, 100 oC, 
10 min; (c) NaH, DMF, BnBr, THF, rt; (d) m-CPBA; (e) LAH, THF, reflux; (f) 40% 
aq. KOH, acrylonitrile, DCM, 18-crown-6; (g) LAH, AlCl3, ether, rt. 
Ph-OH of 160 was protected as benzyl ether to produce 163, and then 6,7-double 
bond was epoxidised with m-CPBA to furnish 164. Reduction of 164 with LAH 
generates 165. Configuration of 7-OH was assigned from 1H NMR data of C-6 
protons. 6α-H appears as a doublet at δ 2.85 with Jgem = -17.7 Hz and is not coupled 
with H-7, which means the dihedral angle between H-7 and 6α-H is very small. On 
the other hand 6β-H shows dd at δ 3.11, Jgem = -17.6 Hz, J6,7 = 3.0 Hz. Coupling 
constant between H-7 and H-6 is consistent with ax- eq coupling. Therefore H-7 must 
have β configuration and the 7-OH has the α configuration. Michael reaction of 
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acrylonitrile with 165 under phase transfer conditions afforded 166.139 The compound 
166 was reduced with mixture of LAH and AlCl3 to furnish 167 (Scheme 35) . 
7-Alkoxy estriol derivative was also synthesized in similar way. The compound 133 
was dehydrated to furnish 168 by heating in DMSO at 160 oC. NMR of the crude 
product showed that MOM protection was partially cleaved. The crude product was 
treated with DIPEA and MOMCl to obtain 168 in 49% yield.  
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Scheme 36. Reagents and conditions (a) i. DMSO, 170 oC; ii. DIPEA, MOMCl; (b) 
m-CPBA, DCM, aq. NaHCO3 rt; (c) LAH, THF, reflux; (d) 40% aq. KOH, 
acrylonitrile, DCM, 18-crown-6; (e) LAH, ether rt; (f) (Boc)2O, Amberlyst-15. 
Epoxidation of the 6,7 double bond in 168 with m-CPBA leads to 169. Opening of the 
epoxide ring with LAH produces the 7α-hydroxy derivative 170. Configuration of 7-
OH was again assigned from 1H NMR data of C-6 protons. H-6α does not couple 
with H-7, which means dihedral angle between H-7 and 6α-H is very small. On the 
other hand 6β-H shows dd at δ 3.11, Jgem = -17.7 Hz, J6,7 = 3.3 Hz. Coupling constant 
between H-7 and H-6 is consistent with ax-eq coupling. Therefore H-7 must have 
β configuration and the 7-OH have α configuration. Michael addition reaction of 170 
with acrylonitrile furnishes 171. The compound 171 was reduced to 172 with LAH. 
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As the amine is not stable and decomposes in a flash column the amino group was 
protected quickly. Treatment of the crude 172 with (Boc)2O and Amberlyst-15 
catalyst gave 173 in 15 min (Scheme 36).  
 
4.6 Synthesis of 8-isoestradiol derivative 
 
Equiline (174) was reduced with sodium borohydride in 89% yield to 175 (Scheme 
37). Both the hydroxyl groups of 175 were protected as benzyl ether (176). 
Hydroxylation at C-7 was carried out by hydroboration with borane dimethyl sulfide 
complex followed by oxidation with H2O2/NaOH (Scheme 30). The addition took 
place from the less hindered α face of 176, resulting in 3O,17O-dibenzyl-8α-estra-
1,3,5(10)-triene-3,7,17-triol (177). Stereochemical assignments were done from NMR 
spectra. H-8 peak was assigned from DQFCOSY spectra (figure 4). In DQFCOSY 
spectra H-7 has correlation with H-6 at 2 ppm, 2.7 ppm and another proton at 3.1 
ppm. Therefore the proton at 3.1 must be H-8. 3JH-7,H-6β  is 5.4 Hz, which indicates that 
H-7 has the β configuration. Also in NOESY spectra (figure 5) of 177 strong 
correlation between 7-H and 18-CH3, suggests that 7-H is situated at the β side and 7-
OH is at the α side. There was no correlation between 8-H and 18-CH3, therefore 8-H 
also has the α configuration.  
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Scheme 37. Reagents and conditions (a) NaBH4, EtOH, rt; (b) NaH, DMF, BnBr, 
THF, rt; (c) (i) BH3.Me2S, THF, (ii) aq. NaOH, H2O2; (d) NaH, DMF, Br(CH2)3CN (e) 
t-BuOK, Br(CH2)3CN, t-BuOH; (f) 40% aq. KOH, acrylonitrile, DCM, 18-crown-6; 
(g) Raney Ni, aq. NaOH, EtOH, reflux; (h) Pd(OH)2/C, H2, rt. 
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Etherification of 177 with 3-bromobutyronitrile to produce 178 failed. Addition of 
side chain was successfully carried out by the Michael reaction. Reaction of 
acrylonitrile with the 7-OH hydroxyl group of 177, gave 179. Reduction of the nitrile 
group as well as the removal of benzylic protecting groups of 179, can be carried out 
by hydrogenation in one step. Hydrogenation of 179 over Raney Ni was carried out in 
the presence of aq. NaOH solution. Hydrogenation of nitrile often results in secondary 
amine.140 Sodium hydroxide was added to avoid formation of secondary amine.141 
Although Raney nickel can cleave both phenolic and alcoholic benzylic ether,142 in 
this case 17-O protecting group did not cleave. A retro Michael reaction was occurred 
and the cyanopropyl linkage was cleaved resulting in 181. Reduction of 180 with 
palladium hydroxide and carbon under hydrogen atmosphere afforded 182 (Scheme 
37).  
 
4.7 Selective debenzylation 
 
During the reduction of 179 with Raney Ni/aq. NaOH the catalyst system showed 
selectivity to hydrogenolysis of the aryl benzyl ether only, the alkyl benzyl ether 
remaining intact. Intrigued by this unexpected result, chemoselectivity of Raney Ni in 
presence aq. NaOH was further investigated. First we thought the amine group 
resulting from reduction of nitrile is poisoning the catalyst. So similar conditions were 
applied to 3O,17O-dibenzylestradiol (183), which resembles 179 but does not 
posseses a nitrile functionality (Scheme 38). In this case also the benzyl protecting 
group on alkyl hydroxy retained. So effect of amine was ruled out. 
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Scheme 38.  
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Then the second factor is aq. NaOH. To understand the effect of the NaOH solution, 
183 was subjected to reduction with Raney Ni varying the quantity of NaOH solution. 
Results of the experiments are summarized in Table 4. In the absence of NaOH both 
the protecting groups were removed smoothly. With increasing amount of NaOH 
solution catalyst activity was decreasing. First upon addition of NaOH Raney Ni was 
unable to cleave aliphatic benzyl ether and with increase in volume of NaOH solution 
difficulty in removing aromatic benzyl ether too was encountered. Further increase in 
NaOH totally inhibited cleavage of both aliphatic and aromatic benzyl ether. 
Therefore fine tuning of Raney Ni/aq.NaOH solution ratio can decrease the catalytic 
activity to such an extent that it is able to hydrogenolyse the aryl benzyl ether only 
and not the alkyl one. In literature declined catalytic activity of Raney Ni by aq. KOH 
is reported for dechlorination reaction.143 Decreased catalytic activity is accounted for 
absorption of aq. KOH on the active sites of catalyst. Very recently selective 
hydrogenolysis of phenoxybenzyl in the presence of alkoxybenzyls is reported by 
poisoning catalyst with triethylamine.144 
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Table 4. Effect of NaOH on hydrogenolysis of estradiol dibenzyl ether with Raney Ni 
(10 mg of 183 in EtOH/THF, 200 mg of Raney Ni and 8% aq. NaOH was refluxed for 
5 hrs.) 
Volume of 8% 
aq. NaOH (ml)  
Equivalent 
(NaOH) 
Results† 
0  0 Both the protecting groups were removed Yield 
(84%) 
0.02  0.002 All the starting materials was consumed Mono 
protected estradiol (184) was produced Yield (79%) 
0.05 0.005 Mixture of starting material (183) and 
monoprotected estradiol (184) 
183: 184 (10:90) 
0.1 0.01 183: 184 (30:70) 
0.2 0.02 183: 184 (76:24) 
1 0.1 No reaction 
 
This method of selective debenzylation was applied to various substrates (primary, 
secondary, phenolic and naphtholic benzyl ether) and relative stability of the benzyl 
protection was studied. The results are summarised in Table 5. Benzyl protection was 
done by literature method, deprotonating with NaH followed by reaction with benzyl 
bromide.145 188 was prepared from 4-(6-methoxy-2-naphthyl)-2-butanone 
(Nabumetone, 187). Excess of L-selectride in refluxing THF reduces the ketone as 
well as removes the O-methyl group in one step (Scheme 39).146  
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Scheme 39. Reagents and conditions (a) L-selectride, THF, reflux; (b) NaH, BnBr. 
                                                
† Ratio of the product was calculated from NMR 
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In all compounds the aliphatic benzyl ether showed considerably high resistance 
towards hydrogenolysis. Secondary alcohol 183 gave 79% of mono benzylated 
compound (184). Primary alcohol 185 also showed similar selectivity. When the aryl 
group is naphthyl then also the alkyl benzyl ether showed quite good stability. Two 
products 190 and 191 were obtained with intact benzyl group. Major product 190 is 
the desired mono protected naphthyl compound, in 191 one of the aromatic rings was 
hydrogenated. Partial hydrogenation of naphthyl group by RaneyNi/aq. alkali is a 
known phenomenon,147 but it is notable that although one of the naphthyl rings was 
reduced, benzyl group was not cleaved. Small amount of deoxygenated product (192) 
was also obtained. One experiment was carried out with substrate containing no 
aromatic benzyl ether (entry 5). Reduction of 193 with BH3.Me2S afforded 194 
(Scheme 40).148 Spectral data of 194 was consistent with the literature values.149 
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Scheme 40. Reagents and conditions (a) BH3.Me2S,  (b) NaH, BnBr 
Subsequent benzylation of 194 produces 195. No debenzylation happened after 
refluxing for 5 hrs. Stability of the benzyl protecting group in this compound (195) 
shows that phenoxide ion has no role on the aforementioned selective debenzylation. 
This reaction also confirmed that dechlorination does not occur under this condition. 
Catalytic hydrogenolysis offers the mildest method for deprotecting benzyl ethers, but 
there is no discrimination between benzyl protected alcohols vs. that of phenols. 
Llacer et al. found difficulties in concomitant removal of aliphatic and aromatic 
benzyl ethers from a Weinreb amide derivative with Raney nickel, but in this 
compound the stability of the aliphatic ether was attributed to the sterically hindered 
position of the ether.150 To our knowledge till date no systematic investigation was 
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carried out on the selective removal of aromatic benzyl ether in presence of aliphatic 
one by Raney Ni. 
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Table 5. Selective debenzylation of various benzylated compounds with Raney Ni/aq. 
NaOH 
 
Entry Substrate Products Yield 
1 
BnO
OBn
 
183 
HO
OBn
 
184 
 
79% 
2 
OBn
BnO
 
185 
OH
BnO
 
186 
 
81% 
3 BnO
OBn  
189 
HO
OBn  
190 
HO
OBn  
191 
HO
 
192 
 
58% 
 
 
 
 
 
7% 
 
 
 
 
 
 
8% 
4 
Cl
BnO
 
195 
No reaction after 5 hrs 100% starting 
material 
recovered. 
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4.8 Synthesis of steroid fatty acid esters 
 
In the human body estradiol is found esterified exclusively at the 17-OH of the steroid 
nucleus. Previously151 in our laboratory the 17β-monoesters were synthesized in two 
steps, by way of the diester followed by selective saponification. We have now 
developed a one-pot method for the synthesis of estradiol 17β-monoesters: the diester 
prepared in ionic liquid is mixed in situ with KOH and toluene and the mixture 
microwave irradiated (Scheme 41).152 Estradiol-17β-oleate (196), estradiol-17β-
linoleate (197), Estradiol-17β-stearate (198) and estradiol-17β-palmitate (199), were 
synthesized in a microwave reactor using neutral IL (Table 6). 
 
HO
OH
HO
O
O
R
a
2
196  R = CH3 (CH2)7CH=CH(CH2)7-cis
197  R = CH3 (CH2)3(CH2CH=CH)2(CH2)7-cis,cis
198  R = CH3 (CH2)16
199  R = CH3(CH2)14  
Scheme 41. Reagents and conditions (a) i. Py, DMAP, fatty acid chloride, [bmim]Cl 
or [bmim]Br, MW, 40 oC; ii. KOH, toluene, MW, 80 oC. 
Table 6. One pot synthesis of estradiol 17β-monoesters: esterification followed by 
KOH hydrolysis in IL in situ. 
Product (%Yield) Substrate 
in situ reaction in [bmim]Br and MW irradiation 1+1 min. 
Estradiol 2 Estradiol 17β-monooleate 196 (88%) 
Estradiol 17β-monolinoleate 197 (87%) 
Estradiol 17β-monostearate 198 (86%) 
Estradiol 17β-palmitate 199 (91%) 
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The entire sequence requires only two minutes. In the absence of toluene the reaction 
is slower. When the synthesis of estradiol 17β-monoester was performed without 
ionic liquid keeping other conditions the same, only the corresponding diesters (200, 
201, 202, 203) were isolated and no estradiol-17β monoesters were formed. Thus in 
the selective hydrolysis of a diester, toluene and IL are needed to dissolve the diester. 
Here the IL may act as a phase transfer agent as well as heat transfer medium. The use 
of ionic liquids as a phase transfer catalyst (PTC) has been studied before. Nuno et al. 
reported that 1-n-butyl-3-methylimidazolium hexafluorophosphate [Bmin][PF6] for 
several nucleophilic substitution reactions.153 Imidazolium based ionic liquids are not 
effective PTC for etherification reaction of 1-octanol with chlorobutane.154 Yadav et 
al. used phosphonium-based IL for etherification of 2-napthol with benzyl chloride.155 
Specially designed, tert- alcohol functionalized imidazolium IL are more effective 
PTC than common imidazolium based IL for several nucleophilic substitution 
reaction.156 This is the first time saponification reactions are carried out where IL act 
as PTC and we found that imidazolium based ionic liquids are effective PTC for 
saponification of phenyl fatty acid esters. The high yield, short reaction time and 
elimination of the diester isolation step make this reaction much more efficient than a 
conventional synthesis or a microwave synthesis without IL. In the absence of IL, the 
formation of estradiol dilinoleate, using 4-(N,N-dimethylamino)pyridine (DMAP), 
pyridine and MW irradiation takes longer time.151 Similarly, the selective hydrolysis 
at C-17 of estradiol FAE, using KOH, t-BuOH and MW irradiation requires a 60 min. 
reaction time.  
The oleate and linoleate esters of DHEA (105), 5α-androstane-3β,17β-diol (206) and 
testosterone (209) are available in a short reaction time (1 min.) in very good yields 
by irradiating a mixture of the steroid, fatty acid chloride, pyridine, DMAP, and IL in 
a closed vial ( Scheme 42, Table 7.).  
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204  R = CH3 (CH2)7CH=CH(CH2)7-cis
205  R = CH3 (CH2)3(CH2CH=CH)2(CH2)7-cis,cis
Py, DMAP, Fatty acid chloride
HO
O
O
O
O
R
105
 
Scheme 42 Reagents and conditions (a) Py, DMAP, fatty acid chloride, [bmin]Br, 
MW, 40 oC 
 
Table 7. Synthesis of fatty acid esters of steroids in IL/MW.  
Entry Substrate Product Yield 
(%) 
1 Estradiol (2) Estradiol dioleate (200) 
Estradiol dilinoleate (201) 
Estradioldistearate (202) 
Estradiol dipalmitate (203) 
89% 
92% 
90% 
91% 
2 Dehydroepiandrosterone (105)  5−Androsten−3β−ol-17−one oleate (204) 
 5−Androsten−3β−ol-17−one linoleate (205) 
85% 
92% 
3 5α-androstane-3β,17β-diol 
(206) 
 5α−Androstane−3β,17β-diol dioleate (207) 
 5α−Androstane−3β,17β-diol dilinoleate 
(208) 
85% 
74% 
4 Testosterone (209)  4−Androsten−17β−ol–3−one oleate (210) 
 4−Androsten−17β−ol–3−one linoleate (211) 
83% 
79% 
 
At the end of the reaction IL forms a separate phase, allowing the separation and 
reuse of IL. Both [bmim]Cl and [bmim]Br worked well. Many of the steroid fatty acid 
mono esters are known as hormonal constituents but have not been previously 
reported as synthetic products in the literature, or in the few instances where synthetic 
work has been carried out, no information on yields is given. Quite often reaction 
times are from a few hours up to 20 hours.  
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Using this methodology [3H] labeled estradiol 17β-oleate, DHEA oleate, DHEA 
linoleate and testosterone linoleate were synthesized in µg scale from the [3H] labeled 
steroid.157 Since esterification and selective saponification were both done in the same 
reaction vessel no significant loss of the costly [3H] labelled materials occurs. This 
methodology is very effective for synthesis with isotopically labeled materials, where 
cost of the materials compels one to run the reactions on a small scale. 
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5. CONCLUSION 
 
Estradiol and estriol haptens containing an alkyl or alkoxy side chain at C-7 were 
prepared. None of these compounds have been reported before. Both of the side 
chains terminating with amino group are suitable for coupling with a protein through 
amide linkage. The site of coupling (C-7) is away from the characteristic functional 
group 3-OH, 16-OH and 17-OH and almost equidistant from them. The length of the 
side chain is also optimal (4 or 5 spacer atoms between the steroid and the amino 
functionality). Therefore these derivatives are expected to act as haptens with good 
specificity. 
Long chain fatty acid esters of estrogens and androgens are synthesized in ionic liquid 
under microwave irradiation. Some of these esters are previously not reported as 
synthetic products. An efficient rapid one pot procedure was developed for synthesis 
of C-17 fatty acid esters of estradiol. IL/MW give excellent rate enhancement of both 
the esterification reaction as well as the regioselective saponification reaction. Using 
this methodology tritium labeled steroids were also esterified. With these compounds 
biological effect of these esters were investigated by our collaborator. 
New 8-isoestradiol derivatives, 7-hydroxy-8-isoestradiol and its aminopropyl ether 
were synthesized. The 7-hydroxy-8-isoestradiol derivative was synthesized from 
equiline.  
A new mild and easy method was developed for selective removal of benzylic 
protecting group on phenol with Raney nickel in presence of aq. NaOH solution 
without affecting the benzylic protecting group on aliphatic OH. 
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6. EXPERIMENTAL 
 
6.1 General methods 
 
1H and 13C NMR spectra were recorded on a Varian Inova 300 MHz spectrometer. 
Mass spectra were obtained with a JEOL JMS SX102, JEOL JMS 700 and Mariner 
ESI TOF 5114 mass spectrometer. Reactions under microwave irradiation were 
carried out in CEM Discover instrument. Low temperature microwave reactions were 
performed in CEM Discover Coolmate. Chemicals were obtained from commercial 
sources and used without further purification. 1-Butyl-3-methylimidazolium chloride 
and 1-butyl-3-methylimidazolium bromide were prepared in our laboratory. Acetone 
was dried over K2CO3 overnight then distilled. Dichloromethane and 
diisopropylamine (DIPA) was dried over CaH2 then distilled. THF was refluxed with 
sodium/benzophenone and then distilled. DMF and DMSO were dried over CaH2 then 
distilled under low pressure onto molecular sieves (3Å and 4Å respectively). Diethyl 
ether was dried on sodium and then distilled. Pyridine was dried over sodium 
hydroxide pellets. Concentration of n-BuLi was determined by literature procedure.158 
Reactions were monitored by TLC (Merck silica gel 60 F254 plates) and visualized 
with UV light or with a mixture of vanillin and sulfuric acid in ethanol. Column 
chromatography was performed on silica gel 60 and with Biotage SP4 system.  
 
6.2 Synthesis of estriol 
  
6.2.1 Synthesis of 3-acetoxyestra-1,3,5(10)16-tetraene-17-one (111) 
 
Compound 111 was synthesized by literature method and the 1H NMR data is 
consistent with literature data.159 13C NMR (CDCl3) δ: 220.97 (C-17), 170.02 
(COCH3), 148.79 (C-3), 138.22 (C-10), 137.60 (C-5), 126.61 (C-1), 121.61 (C-4), 
118.96 (C-2), 50.65 (C-14), 48.14 (C-13), 44.35 (C-9), 38.20 (C-8), 36.05 (C-16), 
31.75 (C-12), 29.58 (C-6), 26.53 (C-7), 25.94 (C-11), 21.78 (C-15), 21.31 (CH3CO), 
14.02 (C-18). 
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6.2.2 Synthesis of 3,17β-diacetoxyestra-1,3,5(10)16-tetraene (114) 
 
A mixture of 400 mg (0.37 mmol) of estrone (1) in 10 ml of isopropenyl acetate and 
0.2 ml of a catalytic solution (prepared by mixing 0.5 ml of isopropenyl acetate and 
0.01 ml of conc. sulfuric acid) was refluxed for 1.5 h. Some solvent was distilled over 
a period of 3.5 h. Fresh solvent was added from time to time. Then the solution was 
cooled and EtOAc was added. The EtOAc solution was washed with ice cold 
saturated sodium bicarbonate solution and dried over anhydrous Na2SO4. Solvent was 
removed under reduced pressure. The residue was purified on a column of silica gel 
using n-hexane/EtOAc (8:1) eluent to yield 409 mg (78%) of 3,17β diacetoxyestra-
1,3,5(10)16tetraene (114) as a white solid. 1H NMR (CDCl3) δ: 7.27 (d, 1H, H-1, J= 
8.7 Hz), 6.84 (dd, 1H, H-2, J = 8.55 Hz, 2.55 Hz), 6.80 (d, 1H, H-4, J = 2.4 Hz), 5.52 
(q, 1H, H-16, J = 3.3 Hz, J = 1.8 Hz), 2.89 (m, 2H), 2.28 (s, 3H, OAc), 2.17(s, 3H, 
OAc), 0.92 (s, 3H, H-18). 13C NMR (CDCl3) δ: 170.03 (COCH3), 169.09 (COCH3), 
159.91 (C-17), 148.67 (C-3), 138.39 (C-5), 138.27 (C-10), 126.22 (C-1), 121.73 (C-
4), 118.75 (C-2), 111.42 (C-16), 53.62 (C-14), 45.24 (C-9), 44.76 (C-13), 36.69 (C-8), 
33.62 (C-12), 29.52 (C-15), 28.91 (C-6), 27.03 (C-7), 26.13 (C-11), 21.32 (CH3CO), 
15.77 (C-18). 
 
6.2.3 Synthesis of 16α ,17α-epoxy-estra-1,3,5(10)triene-3,17β-diol diacetate (116) 
 
m-CPBA (29 mg, 0.14 mmol, 85%) was added to a stirred mixture of 114 (40 mg, 
0.11 mmol) in DCM (3 ml) and aq. NaHCO3 (1 ml, 0.5 M) at 0 oC. After a few 
minutes ice bath was removed and the mixture stirred at room temperature for 2 h. 
Two phases were separated and the organic phase washed successively with 1 N 
NaOH and water and dried over Na2SO4. Removal of the solvent under low pressure 
produced 16α,17α-epoxy-estra-1,3,5(10)triene-3,17β-diol diacetate (116) in 94% 
yield (39 mg) as white solid. 1H NMR (CDCl3) δ: 7.25 (d, 1H, H-1, J = 8.1 Hz), 6.84 
(dd, 1H, H-2, J = 8.7 Hz, 2.4 Hz), 6.80 (d, 1H, H-4, J = 2.4 Hz), 3.91 (s, 1H, H-16), 
2.86 (m, 2H, H-6), 2.27 (s, 3H, OAc), 2.11 (s, 3H, OAc), 0.93 (s, 3H, H-18). 13C 
NMR (CDCl3) δ: 169.22 (COCH3), 168.35 (COCH3), 148.74 (C-3), 138.12 (C-5), 
137.88 (C-10), 126.36 (C-1), 121.73 (C-4), 118.85 (C-2), 90.4 (C-17), 60.03 (C-16), 
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45.94 (C-14), 44.60 (C-9), 43.31 (C-13), 36.85 (C-8), 31.60 (C-12), 29.49 (C-15), 
27.15 (C-6), 26.47 (C-7), 25.94 (C-11), 21.31(CH3CO), 14.88 (C-18). 
 
6.2.4 Reduction of 116 with LAH (normal addition) 
 
A solution of of 116 (20 mg, 0.05 mmol) in dry ether was added dropwise to a 
suspension of 27 mg (0.71 mmol) of LAH in dry ether under argon. After completion 
of the addition the mixture was refluxed for 1.5 h. Then the reaction mixture was 
cooled, poured into aq. HCl and extracted with ethyl acetate. TLC of the crude 
product showed many spots, difficult to separate. 
 
6.2.5 Reduction of 78 with LAH (inverse addition) 
 
A suspension of LAH (900 mg, 23.7 mmol) in dry ether was added dropwise from a 
dropping funnel to the solution of 116 (280 mg, 0.75 mmol) in dry ether (10 ml). 
After the addition was completed the reaction mixture was refluxed for 1 h. TLC 
showed the presence of two products. Therefore refluxing was continued for another 1 
h. but still two products were present. The crude product was subjected to acetylation 
with acetic anhydride and pyridine. The product was separated by flash 
chromatography but NMR showed that the product was actually a mixture of estriol 
triacetate and the triacetate of one of the isomer of estriol. These two isomers were 
inseparable in flash column. In 1H NMR 18-CH3, 16-H and 17-H peaks are 
accompanied with similar peaks of lower intensity, which indicates that another 
similar compound is present. 1H NMR (CDCl3) δ: 7.24 (peak overlapped with CHCl3 
peak), 6.84 – 8.79 (m, 3H), 5.42 (m), 5.21 (m, 1H, H-16), 5.09 (d, J = 5.6 Hz), 4.99 
(d, 1H, J = 5.7 Hz, H-17), 2.89 (m, 3H), 0.87 (s), 0.85 (s, 3H, 18-CH3). 
 
6.2.6 Synthesis of estriol (3) 
 
The compound 116 (1.05 g, 2.8 mmol) was dissolved in 1.5 ml of THF and cooled to 
-10 oC. A solution of 1.5 ml of 6 N H2SO4 in 2 ml of THF cooled at -10 oC was added 
dropwise. The mixture was warmed to 3 oC and stirred for 2 h. After that 3.5 ml of 
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MeOH and an aq. solution of NaOAc were added to the reaction mixture in order to 
keep the pH at 5-6.5. To this mixture 0.3 g (7.92 mmol) of NaBH4 in 2 ml of water 
was added and stirred for 4 h. Acetone was added dropwise to destroy excess reagent. 
After evaporation of solvent the solid obtained was filtered and washed several times 
with water. After drying in a desiccator, estriol (3) was obtained as white amorphous 
solid obtained in 74% yield (605 mg). Product was enough pure, TLC showed single 
spot, therefore it was not recrystallised. 1H NMR (acetone-d6) δ: 7.09 (d, 1H, H-1, J = 
8.4 Hz), 6.59 (dd, 1H, H-2, J = 8.4 Hz, 2.7 Hz), 6.52 (d, 1H, H-4, J = 2.4 Hz), 4.04 
(m, 1H, H-16), 3.79 (d, <1H, OH, J = 3.9 Hz), 3.69 (d, <1H, OH, J = 4.2 Hz), 3.47(d, 
1H, H-17), 2.76 (m, 2H, H-6), 2.27 (m, 1H, H-11), 2.16 (m, 1H, H-9), 1.90- 1.75 (m, 
3H, H-11, H-7, H- 15), 1.59 (dd, 1H, H-15), 1.55-1.27 (m, 5H, H-14, H-11, H-12, H-
7, H-8), 0.79 (s, 3H, H-18). 13C NMR (acetone-d6) δ: 156.54 (C-3), 139.04 (C-5), 
132.68 (C-10), 127.54 (C-1), 116.57 (C-4), 114.19 (C-2), 91.21 (C-17), 79.32 (C-16), 
49.33 (C-14), 45.51 (C-9), 45.30 (C-13), 40.16 (C-8), 38.43 (C-12), 35.61 (C-15), 
28.77 (C-7), 27.48 (C-11), 13.41 (C-18). MS m/z (relative intensity) 288 (100), 213 
(20), 201 (9), 172 (13), 160 (18), 146 (19), 133 (19), 107 (8).  
 
Figure 4. Partial NOESY spectrum of estriol (3). 
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6.3 Protection of estriol 
 
6.3.1 Attempted protection of estriol as triisopropylsilyl ether (117) with 
imidazole and TIPSCl  
 
200 mg (0.69 mmol) of estriol (3) and 117.44 mg (1.72 mmol) of imidazole was 
dissolved in 1 ml of dry DMF under argon. TIPSCl (0.4 ml, 1.66 mmol) was added 
and the reaction mixture which was stirred at rt for 24 h. Then water was added to the 
reaction mixture and extracted with EtOAc. The organic phase was washed 
successively with water, dil. HCl, NaHCO3 solution and brine. After drying over 
Na2SO4 solvent was removed under low pressure. Flash chromatography of the 
residue with n-hexane/EtOAc provided 387 mg (93%) of diprotected estriol. 1H NMR 
(CDCl3) δ: 7.07 (d, 1H, H-1, J = 8.4 Hz), 6.63 (dd, 1H, H-2, J = 8.1 Hz, 2.1 Hz), 6.58 
(d, 1H, H-4, J = 2 Hz), 4.19 (m, 1H, H-16), 3.58 (m, 1H, H-17), 2.77 (m, 2H, H-6), 
2.27 (m, 2H), 1.89 (m, 4H), 1.61 (m, 4H), 1.09 (d, 36H, (SiCH(CH3)2), J= 6.6 Hz), 
0.78 (s, 3H, H-18). 13C NMR (CDCl3) δ: 153.96 (C-3), 137.91 (C-5), 132.91 (C-10), 
126.12 (C-1), 119.94 (C-4), 117.14 (C-2), 90.76 (C-17), 79.45 (C-16), 47.90 (C-14), 
44.13 (C-9), 43.67 (C-13), 38.54 (C-8), 36.85 (C-12), 35.30 (C-15), 29.78 (C-6), 
27.52 (C-7), 26.04 (C-11), 18.21 (Si(CHMe2)3), 12.94 (C-18), 12.58, 12.43 
(SiCH(CH3)2). MS m/z 600 (M+). 
 
6.3.2 Protection of estriol as tert-butyl ether (118) with isobutylene and 
Amberlyst-15 
 
200 mg (0.69 mmol) of estriol (3) and 60 mg of Amberlyst-15 was taken in 15 ml of 
dry dichloromethane under argon and cooled to -78 oC and 3.5 g (62 mmol) of 
isobutylene gas was passed into the solution. During this time the volume of the 
solution increased. The mixture was stirred at room temperature for 3 days. Then the 
mixture was again cooled to -78 oC and 1.3 ml (0.109 mmol) of triethylamine was 
added to quench the reaction. This mixture was warmed to room temperature and 
filtered to remove the solid. After removal of the solvent under low pressure the 
residue was purified by flash column chromatography with 100:1 DCM/EtOAc to 
provide four products. 
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118 in 16% yield (51 mg white foam). 1H NMR (CDCl3) δ: 7.11 (d, 1H, H-1, J = 8.7 
Hz), 6.73 (dd, 1H, H-2, J = 8.1 Hz, 2.4 Hz), 6.66 (d, 1H, H-4, J = 2.4 Hz), 3.85 (m, 
1H, H-16), 3.45 (d, 1H, H-17, J = 6 Hz), 2.78 (m, 2H, H-6), 2.22 (m, 2H), 1.83 (m, 
2H), 1.30 (s, 9H, OCMe3), 1.19 (s, 9H, OCMe3), 1.17 (s, 9H, OCMe3), 0.77 (s, 3H, H-
18). 13C NMR (CDCl3) δ: 153.11 (C-3), 137.42 (C-5), 135.44 (C-10), 125.62 (C-1), 
124.39 (C-4), 121.45 (C-2), 87.62 (C-17), 78.16 (C-16), 73.64 (OCMe3), 73.12 
(OCMe3), 48.31 (C-14), 44.34 (C-9), 44.21 (C-13), 42.04 (C-8), 38.69 (C-12), 38 (C-
15), 34.41 (C-6), 29.91 (OCMe3), 29.08 (OCMe3), 29.02 (OCMe3), 27.24 (C-7), 
26.25 (C-11), 13.05 (C-18). 
119 in 5% yield (13.8 mg pale yellow sticky liquid). 1H NMR (CDCl3) δ: 7.10 (d, 1H, 
H-1, J = 8.4 Hz), 6.61 (d, 1H, H-2, J = 8.4 Hz), 6.53 (s, 1H, H-4), 3.87 (m, 1H, H-16), 
3.46 (d, 1H, H-17, J = 6.6 Hz), 2.75 (m, 2H, H-6), 1.19 (s, 18H, OCMe3), 0.76 (s, 3H, 
H-18). 13C NMR (CDCl3) δ: 153.66 (C-3), 138.34 (C-5), 132.77 (C-10), 126.51 (C-1), 
1115.61 (C-4), 113.05 (C-2), 87.59 (C-17), 78.26 (C-16), 73.91 (OCMe3), 73.224 
(OCMe3), 48.12 (C-14), 43.91 (C-9), 42 (C-13), 38.76 (C-8), 37.91 (C-12), 34.35 (C-
15), 29.89 (OCMe3, C-6), 28.98 (OCMe3), 27.11 (C-7), 26.35 C-11), 13.02 (C-18). 
 120 in 8% yield ( 22 mg pale yellow sticky liquid). 1H NMR (CDCl3) δ: 7.11 (d, 1H, 
H-1, J = 8.7 Hz), 6.72 (d, 1H, H-2, J = 7.8), 6.66 (s, 1H, H-4), 3.86 (m, 1H, H-16), 
3.54 (m, 1H, H-17), 2.78 (m, 2H, H-6), 1.30 (s, 9H, OCMe3), 1.19 (s, 9H, OCMe3), 
0.79 (s, 3H, H-18). 13C NMR (CDCl3) δ: 152.63 (C-3), 136.83 (C-5), 134.80 (C-10), 
125.14 (C-1), 123.9 (C-4), 121.01 (C-2), 87.73 (C-17), 77.82 (C-16), 73.19 (OCMe3), 
48.63 (C-14), 43.82 (C-9), 42.09 (C-13), 37.91 (C-8), 36.38 (C-12), 34.08 (C-15), 
29.33 (C-6), 28.60 (OCMe3), 28.42 (OCMe3), 26.91 (C-7), 25.49 (C-11), 11.95 (C-
18). 
121 in 1% yield (3.5 mg white solid) 1H NMR (CDCl3) δ: 7.18 (s, 1H, H-1), 6.73 (s, 
1H, H-4), 3.85 (m, 1H, H-16), 3.45 (d, 1H, H-17, J = 6 Hz), 2.76 (m, 2H, H-6), 2.24 
(m, 2H), 1.52 (s, 9H, Ar-CMe3), 1.34 (s, 9H, OCMe3), 1.19 (s, 9H, OCMe3), 1.17 (s, 
9H, OCMe3), 0.77 (s, 3H, H-18). 
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6.3.3 Synthesis of estra-1,3,5(10)-triene-3,16α ,17β-triol-3,16,17-
tris(methoxymethyl) ether (122) 
 
DIPEA (18 ml) was added to a suspension of 3 (2.42 g, 8.4 mmol) in dry THF at 0 oC. 
Then 4.8 ml (63.6 mmol) of MOMCl was added dropwise. After stirring at rt for 1 h 
the mixture was refluxed overnight, then cooled to rt, 90 ml of saturated aq. NH4Cl 
solution added and the mixture was extracted with EtOAc (150 ml x 3). Combined 
organic phases were washed with brine and dried over MgSO4. After removal of the 
solvent the residue was purified by flash column chromatography with 10:1 
DCM/EtOAc to provide 122 as pale yellow sticky liquid (3.02 g, 86%). 1H NMR 
(CDCl3) δ: 7.19 (d, 1H, H-1, J = 9 Hz), 6.82 (dd, 1H, H-2, J = 8.7 Hz, 2.7 Hz), 6.76 
(d, 1H, H-4, J = 2.7 Hz), 5.14 (s, 2H, OCH2O), 4.76 (ABq, 2H, OCH2O, Δν =  26.7 
Hz, J = -6.45 Hz), 4.68 (d, 2H, OCH2O, J = 0.9 Hz), 4.13 (m, 1H, H-16), 3.63 (d, 1H, 
H-17, J = 5.7 Hz), 3.47 (s, 3H, OCH3), 3.41 (s, 3H, OCH3), 3.39 (s, 3H, OCH3), 2.84 
(m, 2H, H-6), 2.27 (m, 2H), 1.97 (m, 1H), 1.84 (m, 1H), 1.7 2(m, 2H), 1.58-1.35 (m, 
5H), 0.82 (s, 3H, H-18). 13C NMR (CDCl3) δ: 155.32 (C-3), 138.19 (C-5), 133.97 (C-
10), 126.45 (C-1), 116.48 (C-4), 113.99 (C-2), 96.68 ( OCH2O), 96.1 (OCH2O), 94.71 
(OCH2O), 93.09 (C-17), 82.23 (C-16), 56.09 (OCH3), 55.78 (OCH2O), 55.62 
(OCH2O), 48.31 (C-14), 44.03 (C-9), 43.34 (C-13), 38.37 (C-8), 37.49 (C-12), 31.31 
(C-15), 29.87 (C-6), 27.32 (C-7), 26.15 (C-11), 13.41 (C-18).  
 
6.4 C-6 oxidation of estradiol 
 
6.4.1 Synthesis of estra-1,3,5(10)-triene-3,17β-diol diacetate (123) 
 
Compound 123 was prepared by literature method and 1H NMR data are consistent 
with those described in literature.124 13C NMR data are given below. 
13C NMR (CDCl3) δ: 171.38 (COCH3), 170.02 (COCH3), 148.65 (C-3), 138.37 (C-
10), 138.07 (C-5), 126.61 (C-1), 121.7 (C-4), 118.78 (C-2), 82.86 (C-17), 50.04 (C-
14), 44.19 (C-9), 43.07 (C-13), 38.41 (C-8), 37.07 (C-12), 29.69 (C-6), 27.76 (C-16), 
27.22 (C-7), 26.22 (C-11), 23.46 (C-15), 21.32 (COCH3), 12.24 (C-18). 
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6.4.2 Synthesis of 6-oxo-estra-1,3,5(10)-triene-3,17β-diol diacetate (124) 
(oxidation with CrO3/ 3,5-dimethyl pyrazole) 
 
To a stirred mixture of CrO3 (599 mg, 5.99 mmol) in dichloromethane (8 ml) at -30 
oC was added 3,5-dimethylpyrazole (570 mg, 5.93 mmol). After 15 min, a solution of 
86 mg (0.24 mmol) of estradiol diacetate (123) in DCM was added to the stirred 
complex and stirring continued for 3 h keeping the temperature -20 oC to -30 oC. Then 
5 ml of aq. NaOH solution (5 M) was added and stirred for a further 45 min at -5 oC 
to -10 oC. The dichloromethane layer was separated and the aqueous layer was 
extracted with DCM (10 ml x 3). The combined organic phases were washed 
successively with dil. HCl, NaHCO3 solution and brine and dried over MgSO4. 
Filtration and evaporation of the solvent gave a crude product, which was 
chromatographed on silica gel column with n-hex/EtOAc to afford 20 mg of 6-oxo 
estriol triacetate (124) (22% yield). 1H and 13C NMR data are consistent with those 
described in literature.42 
 
6.4.3 Synthesis of estra-1,3,5(10)-triene-3,17β-diol dibenzoate (125) 
 
To a solution of 100 mg (0.37 mmol) of estradiol (2) in of DCM (2 ml) and cooled 
down to 0 oC. Then benzoyl chloride (0.17 ml, 1.48 mmol) was added and the mixture 
stirred overnight at rt. Reaction was quenched with water and the two phase mixture 
was stirred for 45 min. The reaction mixture was extracted with DCM (5 ml x 3). 
Combined organic layers were washed successively with dil. HCl, NaHCO3 solution 
and brine. After drying over MgSO4, solvent was evaporated and residue was purified 
by flash column chromatography. 1H NMR (CDCl3) δ: 8.19- 6.9 (m, Ar-H), 4.97 (t, 
1H, H-17, J = 8.4 Hz), 2.9 (m, 2H), 2.31 (m, 3H), 0.98 (s, 3H, H-18). 13C NMR 
(CDCl3) δ: 166.76 (COPh), 165.65 (COPh), 148.96 (C-3), 138.45 (C-10), 138.11 (C-
5), 138.45-128.54 (COPh)), 126.7 (C-1), 121.84 (C-4), 118.92 (C-2), 83.41 (C-17), 
50.12 (C-14), 44.26 (C-9), 43.54 (C-13), 38.51 (C-8), 37.21 (C-12), 29.77 (C-6), 
27.99 (C-16), 27.29 (C-7), 26.31 (C-11), 23.64 (C-15), 12.56 (C-18). 
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6.4.4 Synthesis of 6-oxo-estra-1,3,5(10)-triene-3,17β-diol dibenzoate (126) 
(oxidation with K2S2O8/CuSO4.5H2O) 
 
CuSO4·5H2O (52.43 mg, 0.21 mmol) and K2S2O8 (170.3 mg, 0.63 mmol) were added 
to a suspension of 125 (100 mg, 0.21 mmol) in acetonitrile (7 ml) and water (7 ml). 
Reaction mixture was refluxed for 30 min and then water was added to quench the 
reaction, extracted with DCM (15 ml x 3). Combined organic fractions were 
successively washed with 5% sodium thiosulfate solution and brine and then dried. 
Purification of the crude product by column chromatography on silica gel afforded 7 
mg (yield 7%) of 126 as off white amorphous solid. 1H NMR (CDCl3) δ: 8.19- 7.41 
(m, Ar-H), 4.97 (t, 1H, H-17, J = 8.45 Hz), 2.8 (dd, 1H, H-7, J = -16.8 Hz, 3.3 Hz), 
2.6 (m, 1H), 2.39 (m, 1H), 2.19 (dd, 1H, H-7, J = -16.8 Hz, 3.3 Hz), 2.05 (m, 2H), 
0.99 (s, 3H, H-18). 13C NMR (CDCl3) δ: 197.03 (C-6), 166.7 (OCOPh), 166.5 
(OCOPh), 149.87 (C-3), 144.52 (C-5), 134.73 (C-10), 133.96 (C-1), 133.12 (C-4), 
130.78-127.35 (OCOPh), 120.33 (C-2), 80.87 (C-17), 50.04 (C-14), 44.19 (C-9), 
43.38 (C-7), 43.29 (C-13), 39.81 (C-8), 36.79 (C-12), 27.81 (C-16), 25.61 (C-11), 
23.35 (C-15), 12.39 (C-18). 
 
6.4.5 Synthesis of estra-1,3,5(10)-triene-3,17β-diol-3,17-di-tert-butyl ether (127)  
 
2.00 g (7.35 mmol) of estradiol (2) and 0.4 g of Amberlyst-15 were taken in 60 ml of 
dry dichloromethane under argon. The mixture was cooled to -78 oC and 20.9 g (373 
mmol) of isobutylene gas was passed into the solution. During this time the volume of 
the solution increased. Then the mixture was stirred at room temperature for 3 days. 
Then the mixture was again cooled to -78 oC and 8 ml (0.109 mmol) of triethylamine 
was added to quench the reaction. This mixture was warmed to room temperature and 
filtered to remove the catalyst. After removal of the solvent under low pressure the 
residue was purified by flash column chromatography with 9:1 n-hexane/EtOAc. Two 
compounds 127 (2.13 g, 76%) and 128 (253 mg, 9%) were obtained. 
127 white solid. 1H NMR (CDCl3) δ: 7.16 (d, 1H, H-1, J = 8.4 Hz), 6.75 (dd, 1H, H-2, 
J = 8.3 Hz, 2.5 Hz), 6.68 (d, 1H, H-4, J = 2.4 Hz), 3.45 (t, 1H, H-17, J = 8.25 Hz), 
2.81 (m, 2H, H-6), 2.3 (m, 1H), 2.17 (m, 1H), 2.23 (m, 1H), 1.91 (m, 3H), 1.39 (s, 
9H, OCMe3), 1.15 (s, 9H, OCMe3), 0.76 (s, 3H, H-18). 13C NMR (CDCl3) δ: 153.10 
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(C-3), 137.46 (C-5), 135.58 (C-10), 125.75 (C-1), 124.33 (C-4), 121.39 (C-2), 81.05 
(C-17), 79 (OCMe3), 72.34 (OCMe3), 50.33 (C-14), 44.5 (C-9), 42.98 (C-13), 38.82 
(C-8), 37.51 (C-12), 31.46 (C-15), 29.91 (OCMe3), 29.08 (OCMe3), 28.97 (C-6), 
27.52 (C-7) 26.47 (C-11), 23.73 (C-16), 11.85 (C-18). 
128 white solid. 1H NMR (CDCl3) δ: 7.19 (s, 1H, H-1), 6.38 (s, 1H, H-4), 3.45 (t, 1H, 
H-17, J = 8.1 Hz), 2.74 (m, 2H, H-6), 2.17 (m, 1H), 2.23 (m, 1H), 1.88 (m, 2H) 1.33 
(s, 9H, Ar-CMe3), 1.15 (s, 9H, OCMe3), 0.88 (s, 3H, H-18). 13C NMR (CDCl3) δ: 
152.09 (C-3), 135.6 133.46, 132.25 (C-5, C-10, C-2), 124.26 (C-1), 116.76 (C-4), 
81.2 (C-17), 72.54 (OCMe3), 50.25 (C-14), 44.63 (C-9), 42.96 (C-13), 39.08 (C-8), 
37.58 (C-12), 31.36 (C-15), 29.94 (CMe3), 29.08 (OCMe3), 29.19 (C-6), 27.45 (C-7), 
26.65 (C-11), 23.68 (C-16), 11.88 (C-18). 
 
6.4.6 Synthesis of 6-hydroxy-estra-1,3,5(10)-triene-3,17β-diol-3,17di-tert-butyl 
ether (130)  
 
n-Butyl lithium (1.2 M solution in THF, 13 ml, 15.6 mmol) was taken in a dry two 
neck fask and cooled to -78 oC. DIPA (2.18 ml, 15.6 mmol) was added to it followed 
by 15.6 ml (15.6 mmol) of t-BuOK solution (1M in THF). After 15 min a solution of 
127 (497 mg, 3.9 mmol) in dry THF cooled at -78 oC was added to the flask. The 
solution was stirred at -78 oC for 3 h. Then 4 ml of B(OMe)3 was added and the 
mixture was warmed to 0 oC and stirred for 2 h. Then 20 ml of H2O2 (35% in water) 
was added and stirred vigorously with mechanical stirrer at rt for 1 h. After that water 
was added and the mixture was extracted with EtOAc (50 ml x 3). Combined organic 
phases were washed with soudium thiosulfate solution and brine. Purification by flash 
column chromatography with 10:1 DCM/n-hexane yielded 51% of 130 (off white 
solid). The product was enough pure TLC showed single spot, therefore it was not 
recrystalized and proceeded to next step. 1H NMR (CDCl3) δ: 7.17 (s, 1H, H-4), 7.15 
(d, 1H, H-1, J = 8.4 Hz), 6.82 (d, 1H, H-2, J = 8.7 Hz), 4.77 (m, 1H, H-6), 3.45 (t, 1H, 
H-17, J = 8.1 Hz), 2.25 (m, 3H), 1.95 (m, 3H), 1.66 (m, 2H), 1.34 (s, 9H, OCMe3), 
1.15 (s, 9H, OCMe3), 0.75 (s, 3H, H-18). 13C NMR (CDCl3) δ: 154 (C-3), 141 (C-5), 
135.33 (C-10), 125.78 (C-1), 123.25 (C-4), 122.6 (C-2), 80.91 (C-17), 78.2 (OCMe3), 
72.43 (OCMe3), 70.08 (C-6), 49.68 (C-14), 44.81 (C-9), 42.89 (C-13), 38.39 (C-8), 
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38.18 (C-7), 37.35 (C-12), 31.35 (C-15), 29.06 (OCMe3), 28.96 (OCMe3), 26.37 (C-
11), 23.67 (C-16), 11.79 (C-18). 
 
6.4.7 Oxidation of 130 to 6-oxo-estra-1,3,5(10)-triene-3,17β-diol-3,17di-tert-butyl 
ether (129)  
 
PCC (400 mg, 1.84 mmol) was added to a solution of 130 (420 mg, 1.05 mmol) in 
DCM. Few drops of pyridine was added to maintain the pH between 5-6. After 
stirring at rt for 1.5 h the mixture was filtered through a short pad of silica. Filtrate 
was washed successively with NaHCO3 solution and brine, dried over MgSO4. After 
removal of solvent under low pressure crude was purified by flash column 
chromatography with 4:1 n-hexane/EtOAc to afford compound 129 in 87% yield (364 
mg) as white solid. The product was enough pure TLC showed single spot, therefore 
it was not recrystallised and preceded to next step. 1H NMR (CDCl3) δ:  7.67 (d, 1H, 
H-4, J = 2.4 Hz), 7.32 (d, 1H, H-1, J = 8.1 Hz), 7.14 (dd, 1H, H-2, J = 8.4 Hz, 2.7 Hz), 
3.47 (t, 1H, H-17, J =8.25 Hz), 2.76 (dd, 1H, H-7, J = -16.8 Hz, 3.1 Hz), 2.46 (m, 1H), 
2.35 (m, 1H), 2.19 (dd, 1H, H-7, J = 13.5 Hz, 16.8 Hz), 1.95 (m, 3H), 1.36 (s, 9H, 
OCMe3), 1.16 (s, 9H, OCMe3), 0.77 (s, 3H, H-18). 13C NMR (CDCl3) δ: 198.2 (C-6), 
154.15 (C-3), 142.37 (C-5), 133.33 (C-10), 129.84 (C-1), 126.19 (C-4), 121.65 (C-2), 
80.68 (C-17), 78.96 (OCMe3), 72.43 (OCMe3), 50.21 (C-14), 44.37 (C-9), 43.45 (C-
7), 42.79 (C-13), 40.12 (C-8), 36.94 (C-12), 31.23 (C-15), 28.98 (OCMe3), 28.94 
(OCMe3), 25.68 (C-11), 23.45 (C-16), 11.68 (C-18). 
6.5 Oxidation of estriol 
 
6.5.1 Oxidation of 131 with PCC 
 
A finely powdered homogenized mixture of PCC (232 mg, 1.08 mmol) and Celite 
was added to a solution of 50 mg (0.12 mmol) of estriol triacetate (131) in benzene. 
The reaction mixture was stirred and refluxed for 24 h then diluted with ether and 
filtered through a short pad of Celite. The filtrate was dried over anhydrous MgSO4, 
solvent evaporated under reduced pressure and crude product purified on silica gel 
column with n-hexane/EtOAc to provide 26% (13 mg) of 132 as white solid. 1H NMR 
data are consistent with the reported.84  
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6.5.2 Oxidation of 131 with CrO3/3,5-dimethylpyrazole  
 
3,5-Dimethylpyrazole (570 mg, 5.93 mmol) was added to a stirred mixture of CrO3 
(599 mg, 5.99 mmol) in dichloromethane (8 ml) at -30 oC. After 15 min, a solution of 
100 mg (0.24 mmol) of 131 in DCM was added to the stirred complex and stirring 
continued for 3 h keeping the temperature at -20 oC to -30 oC. Then 5 ml of aq. NaOH 
solution (5 M) was added and stirred for a further 45 min at -5 oC to -10 oC. The 
dichloromethane layer was separated and the aqueous layer was extracted with DCM 
(10 ml x 3). The combined organic phases were washed successively with dil. HCl, 
NaHCO3 solution and brine and dried over MgSO4. Filtration and evaporation of the 
solvent gave a crude product, which was chromatographed on silica gel column to 
afford 132 in 23% yield (24 mg). 
 
6.5.3 Synthesis of 6-hydroxy-estra-1,3,5(10)-triene-3,16α ,17β-triol-3,16,17-
tris(methoxymethyl) ether (133) 
 
Diisopropylamine (3.07 ml, 22 mmol) was added to a stirred solution of n-BuLi (16.8 
ml, 1.3 M in THF, 22 mmol) maintained at -78 oC, immediately followed by KOt-Bu 
solution (22 ml, 1M in THF, 22 mmol). After 15 min a solution of 131 (2.3 g, 5.47 
mmol) in dry THF cooled at -78 oC was added. The resulting dark red solution was 
stirred at -78 oC for 3 h. Then the dry ice- acetone bath was replaced with ice-water 
bath and trimethylborate (8 ml) was added. After stirring at 0 oC for 2 h the stirring 
bar was removed and the flask was equipped with a mechanical stirrer. To the flask 
30% H2O2 (30 ml) was added and the reaction was vigorously stirred at rt overnight. 
The reaction mixture was cooled to 0 oC and 25% Na2S2O3 (100 ml) was added. The 
solution was stirred for 10 min and extracted with EtOAc (140 ml x 2). Combined 
organic phases were dried and solvent was removed. Crude was purified by flash 
chromatography with 1:1 DCM/EtOAc producing 133 as colorless sticky liquid 
(1.821 g, 76%). 1H NMR (CDCl3) δ: 7.25 (d, 1H, H-1, J = 2.1 Hz), 7.19 (d, 1H, H-4, J 
= 9 Hz), 6.91 (dd, 1H, H-2, J = 8.8 Hz, 2.5 Hz), 5.16 (ABq, 2H, OCH2O, Δν = 7.3 Hz 
J = -6.75 Hz), 4.75 (ABq, 2H, OCH2O, Δν = 27 Hz,  J = -6.45 Hz), 4.68 (s, 2H, 
OCH2O), 4.13 (m, 1H, H-16), 3.63 (d, 1H, H-17, J = 5.7 Hz), 3.47 (s, 3H, OCH3), 
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3.41 (s, 3H, OCH3), 3.39 (s, 3H, OCH3), 2.28 (m, 3H), 1.96 (m, 1H), 1.72 (m, 2H), 
1.62- 1.32 (m, 5H), 0.81 (s, 3H, H-18). 13C NMR (CDCl3) δ: 155.95 (C-3), 141.06 (C-
5), 133.64 (C-10), 126.5 (C-1), 115.87 (C-4), 114.85 (C-2), 96.71 (OCH2O), 96.17 
(OCH2O), 94.72 (OCH2O), 92.98 (C-17), 82.16 (C-16), 70.03 (C-6), 56.19 (OCH3), 
55.82 (OCH2O), 55.64 (OCH2O), 47.70 (C-14), 44.4 (C-9), 43.24 (C-13), 38.23 (C-
8), 37.69 (C-7), 37.35 (C-12), 31.28 (C-15), 26.09 (C-11), 13.02 (C-18). 
 
6.5.4 Synthesis of 6-oxo-estra-1,3,5(10)-triene-3,16α ,17β-triol-3,16,17-
tris(methoxymethyl) ether (134) 
 
Dry DMSO (0.38 ml, 4.9 mmol) was added slowly to the solution of oxalyl chloride 
(0.23 ml, 2.68 mmol) in dry DCM (12 ml) cooled in dry ice-acetone bath. After that 1 
g (2.29 mmol) of 133 dissolved in 12 ml of dry DCM was added dropwise. Internal 
temperature was always maintained below -55 oC. After 1 h triethylamine (1 ml) was 
added and stirred for 5 min. reaction mixture was allowed to warm at rt and 
partitioned between DCM and water. Aqueous phase was extracted with DCM (30 ml 
x 3), combined organic phases were washed with brine and dried over Na2SO4. After 
removal of the solvent under reduced pressure the residue was purified by column 
chromatography to provide 134 as colorless liquid in 95% yield (948 mg). 1H NMR 
(CDCl3) δ: 7.7 (d, 1H, H-1, J = 3 Hz), 7.34 (d, 1H, H-4, J = 9 Hz), 7.21 (dd, 1H, H-2, 
J = 8.6 Hz, 2.9 Hz), 5.2 (s, 2H, OCH2O), 4.77 (ABq, 2H, OCH2O, Δν =  27.4 Hz,  J = 
-6.3 Hz), 4.67 (s, 2H, OCH2O), 4.13 (m, 1H, H-16), 3.64 (d, 1H, H-17, J = 5.1 Hz), 
3.47 (s, 3H, OCH3), 3.41 (s, 3H, OCH3), 3.39 (s, 3H, OCH3), 2.72 (dd, 1H, H-7, J = -
17.1 Hz, 3.3 Hz), 2.52 (m, 1H), 2.36 (m, 1H), 2.24 (dd, 1H, H-7, J = -16.9 Hz, 13.3 
Hz), 2.04 (m, 1H), 1.93(m, 1H), 1.75-1.48 (m, 5H), 0.83 (s, 3H, H-18). 13C NMR 
(CDCl3) δ: 197.54 (C-6), 155.95 (C-3), 140.58 (C-5), 133.7 (C-10), 126.73 (C-1), 
122.69 (C-4), 113.84 (C-2), 96.76 (OCH2O), 96.21 (OCH2O), 94.65 (OCH2O), 92.85 
(C-17), 81.99 (C-16), 56.31 (OCH3), 55.84 (OCH2O), 55.69 (OCH2O), 48.19 (C-14), 
44.09 (C-9), 43.03 (C-13, C-7), 39.58 (C-8), 36.99 (C-12), 31.12 (C-15), 25.4 (C-11), 
12.92 (C-18). 
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6.6 Alkylation of estradiol 
  
6.6.1 Procedure for synthesis of 7-alkylated 6-oxo-estra-1,3,5(10)-triene-3,17β-
diol-3,17di-tert-butyl ether (145, 146, 147) 
 
Conventional method 
t-BuOK solution was added (1.24 ml, 1M in THF, 1.23 mmol) to a solution of 129 
(428 mg, 1.075 mmol) in dry THF (20 ml) at 0 oC. After stirring for 45 min the dark 
red coloured solution was cooled to -78 oC and a solution of 144 (685 mg, 3.27 mmol) 
in 5 ml of dry THF cooled at -78 oC was added. The mixture was allowed to warm at 
0 oC and stirred for 2 h. The reaction was quenched with water and extracted with 
EtOAc (20 ml x 3). The combined organic phase was dried over Na2SO4 and after 
removal of the solvent crude was purified by column chromatography with 50:1 
DCM/EtOAc.  
New method under microwave irradiation 
t-BuOK solution was added (0.3 ml, 1M, 0.3 mmol) to stirred solution of 129 (107 
mg, 0.27 mmol) in dry THF at 0 oC under argon. The mixture was microwave 
irradiated (power = 250 W) and temperature was maintained at 0 oC controlling the 
flow rate of cooling fluid. After 40 min without irradiation the reaction mixture was 
cooled to -68 oC and 5-iodopentanenitrile (144, 169 mg, 0.81 mmol) solution in 0.5 
ml of THF maintained at -78 oC was added. Then the temperature of the mixture was 
brought to 0 oC under microwave irradiation. The mixture was microwave irradiated 
(0 oC/250 W) for 2 h. Then water was added and extracted with EtOAc (8 ml x 3). 
The combined organic phases were dried over Na2SO4 and after removal of the 
solvent purified by column chromatography with 50:1 DCM/EtOAc. 
Both the procedure yielded same products, 7α-alkylated product (145), 7β-alkylated 
product (146) and doubly alkylated product (147) 
145 (colorless sticky liquid) 
1H NMR (CDCl3) δ: 7.63 (d, 1H, H-4, J = 2.4 Hz), 7.29 (d, 1H, H-1, J = 8.7 Hz), 7.14 
(dd, 1H, H-2, J = 8.4 Hz, 2.4 Hz), 3.49 (t, 1H, H-17, J = 8.25 Hz), 2.46 (m, 1H), 2.36 
(m, 1H), 2.31 (t, 2H, J = 7.05 Hz), 2.3 (m, 1H), 1.95 (m, 2H), 1.36 (s, 9H, OCMe3), 
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1.16 (s, 9H, OCMe3), 0.76 (s, 3H, H-18). 13C NMR (CDCl3) δ: 200.69 (C-6), 154.28 
(C-3), 141.2 (C-5), 131.87 (C-10), 129.76 (C-1), 126.8 (C-4), 122.07 (C-2), 119.77 
(CN), 80.7 (C-17), 78.97 (OCMe3), 72.51 (OCMe3), 48.39 (C-14), 45.41 (C-9), 42.97 
(C-13), 42.39 (C-7), 37.71 (C-8), 37.13 (C-12), 31.11 (C-15), 28.99, 28.92, 26.72 (C-
1´, C-2´, COMe3), 25.60 (C-11), 23.13 (C-16), 22.88 (C-3´), 17.25 (C-4´), 11.60 (C-
18). MS m/z (relative intensity) 479 M+ (0.5), 464 (5), 423 (13), 367 (100). 
146 white solid. 1H NMR (CDCl3) δ: 7.42 (d, 1H, H-4, J = 2.4 Hz), 7.28 (d, 1H, H-1, 
J = 8.6 Hz), 7.14 (dd, 1H, H-2, J = 8.4 Hz, 2.4 Hz), 3.43 (t, 1H, H-17, J = 7.5 Hz), 
2.32 (m, 4H), 1.95 (m, 3H), 1.79 (m, 3H), 1.62 (m, 6H), 1.35 (s, 9H, OCMe3), 1.16 (s, 
9H, OCMe3), 0.80 (s, 3H, H-18). 13C NMR (CDCl3) δ: 202.3 (C-6), 154.32 (C-3), 
141.04 (C-5), 134.52 (C-10), 129.46 (C-1), 125.27 (C-4), 121.27 (C-2), 119.82 (CN), 
80.26 (C-17), 79.05 (OCMe3), 72.58 (OCMe3), 52.81 (C-14), 51.5 (C-9), 43.84 (C-
13), 41.35 (C-7, C-8), 36.86 (C-12), 31.37 (C-15), 28.99 (COCH3), 31.26, 26.18, 
26.09, 25.91, 25.37 (C-1´, C-2´, C-3´, C-11, C-16), 17.16 (C-4´), 11.99 (C-18). 
147 sticky solid. 1H NMR (CDCl3) δ: 7.6 (d, 1H, H-4, J= 2.4 Hz), 7.38 (d, 1H, H-1, J 
= 8.6 Hz), 7.17 (dd, 1H, H-2, J = 8.4 Hz, 2.4 Hz), 3.43 (m, 1H, H-17), 2.31 (m, 3H) 
2.26 (t, 4H), 1.36 (s, 9H, OCMe3), 1.16 (s, 9H, OCMe3), 0.85 (s, 3H, H-18). 13C 
NMR (CDCl3) δ: 202.3 (C-6), 154.34 (C-3), 140.42 (C-5), 132 (C-10), 130.10 (C-1), 
126.9 (C-4), 121.82 (C-2), 119.86 (CN), 80.33 (C-17), 79.05 (OCMe3), 72.58 
(OCMe3), 52.31 (C-14), 46.85 (C-9), 44.39 (C-13), 42.01, 38.94, 37.64, 33.77, 32, 
31.15, 29.02, 27.76, 26.47,26.38, 24.74, 23.83, 17.22 (C-4´), 11.96 (C-18). MS m/z 
(relative intensity) 560 (M+, 0.5), 545 (4), 504 (8), 448 (60), 367 (100).  
 
6.6.2 Reduction of 145 with LAH/AlCl3 
 
A slurry of LAH (39 mg, 1.03 mmol) in diethyl ether was added to the slurry of 
aluminium chloride (136 mg, 1.02 mmol) in dry ether at 0 oC. After stirring for 15 
min mixture of 49 mg (0.102 mmol) of 145 and 14 mg (0.105 mmol) of AlCl3 in dry 
ether was added to it and stirred at rt for 2 h. then water was added to quench the 
reaction. Then 5 N aq. NaOH solution was added and stirred for 2 h. Aqueous phase 
was extracted with EtOAc (8 ml x 3). Combined organic phases were dried over 
Na2SO4 and solvent was removed under low pressure. Purification of the crude by 
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reverse phase column chromatography with acetonitrile/water provided four products 
in very low yield, which could not be identified. 
NMR of the crude 1H NMR (CDCl3) δ: 7.06 (s, 1H, H-4), 7 (d, 1H, H-1, J = 8.1 Hz), 
6.59 (d, 1H, H-2, J = 8.1 Hz), 4.8 (m, 1H, H-6), 3.44 (m, 1H, H-17), 2.65 (m, 2H), 
1.15 (s, 9H, OCMe3), 0.72 (s, 3H, H-18). 13C NMR (CDCl3) δ: 155.67 (C-3), 140.05 
(C-5), 130.63 (C-10), 127.07 (C-1), 115.08, 113.81 (C-4, C-2), 81.03 (C-17), 74.02 
(OCMe3), 72.47 (C-6), 46.36 (C-14), 43.10 (C-13), 41.38 (C-9), 40.41 (C-7), 38.75 
(C-8), 37.52 (C-12), 31.32 (C-15), 30.42, 29.89, 28.99 (OCMe3), 27.52, 27.03 (C-11), 
23.75 (C-16), 23.10, 11.88 (C-18). 
 
6.6.3 Reduction of 145 to 148 with LAH  
 
A solution of 20 mg (0.04 mmol) of 145 in dry ether was added slowly to the 
suspension of LAH (37.95 mg. 0.4 mmol) in diethylether at 0 oC under argon. The 
mixture was stirred at rt for 2.5 h. Then the reaction was quenched with aqueous 
NaHCO3 solution. Aqueous phase was extracted 3 times with EtOAc. Combined 
organic phases were dried over Na2SO4. After removal of solvent 13 mg (64%) of 148 
was obtained. 1H NMR (acetone-d6) δ: 7.30 (d, 1H, H-4, J = 2.7 Hz), 7.15 (d, 1H, H-
1, J = 8.4 Hz), 6.77 (dd, 1H, H-2, J = 8.5 Hz, 2.5 Hz), 4.86 (d, 1H, H-6, J = 5.4 Hz), 
3.56 (m, 1H, H-17), 3.16 (t, 2H, CH2NH2, J = 7.05 Hz) 2.39 (m, 1H), 1.31 (s, 9H, 
OCMe3), 1.15 (s, 9H, OCMe3), 0.77 (s, 3H, H-18). 13C NMR (acetone-d6) δ: 155.14 
(C-3), 142.16 (C-5), 135.40 (C-10), 127.16 (C-1), 123.49, 123.28 (C-4, C-2), 82.01 
(C-17), 78.50 (OCMe3), 74.45 (C-6), 73.21 (OCMe3), 52.22, 47.54 (C-14), 44.35 (C-
13), 42.85 (C-9), 42.33 (C-7), 40.54 (C-8), 38.72 (C-12), 32.52 (C-15), 32.27, 31.99, 
29.88, 29.68, 28.62 (C-11), 24.86 (C-16), 24.53, 12.69 (C-18). MS m/z (relative 
intensity) 525 (14), 497 (10), 468 (22), 411 (28).  
 
6.6.4 Synthesis of 6-hydroxy-7-(4-cyanobutyl)-estra-1,3,5(10)-triene-3,17β-diol-
3,17di-tert-butoxy ether (149) 
 
Sodiumborohydride (34mg, 0.9 mmol) was added portion wise to the stirred solution 
of 145 (22 mg, 0.045 mmol) of  in methanol. After stirring at rt for 4 hr all the starting 
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materials was consumed. Methanol was evaporated under low pressure. The residue 
was partitioned between water and EtOAc. Aqueous fraction was extracted with ethyl 
acetate. Combined organics was dried over magnesium sulfate. After removal of 
solvent crude was purified by flash column chromatography with 20:1 DCM/EtOAc 
to yield 13.1 mg (60%) of 149. 1H NMR (CDCl3) δ: 7.16 (overlapped multiplet, 2H), 
6.82 (d, 1H, H-1, J= 8.7 Hz), 4.77 (m, 1H, H-6), 3.45 (t, 1H, H-17, J= 8.1 Hz), 2.24 
(m, 3H), 1.91 (m, 3H), 1.34 (s, 9H, OCMe3), 1.16 (s, 9H, OCMe3) 0.75 (s, 3H, H-18). 
13C NMR (CDCl3) δ: 154.05 (C-3), 139.46 (C-5), 134.32 (C-10), 126.36 (C-1), 
122.79, 121.80 (C-4, C-2), 120 (CN), 80.90 (C-17), 78.31 (OCMe3), 74.07 (C-6), 72.5 
(OCMe3), 46.43 (C-14), 43.21 (C-13), 41.23 (C-9), 40.85 (C-7), 39.02 (C-8), 37.50 
(C-12), 31.29 (C-15), 30.38 (C-1´), 29.15 (OCMe3), 28.98 (OCMe3), 27.34 (C-2´), 
26.31 (C-11), 23.75 (C-16), 22.67 (C-3´), 17.24 (C-4´), 11.86 (C-18). MS m/z 
(relative intensity) 481 (M+, 8), 466 (3), 425 (100), 369 (30), 351 (76), 332 (44), 307 
(25), 269 (39), 238 (50). 
 
6.6.5 Reduction of 149 with Pd(OH)2/C 
 
In an autoclave 11 mg of 10% Pd(OH)2/C was added to a solution of 149 (11 mg, 0.02 
mmol) in ethanol (5 ml). The mixture was stirred at 60 oC under 3 bar pressure of 
hydrogen for 24 h. The mixture was then diluted with ethanol and filtered through 
celite. Filtrate was evaporated under reduced pressure and residue was analyzed by 
NMR. 1H NMR (acetone-d6) δ: 7.29 (d, 1H, H-4, J = 2.1 Hz), 7.15 (d, 1H, H-1, J = 
8.1 Hz), 6.77 (dd, 1H, H-2, J = 8.5 Hz, 2.5 Hz), 4.86 (d, 1H, H-6, J = 4.8 Hz), 3.57 
(m, 1H, H-17), 1.31 (s, 9H, OCMe3), 1.15 (s, 9H, OCMe3), 0.77 (s, 3H, H-18). 13C 
NMR (acetone-d6) δ: 155.2 (C-3), 142.16 (C-5), 135.44 (C-10), 127.21 (C-1), 123.52, 
123.32 (C-4, C-2), 82.06 (C-17), 78.54 (OCMe3), 74.55 (C-6), 73.25 (OCMe3), 54.30, 
48.31 (C-14), 44.39 (C-13), 42.90 (C-9), 42.46 (C-7), 40.59 (C-8), 38.76 (C-12), 
32.56 (C-15), 32.33 (C-1´), 28.66, 24.89, 24.59, 23.93, 12.72 (C-18). 
 
 87 
6.6.6 Synthesis of 7-(4-cyanobutyl)-estra-1,3,5(10)-triene-3,17β-diol (151) 
 
Triethyl silane was added to a solution of 145 (145 mg, 0.30 mmol) in 3 ml of dry 
CH2Cl2. The solution was cooled to 0 oC and 6 ml of BF3.Et2O was added dropwise. 
The yellow mixture was stirred at room temperature overnight. After quenching the 
reaction with 20% aq. K2CO3 solution (20 ml), the mixture was extracted with EtOAc 
(10 ml x 3). The combined organic phase was dried over Na2SO4. After removal of 
the solvent crude was purified by flash column chromatography with 1:1 
DCM/EtOAc to yield 151 as white foam like solid (83 mg, 78%). 1H NMR (CDCl3) 
δ: 7.15 (d, 1H, H-1, J = 8.1 Hz), 6.64 (dd, 1H, H-2, J = 8.4 Hz, 2.7 Hz), 6.54 (d, 1H, 
H-4, J = 2.4 Hz), 3.75 (t, 1H, H-17, J = 8.25 Hz), 2.90 (dd, 1H, H-6, J = 17.25 Hz, 5.5 
Hz), 2.69 (d, 1H, H-6, J = 16.5 Hz), 2.12 (m, 1H), 1.91 (m, 1H), 1.7 (m, 1H), 0.79 (s, 
3H, H-18). 13C NMR (CDCl3) δ: 153.68 (C-3), 136.83 (C-5), 131.92 (C-10), 127.39 
(C-1), 119.85 (CN), 116.35 (C-4), 113.24 (C-2), 82.16 (C-17), 46.7 (C-14), 43.65 (C-
13), 42.10 (C-9), 38.34 (C-8), 37.08 (C-12), 34.7 (C-15), 33.36 (C-1´), 30.76, 27.49, 
25.88 (C-11), 25.22, 22.9, 17.45 (C-4´) 11.29 (C-18). MS m/z (relative intensity) 353 
M+ (80), 335 (2), 294 (16), 367 (16), 157 (30). 
 
6.6.7 Synthesis of 7-(5-aminopentyl)-estra-1,3,5(10)-triene-3,17β-diol (152) 
 
Suspension of LAH (32 mg, 0.85 mmol) in dry ether was cooled at 0 oC and  a 
solution of 151 (30 mg, 0.85 mmol) was added to it. The mixture was stirred at rt for 
2.5 h. then aq. NaHCO3 solution (25 ml) was added and extracted with EtOAc (40 ml 
x 3). Combined organic phase was dried over Na2SO4. Removal of the solvent at 
reduced pressure afforded 152 as off white sticky solid in 92% yield (28 mg) which 
turns to brown oil on standing at rt. 1H NMR (acetone-d6) δ: 7.10 (d, 1H, H-1, J = 8.7 
Hz), 6.61 (dd, 1H, H-2, J = 8.6 Hz, 2.55 Hz), 6.55 (d, 1H, H-4, J = 2.4 Hz), 3.69 (t, 
1H, H-17, J = 8.4 Hz), 3.17 (t, 1H, CH2NH2, J = 6.9 Hz) 2.81 (m, 1H, H-6), 2.70 (d, 
1H, H-6, J = 16.2 Hz), 2.12 (m, 1H), 0.78 (s, 3H, H-18). 13C NMR (acetone-d6) δ: 
156.63 (C-3), 137.81 (C-5), 131.75 (C-10), 128.16 (C-1), 117.39 (C-2), 114.30 (C-4), 
82.33 (C-17), 52.23 (C-5´), 47.95 (C-14), 44.75 (C-13), 43.78 (C-9), 39.71 (C-7), 
38.55 (C-8), 35.97 (C-6), 34.77 (C-12), 32.14 (C-15), 31.55 (C-1´), 37.50 (C-12), 
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31.29 (C-15), 30.38 (C-1´), 29.34, 29.16, 28.86, 26.87, 23.95, 12.24 (C-18). MS m/z 
(relative intensity) 342 (21), 286 (100), 268 (10), 258 (12), 227 (20). 
 
6.7 Synthesis of 7-alkyl substituted estriol 
 
6.7.1 Synthesis of tert-butyl(3-hydroxypropyl)carbamate (138) 
 
(Boc)2O (3.3 g, 15 mmol) was added to a solution of 1.15 g (15.3 mmol) of 3-
aminopropanol (137) in acetonitrile followed by catalytic amount of ZrCl4 (350 mg, 
1.5 mmol). After stirring at rt for 20 min solvent was removed under reduced pressure 
and the mixture diluted with water, extracted with ethyl acetate. The combined 
organic layers were washed successively with water and brine, dried over Na2SO4 and 
evaporated under reduced pressure. Crude product was purified by column 
chromatography on silica gel to produce 1.95 g (73% yield) of 138. NMR of 138 was 
identical to that of literature.160 
 
6.7.2 Synthesis of 7-alkylated of 6-oxo-estra-1,3,5(10)-triene-3,16α ,17β-triol-
3,16,17-tris(methoxymethyl) ether (153, 154) 
 
t-BuOK (2.35 ml, 1M in THF, 2.35 mmol) was added to a solution of 133 (887 mg, 
2.04 mmol) in dry THF at 0 oC. After 45 min the dark red coloured solution was 
cooled to -78 oC and a solution of 144 (1.3 g, 6.22 mmol) in 5 ml of dry THF cooled 
at -78 oC was added. The mixture was allowed to warm at 0 oC and stirred for 2 h. 
After stirring overnight at rt water was added and the mixture was extracted with 
EtOAc (25 ml x 2). The combined organic phase was dried over Na2SO4 and after 
removal of the solvent purified by column chromatography with 2:3 n-hexane/EtOAc 
to give 490 mg (47%) of mono substituted product 153 and 211 mg (17%) of 
disubstituted product 154. The product 153 was a mixture of α and β isomer (α:β = 
84:16). For epimerisation the product 153 (490 mg, 96.6 mmol) was dissolved in 15 
ml of methanol and 10 mg of NaOMe was (0.19mmol) added. After refluxing for 3 
days α:β was 94:6.  
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153 1H NMR (CDCl3) δ: 7.67 (d, 1H, H-1, J = 2.7 Hz), 7.33 (d, 1H, H-4, J = 9 Hz), 
7.21 (dd, 1H, H-2, J = 8.6 Hz, 2.9 Hz), 5.20 (s, 2H, OCH2O), 4.76 (ABq, 2H, OCH2O, 
Δν = 25.64 Hz, J = -6.3 Hz), 4.69 (s, 2H), 4.13 (m, 1H, H-16), 3.65 (d, 1H, H-17, J = 
5.1 Hz), 3.48 (s, 3H, OCH3), 3.41 (s, 3H, OCH3), 3.40 (s, 3H, OCH3), 2.41 (m, 2H), 
2.30 (t, 2H, H-4´, J = 6.75 Hz), 2.03 (m, 2H), 1.88 (m, 1H), 0.82 (s, 3H, H-18). 13C 
NMR (CDCl3) δ: 200.08 (C-6), 156.12 (C-3), 139.59 (C-5), 132.27 (C-10), 127.37 
(C-1), 122.82 (C-4), 119.7 (CN), 114.4 (C-2), 96.8 (OCH2O), 96.29 (OCH2O), 94.69 
(OCH2O), 92.85 (C-17), 81.83 (C-16), 56.38 (OCH3), 55.86 (OCH2O), 55.71 
(OCH2O), 43.32 (C-13, 41.92 (C-7), 37.41 (C-8), 37.19 (C-12), 30.62 (C-15), 26.73 
(C-1´), 26.47 (C-2´), 25.66 (C-11), 23.22 (C-3´), 17.32 (C-4´), 12.92 (C-18). MS m/z 
(relative intensity) 515 (33), 484 (8), 440 (48), 409 (100), 394 (49), 328 (41).  
154 yellow sticky liquid (211 mg, 17%). 1H NMR (CDCl3) δ: 7.65 (d, 1H, H-1, J = 2.4 
Hz), 7.37 (d, 1H, H-4, J = 8.4 Hz), 7.21 (dd, 1H, H-2,  J= 8.7 Hz, 2.7 Hz), 5.19 (s, 2H, 
OCH2O), 4.83-4.7 (ABq and s overlapped, 4H, OCH2O), 4.10 (m, 1H, H-16), 3.60 (d, 
1H, H-17, J = 5.4 Hz), 3.48 (s, 3H, OCH3), 3.41 (s, 6H, OCH3), 2.78 (m, 1H), 2.41 
(m, 2H), 2.44 (m, 1H), 2.36-2.24 (m, 6H), 1.88 (m, 1H),  0.90 (s, 3H, H-18). 13C 
NMR (CDCl3) δ: 200.49 (C-6), 156.06 (C-3), 138.575 (C-5), 132.27 (C-10), 127.36 
(C-1), 123.12 (C-4), 119.76, 119.65 (CN), 114.08 (C-2), 96.73 (OCH2O), 96.29 
(OCH2O), 94.62 (OCH2O), 92.32 (C-17), 81.52 (C-16), 56.32 (OCH3), 55.88 
(OCH2O), 55.67 (OCH2O), 52.17, 44.88, 44.69,  41.57 (C-7), 38.47 (C-8), 37.61 (C-
12), 33.90, 33.49, 31.39, 27.4, 26.34, 25.97, 24.67, 23. 67, 17.21 (C-4´), 13.06 (C-18). 
 
6.7.3 Synthesis of 6-oxo-7(4-cyanobutyl)-estra-1,3,5(10)-triene-3,16α ,17β-triol 
(156) 
 
Two drops of conc. HCl was added to a stirred solution of 245 mg (0.47 mmol) of 
153 in methanol (50 ml). The mixture was refluxed for 20 min. then cooled down to rt 
and was neutralized with NaHCO3 solution. The mixture was concentrated under 
reduced pressure, residue was extracted with EtOAc (30 ml x 3). Combined organic 
phases were washed with brine and dried over Na2SO4. Removal of solvent under 
reduced pressure afforded 156 as off-white solid (171 mg, 94%). 1H NMR (acetone-
d6) δ: 7.42 (d, 1H, H-1, J = 3.3 Hz), 7.35 (d, 1H, H-4, J = 9 Hz), 7.05 (dd, 1H, H-2, J 
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= 8.6 Hz, 3 Hz), 4.06 (m, 1H, H-16), 3.9 (d, <1H, OH, J = 4.5 Hz), 3.8 (d, <1H, OH, J 
= 5.4 Hz), 3.54 (m, 1H, H-17, J = 5.1 Hz), 2.80 (m, 3H), 2.46- 2.35 (m, 5H), 0.81 (s, 
3H, H-18). 13C NMR (acetone-d6) δ: 200.83 (C-6), 157.32 (C-3), 138.93 (C-5), 
133.73 (C-10), 128.76 (C-1), 122.52 (C-4), 121.13 (CN), 114.23 (C-2), 90.93 (C-17), 
79.05 (C-16), 49.87 (C-14), 45.23 (C-9), 44.52 (C-13), 43.61 (C-7), 38.67 (C-8), 
38.12 (C-12), 34.64 (C-15), 27.89 (C-1´), 27.74 (C-2´), 26.79 (C-11), 24.23 (C-3´), 
17.63 (C-4´), 13.26 (C-18). MS m/z (relative intensity) 365 (3), 279 (45), 167 (43), 
149 (100).  
 
6.7.4 Synthesis of 7(4-cyanobutyl)-estra-1,3,5(10)-triene-3, 16α ,17β-triol (157) 
 
Triethyl silane (2 ml, 12.5 mmol) was added to a suspension of 100 mg (0.26 mmol) 
of 156 in dry CH2Cl2 (8 ml). The solution was cooled to 0 oC and 5 ml of BF3.Et2O 
was added dropwise. The yellow mixture was stirred at room temperature for three 
days. Then cooled to 0 oC and 20% aq. K2CO3 solution (40 ml) was added slowly. 
After separating the DCM layer, aq. phase was extracted with EtOAc (3 x 50 ml). 
Combined organic phase was dried over Na2SO4. After removal of the solvent crude 
was purified by flash column chromatography with 20:1 EtOAc/MeOH to yield 48 
mg (50%) of 157. 11 mg of unreacted 156 was recovered. 1H NMR (acetone-d6) δ: 
7.10 (d, 1H, H-1, J = 8.4 Hz), 6.60 (dd, 1H, H-2, J = 8.7 Hz, 2.1 Hz), 6.53 (d, 1H, H-
4, J = 2.3 Hz), 3.86 (d, <1H, OH, J = 5.1 Hz), 3.77 (d, <1H, OH, J = 4.8 Hz), 3.51 (t, 
1H, H-17, J= 5.1 Hz), 2.84 (m, 2H), 2.71 (d, 1H, J = 16.5 Hz), 2.44 (t, 2H, H-4´, J = 
6.75 Hz), 2.30 (m, 2H), 0.80 (s, 3H, H-18). 13C NMR (acetone- d6)) δ: 156.55 (C-3), 
137.59 (C-5), 131.73 (C-10), 128.09 (C-1), 121.13 (CN), 117.36 (C-4), 114.35 (C-2), 
91.11 (C-17), 79.18 (C-16), 45.69 (C-14), 45.37 (C-9), 43.10 (C-13), 39.6 (C-7), 
38.49 (C-8), 35.69 (C-12), 34.95 (C-15), 34.66 (C-6), 28.49 (C-1´), 28.37 (C-2´), 
27.07 (C-11), 26.17 (C-3´), 17.7 (C-4´), 13.32 (C-18). MS m/z (relative intensity) 369 
M+ (100), 294 (19), 269 (11), 239 (24), 213 (11), 157 (36). 
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6.7.5 Synthesis of 7(4-cyanobutyl)-estra-1,3,5(10)-triene-3,17β-diol (157) in 
presence of [bmim]BF4 
 
[bmim]BF4 was added to a suspension of 60 mg (0.16 mmol) of 156 in dry CH2Cl2 (8 
ml) under Ar until a clear solution was formed (340 mg of [bmim]BF4 was added). 
Triethylsilane (1.6 ml, 10 mmol) was added to the solution and cooled to 0 oC. Then 
3.2 ml  (26 mmol) of BF3.Et2O was added and the mixture was stirred at rt for one 
day. After cooling to 0 oC and 20% aq. K2CO3 solution (40 ml) was added slowly and 
stirred for 20 min. The mixture was extracted with EtOAc (3 x 50 ml). Combined 
organic phase was dried over Na2SO4. After removal of the solvent crude was purified 
by flash column chromatography with 20:1 EtOAc/MeOH to yield 10.1 mg (17%) of 
157. 
 
6.8 Synthesis of 7-alkoxy substituted estradiol 
 
6.8.1 Synthesis of estra-1,3,5(10)-triene-3,17β-diol-3,17di-triisopropylsilyl ether 
(158)  
 
Triisopropylsilylchloride (0.14 ml, 0.58 mmol) was added to a solution of 2 (100 mg, 
0.37 mmol) and 42 mg (0.0.61 mmol) of imidazole in 1 ml of dry DMF under argon. 
The reaction mixture was stirred at rt for 24 h. Then water was added to the reaction 
mixture and extracted with EtOAc. Organic phase was washed successively with 
water, dil. HCl, NaHCO3 solution and brine. After drying over Na2SO4 solvent was 
removed under low pressure. Flash chromatography of the residue with n-
hexane/EtOAc provided 158 in 83% yield. 1H NMR (CDCl3) δ: 7.10 (d, 1H, H-1, J = 
8.1 Hz), 6.64 (dd, 1H, H-2, J = 8.1 Hz, 2.7 Hz), 6.58 (d, 1H, H-4, J = 2.6 Hz), 3.80 (t, 
1H, H-17, J = 8.25 Hz), 2.77 (m, 2H, H-6), 2.26 (m, 1H), 2.15 (m, 1H), 1.98 (m, 2H), 
1.85 (m, 1H), 1.11-1.07 (one doublet and one singlet overlapped, 36 H), 0.77 (s, 3H, 
H-18). 
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6.8.2 Synthesis of estra-1,3,5(10)6-tetraene-3,17β-diol-3,17di-tert-butyl ether 
(160) 
 
The compound 130 (203 mg, 0.51 mmol) was dissolved in 2 ml of DMSO and stirred 
at 170 oC for 1 h. After cooling down to rt, 15 ml of water was added and the mixture 
was extracted with EtOAc (15 ml x 3). Combined organic phases were washed with 
water, dried over Na2SO4. After removal of solvent crude was purified flash 
chromatography with 16:1 DCM/EtOAc to provide two compound 160 (101 mg, 
52%) and 161 (78 mg, 47%). 
160 white solid. 1H NMR (CDCl3) δ: 7.11 (d, 1H, H-1, J = 8.1 Hz), 6.65 (dd, 1H, H-2, 
J = 8.25 Hz, 2.25 Hz), 6.56 (d, 1H, H-4, J = 2.4 Hz), 6.39 (dd, 1H, H-7, J = 9.5 Hz, 
2.25 Hz), 5.98 (d, 1H, H-6, J = 9.3 Hz), 3.48 (t, 1H, H-17, J = 7.95 Hz), 2.30 (m, 1H), 
2.13 (m, 1H), 1.90 (m, 2H), 1.80 (m, 2H), 1.35 (m, 2H), 1.16 (s, 9H, OCMe3), 0.75 (s, 
3H, H-18). 13C NMR (CDCl3) δ: 157.16 (C-3), 135.94 (C-5), 133.66 (C-10), 131.95 
(C-7), 127.68 (C-1), 124.69 (C-6), 113.39, 113.15 (C-2, C-4), 80.9 (C-17), 72.62 
(OCMe3), 48.49 (C-14), 43.57 (C-13), 42.40 (C-9), 38.91 (C-8), 36.93 (C-12), 31.28 
(C-16), 28.98 (OCMe3), 24.43 (C-11), 23.61 (C-15), 11.63 (C-18). 
161 white solid. 1H NMR (CDCl3) δ: 7.13 (d, 1H, H-1, J = 8.4 Hz), 6.81 (dd, 1H, H-2, 
J = 8.1 Hz, 2.4 Hz), 6.7 (d, 1H, H-4, J = 21.8 Hz), 6.42 (dd, 1H, H-7, J = 9.6 Hz, 2.1 
Hz), 5.98 (d, 1H, H-6, J = 9.3 Hz), 3.48 (t, 1H, H-17, J = 7.9 Hz), 2.34 (m, 1H), 2.16 
(m, 2H), 1.94 (m, 2H), 1.80 (m, 2H), 1.34 (s, 9H, OCMe3), 1.16 (s, 9H, OCMe3), 0.76 
(s, 3H, H-18). 13C NMR (CDCl3) δ: 153.77 (C-3), 135.13 (C-5), 134.52 (C-10), 132.9 
(C-7), 127.94 (C-1), 123.87 (C-6), 122.50, 121.91 (C-2, C-4), 80.79 (C-17), 78.28 
(OCMe3), 72.62 (OCMe3), 48.58 (C-14), 43.55 (C-13), 42.57 (C-9), 38.7 (C-8), 36.92 
(C-12), 31.31 (C-16), 29.07, 28.96 (OCMe3), 24.31 (C-11), 23.62 (C-15), 11.60 (C-
18). 
 
6.8.3 Dehydration of 130 under microwave irradiation 
 
A mixture of 130 (20 mg, 0.05 mmol) and [bmim]Cl (155 mg) was dried in oil pump 
then heated in oil bath to melt the IL. After irradiating in microwave oven at 100 oC 
for 10 min the mixture was partitioned between EtOAc and water. Aq. phase was 
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extracted with EtOAc (10 ml x 3). Combined organic phases was washed with water 
and dried over Na2SO4. After removal of solvent crude was purified by flash column 
chromatography with 10:1 DCM/EtOAc to afford 12 mg (89%) of 162 as white solid. 
1H NMR (CDCl3) δ: 7.11 (d, 1H, H-1, J = 8.4 Hz), 6.65 (dd, 1H, H-2, J = 8.4 Hz, 2.4 
Hz), 6.57 (d, 1H, H-4, J = 2.4 Hz), 6.41 (dd, 1H, H-7, J = 9.9 Hz, 2.7 Hz), 5.98 (d, 
1H, H-6, J = 9.3 Hz), 3.76 (m, 1H, H-17), 2.33 (m, 1H), 2.17 (m, 3H), 1.97 (m, 1H), 
1.86 (m, 1H), 1.72 (dd, 2H, J = 12 Hz, 3.9 Hz), 0.79 (s, 3H, H-18). 
 
6.8.4 Synthesis of estra-1,3,5(10)6-tetraene-3,17β-diol-3-benzyl-17-tert-butyl 
ether (163) 
 
Under Ar atmosphere 12 mg (0.3 mmol) of sodium hydride (60% in paraffin) was 
washed three times with hexane. Then it was suspended in DMF and a solution of 160 
(81 mg, 5.55 mmol) in 5 ml of dry THF was added dropwise at room temperature. 
After stirring for 15 min, 0.04 ml of benzylbromide was added dropwise. The reaction 
mixture was stirred at rt overnight then quenched with water and was extracted with 
EtOAc (10 ml x 3). Combined organic phases was washed with brine and dried over 
Na2SO4. After removal of solvent the oily residue was purified on silica gel column 
with DCM/EtOAc to produce 100 mg of 163 as off white solid (97% yield). 1H NMR 
(CDCl3) δ: 7.42-7.3 (m, 5H, OCH2Ph), 7.16 (d, 1H, H-1, J = 8.4 Hz), 6.78 (d, 1H, H-
2, J = 8.4 Hz), 6.72 (s, 1H, H-4), 6.42 (d, 1H, H-7, J = 9.9 Hz), 5.98 (d, 1H, H-6, J = 
9.6 Hz), 5.05 (s, 1H, OCH2Ph), 3.47 (t, 1H, H-17, J = 8.1 Hz), 2.30 (m, 1H), 2.13 (m, 
1H), 1.90 (m, 2H), 1.80 (m, 1H), 1.74 (m, 1H), 1.35 (m, 2H), 1.16 (s, 9H, OCMe3), 
0.75 (s, 3H, H-18). 13C NMR (CDCl3) δ: 157.55 (C-3), 135.76 (C-5), 133.53 (C-10), 
132.23 (C-7), 128.75-127.63 (OCH2Ph, C-1), 124.51 (C-6), 112.97, 112.84 (C-2, C-
4), 80.82 (C-17), 72.33 (OCMe3), 70.3 (OCH2Ph), 48.52 (C-14), 42.58 (C-13), 42.44 
(C-9), 38.89 (C-8), 36.92 (C-12), 31.32 (C-16), 28.98 (OCMe3), 24.41 (C-11), 23.63 
(C-15), 11.59 (C-18). 
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6.8.5 Synthesis of 6,7-epoxy-estra-1,3,5(10)-triene-3,17β-diol-3-benzyl-17-tert-
butyl ether (164) 
 
Compound 163 (91mg, 0.22 mmol) was dissolved in dry DCM (8 ml) and 49 mg 
(0.22 mmol) of m-CPBA (77%) was added. After stirring overnight at rt the reaction 
was quenched with NaHCO3 solution. The reaction mixture was extracted with DCM 
(3 x 10 ml) and combined organic phases were washed successively with saturated 
sodium thiosulfate solution and brine. After drying over MgSO4 solvent was removed 
to yield 94 mg (99%) of 164 as colorless oil. 1H NMR (CDCl3) δ: 7.30 (m, 5H, 
OCH2Ph), 7.05 (d, 1H, H-1, J = 8.7 Hz), 6.94 (s, 1H, H-4), 6.80 (d, 1H, H-2, J= 7.8 
Hz), 4.97 (s, 2H, OCH2Ph), 4.47 (s, 1H, H-6), 3.73 (d, 1H, H-7), 3.42 (m, 2H), 2.32 
(m, 1H), 2.12 (m, 1H), 1.82 (m, 3H), 1.07 (s, 9H, OCMe3), 0.67 (s, 3H, H-18). 13C 
NMR (CDCl3) δ:  157.08 (C-3), 137.22 (C-5), 133.75 (C-10), 132.72, 128.73-127.55 
(OCH2Ph), 125.36 (C-1), 116.62 (C-4), 114.32 (C-2), 80.57 (C-17), 72.48 (OCMe3), 
70.26 (OCH2Ph), 56.31 (C-7), 54.01 (C-6), 47.16 (C-14), 43.62 (C-13), 37.62 (C-9), 
36.66 (C-8), 36.43 (C-12), 31.37 (C-16), 28.92 (OCMe3), 24.43 (C-11), 23.93 (C-15), 
11.38 (C-18). 
 
6.8.6 Synthesis of 7-hydroxy-estra-1,3,5(10)-triene-3,17β-diol-3-benzyl-17-tert-
butyl ether (165) 
 
Compound 164 (94 mg, 0.22 mmol) in dry THF (4 ml) was added to the suspension 
of LAH (271 mg, 7 mmol) in dry THF (10 ml) at 0 oC under Ar atmosphere. After 
refluxing for 2.5 h the reaction mixture was cooled to 0 oC and EtOAc was added to 
destroy the excess LAH. Reaction mixture was partitioned between EtOAc and water 
and aq. phase was extracted with EtOAc (10 ml x 3). Combined organic phases was 
washed with water and dried over Na2SO4. After removal of solvent crude was 
purified by flash column chromatography with 7:1 DCM/EtOAc to afford 42 mg 
(45%) of 165 (white solid). 1H NMR (CDCl3) δ: 7.40 (m, 5H, OCH2Ph), 7.24 (d, 1H, 
H-1, J = 8.4 Hz), 6.81 (d, 1H, H-2, J = 8.4 Hz), 6.71 (s, 1H, H-4), 5.02 (s, 2H, 
OCH2Ph), 4.11 (m, 1H, H-7), 3.49 (t, 1H, H-17), 3.11 (dd, 1H, H-6, J = 17.6 Hz, 3 
Hz), 2.85 (d, 1H, H-6, J = 17.7 Hz), 2.57 (m, 1H), 2.37 (m, 1H), 1.95-1.86 (m, 2H), 
1.86(m, 1H), 1.72 (m, 1H), 1.15 (s, 9H, OCMe3), 0.75 (s, 3H, H-18). 13C NMR 
(CDCl3) δ: 157.18 (C-3), 137.47 (C-5), 134.66, 132.2, 128.74, 128.05, 127.61, 126.82 
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(C-1, C-10, OCH2Ph), 115.74 (C-4), 113.15 (C-2), 80.92 (C-17), 72.46 (OCMe3), 
70.18 (OCH2Ph), 66.19 (C-7), 43.66 (C-14), 43.02 (C-13), 42.49 (C-9), 38.99 (C-6), 
37.28 (C-8), 35.98 (C-12), 31.36 (C-16), 28.97 (OCMe3), 26.53 (C-11), 23.13 (C-15), 
11.68 (C-18). 
 
6.8.7 Synthesis of 7O-(3-cyanopropyl)-estra-1,3,5(10)-triene-3,17β-diol-3-benzyl-
17-tert-butyl ether (166) 
 
Compound 165 (36 mg, 0.082 mmol) was dissolved in 2.5 ml of DCM. A mixture of 
acrylonitrile (0.33 ml, 5 mmol) and 40% aq. KOH (0.5 ml) was added followed by 43 
mg of 18-crown-6. After stirring overnight at rt water (5 ml) was added. The reaction 
mixture was neutralized with HCl and extracted with DCM (3 x 8 ml). The combined 
organic fractions were washed successively with NaHCO3 solution and brine, dried 
over MgSO4. After removal of solvent crude was purified by flash column 
chromatography with 2.5:1 DCM/EtOAc to afford 38 mg (94%) of 166 as pale yellow 
sticky liquid. 
1H NMR (CDCl3) δ: 7.40 (m, 5H, OCH2Ph), 7.24 (d, 1H, H-1, J = 9 Hz), 6.80 (dd, 
1H, H-2, J = 8.25 Hz, 1.95 Hz), 6.7 (d, 1H, H-4, J = 1.9 Hz), 5.02 (s, 2H, OCH2Ph), 
3.82 (m, 1H, H-1´), 3.75 (m, 1H, H-7), 3.63 (t, 1H, H-17, J = 6.45 Hz), 3.02 (d, 1H, 
H-6, J = 17.7 Hz), 2.87 (d, 1H, H-6, J = 17.7 Hz), 2.52 (t, 2H, J = 5.7 Hz), 2.35 (m, 
1H), 1.98 (m, 1H), 1.85 (m, 1H), 1.15 (s, 9H, OCMe3), 0.73 (s, 3H, H-18). 13C NMR 
(CDCl3) δ: 156.96 (C-3), 137.44 (C-5), 134.66, 132.52, 128.68, 128.01, 127.59, 
126.72 (C-1, C-10, OCH2Ph), 118.15 (CN), 115.47 (C-4), 112.80 (C-2), 80.81 (C-17), 
74.72 (C-1´), 72.39 (OCMe3), 70.11 (OCH2Ph), 64.06 (C-7), 45.12 (C-14), 42.93 (C-
13), 42.51 (C-9), 37.08 (C-6), 36.39 (C-8), 34.04 (C-12), 31.3 (C-16), 28.91 
(OCMe3), 26.60 (C-11), 23.46 (C-15), 19.34 (C-2´), 11.51 (C-18). 
 
6.8.8 Synthesis of 7O-(3-aminopropyl)-estra-1,3,5(10)-triene-3,17βdiol-3benzyl-
17tert-butyl ether (167) 
 
A slurry of aluminium chloride (101 mg, 0.76 mmol) in dry ether was added to a 
suspension of 29 mg (0.76 mmol) LAH in dry ether at 0 oC. Then a solution of 166 
(37 mg, 0.076 mmol) in dry ether was added. After stirring at rt for 2 h the mixture 
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was again cooled to 0 oC and water was added to quench the reaction. The mixture 
was made basic by addition of KOH solution and extracted with DCM (20 ml x 3). 
The combined organic fractions was washed with brine and dried over Na2SO4. 
Removal of solvent under reduced pressure afforded 20 mg (59%) of 167 as sticky 
white solid. 1H NMR (CDCl3) δ: 7.40 (m, 5H, OCH2Ph), 7.19 (d, 1H, H-1, J = 8.4 
Hz), 6.76 (d, 1H, H-2, J = 8.1 Hz), 6.68 (s, 1H, H-4), 5.01 (s, 2H, OCH2Ph), 3.62 (m, 
2H, H-1´), 3.47 (m, 1H), 3.41 (m, 1H), 3.03 (d, 1H, H-6, J = 16.8 Hz), 2.79 (m, 2H, 
H-3´), 2.58 (m, 1H), 2.31 (m, 1H), 1.14 (s, 9H, OCMe3), 0.71 (s, 3H, H-18). 13C 
NMR (CDCl3) δ: 156.99 (C-3), 137.55 (C-5), 135.18, 132.94, 128.72, 128.03, 127.70, 
(C-10, OCH2Ph), 126.8 (C-1), 115.62 (C-4), 112.74 (C-2), 80.87 (C-17), 73.96 (C-
1´), 72.46 (OCMe3), 70.16 (OCH2Ph), 67.19 (C-7), 45.51 (C-14), 42.98 (C-13), 42.59 
(C-9), 39.62 (C-3´), 37.14 (C-6), 36.74 (C-8), 34.12 (C-12), 31.35 (C-16), 29.88 (C-
2´), 28.98 (OCMe3), 26.73 (C-11), 23.56 (C-15), 11.57 (C-18). MS m/z (relative 
intensity) 491 M+ (5), 440 (32), 416 (12), 396 (11), 359 (10), 341 (4), 269 (6). 
 
6.9 Alkoxy substitution at C-7 of estriol 
 
6.9.1 Synthesis of estra-1,3,5(10)6-tetraene-3,16α ,17β-triol-3,16,17-
tris(methoxymethyl) ether (168)  
 
The compound 132 (1.097 g, 2.52 mmol) was dissolved in 4 ml of dry DMSO and the 
solution was stirred at 160 oC for 1 h. After cooling down to rt 100 ml of water was 
added and the mixture was extracted with EtOAc (100 ml x 2). The combined organic 
fractions were washed with water, dried over Na2SO4 and solvent was removed under 
reduced pressure. The residue obtained was dissolved in dry THF under Ar and 
cooled to 0 oC. DIPEA  (7 ml) was added followed by MOMCl (1.7 ml, 22.5 mmol). 
After stirring at rt for 1 h the mixture was refluxed overnight. Then cooled to rt and 
90 ml of saturated aq. NH4Cl solution was added and the mixture was extracted with 
EtOAc. Combined organic phases were washed with brine and dried over MgSO4. 
After removal of the solvent the residue was purified by flash column 
chromatography with DCM/EtOAc to provide 168 as pale yellow sticky liquid (513 
mg, 49%). 1H NMR (CDCl3) δ: 7.14 (d, 1H, H-1, J = 8.4 Hz), 6.87 (dd, 1H, H-2, J = 
8.3 Hz, 2.5 Hz), 6.78 (d, 1H, H-4, J = 2.7 Hz), 6.46 (dd, 1H, H-6, J = 9.6 Hz, 2.7 Hz), 
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5.94 (dd, 1H, H-7, J = 9.6 Hz, 1.5 Hz), 5.15 (s, 2H, OCH2O), 4.76 (ABq, 2H, OCH2O, 
Δν = 29.3 Hz, J = -6.3 Hz), 4.69 (d, 2H, OCH2O, J = 1.8 Hz), 4.13 (m, 1H, H-16), 
3.65 (d, 1H, H-17, J = 5.4 Hz), 3.47 (s, 3H, OCH3), 3.41 (s, 3H, OCH3), 3.40 (s, 3H, 
OCH3), 2.39 (m, 1H), 2.27 (m, 2H), 1.98 (m, 1H), 1.86 (m, 1H), 1.75 (m, 3H), 1.43 
(m, 1H), 0.82 (s, 3H, H-18). 13C NMR (CDCl3) δ: 156.03 (C-3), 135.65 (C-5), 132.8 
(C-10), 132.62 (C-7), 128.23 (C-1), 124.47 (C-6), 114.67 (C-4), 114.31 (C-2), 96.72 
(OCH2O), 96.2 (OCH2O), 94.81 (OCH2O), 92.79 (C-17), 82.16 (C-16), 56.12 
(OCH3), 55.83 (OCH2O), 55.66 (OCH2O), 46.66 (C-14), 43.82 (C-9), 42.16 (C-13), 
38.3 (C-8), 36.93 (C-12), 31.26 (C-15), 24.08 (C-11), 12.87 (C-18). 
 
6.9.2 Synthesis of 6,7-epoxy-estra-1,3,5(10)-triene-3,16α ,17β-triol-3,16,17-
tris(methoxymethyl) ether (169)  
 
Compound 168 (413 mg, 0.99 mmol) was dissolved in DCM and 3 ml of 0.5 M aq. 
NaHCO3 solution was added and cooled to 0 oC. Then m-CPBA (77%, 222 mg, 0.99 
mmol) was added portionwise. After stirring overnight at rt, organic phase was 
separated. Aqueous phase was extracted with DCM. Combined organic phases were 
washed successfully with NaOH solution and brine, dried over MgSO4. After 
filtration and removal of solvent 169 was obtained in 93% yield (398 mg). 1H NMR 
(CDCl3) δ: 7.16- 7.11 (m, 2H, H-1, H-4), 6.97 (dd, 1H, H-2, J = 8.4 Hz, 2.4 Hz), 5.17 
(s, 2H, OCH2O), 4.76 (ABq, 2H, OCH2O, Δν = 29 Hz, J = -6.2 Hz), 4.69 (d, 2H, 
OCH2O, J = 2.4 Hz), 4.17 (m, 1H, H-16), 3.86 (d, 1H, H-6, J = 4.2 Hz), 3.65 (d, 1H, 
H-17, J = 5.4 Hz), 3.51 (d, 1H, H-7, J = 4.5 Hz), 3.48 (s, 3H, OCH3), 3.41 (s, 3H, 
OCH3), 3.40 (s, 3H, OCH3), 2.45 (m, 1H), 2.23 (m, 1H), 1.93 (m, 4H), 1.59 (m, 2H), 
1.43 (m, 1H), 0.82 (s, 3H, H-18). 13C NMR (CDCl3) δ: 155.62 (C-3), 135.72 (C-5), 
133.38 (C-10), 125.34 (C-1), 117.85 (C-4), 116.14 (C-2), 96.74 (OCH2O), 96.21 
(OCH2O), 94.77 (OCH2O), 92.64 (C-17), 82.18 (C-16), 56.13 (OCH3), 56.01 
(OCH2O), 55.85 (OCH2O), 55.64 (C-7), 53.87 (C-6), 45.38 (C-14), 43.86 (C-13), 
37.24 (C-9), 36.68 (C-8), 36.23 (C-12), 31.46 (C-15), 24.12 (C-11), 12.66 (C-18). MS 
m/z (relative intensity) 434 M+ (38), 418 (66), 327 (100), 311 (22), 295 (16). 
 
 98 
6.9.3 Synthesis of 7α-hydroxy-estra-1,3,5(10)-triene-3,16α ,17β-triol-3,16,17-
tris(methoxymethyl) ether (170)  
 
Compound 169 (398 mg, 0.92 mmol) was added to a suspension of LAH (1.1 g, 29 
mmol) in dry THF. After refluxing for 1.5 h the reaction mixture was cooled to 0 oC 
and EtOAc was added to destroy the excess LAH. Reaction mixture was partitioned 
between EtOAc and water and aq phase was extracted with EtOAc (50 ml x 3). 
Combined organic phases was washed with water and dried over Na2SO4. After 
removal of solvent crude was purified by flash column chromatography with 1:3 
DCM/EtOAc to afford 297 mg (74%) of 170 as pale yellow sticky liquid. 1H NMR 
(CDCl3) δ: 7.22 (d, 1H, H-1, J = 8.7 Hz), 6.86 (dd, 1H, H-2, J= 8.4 Hz, 2.7 Hz), 6.78 
(d, 1H, H-4, J = 2.4 Hz) 5.13 (s, 2H, OCH2O), 4.75 (ABq, 2H, OCH2O, Δν = 27.5 
Hz, J = -6.3 Hz), 4.64 (d, 2H, OCH2O, J = 1.8 Hz), 4.13 (m, 1H, H-16), 3.69 (m, 1H, 
H-7), 3.66 (d, 1H, H-17, J = 5.4 Hz), 3.46 (s, 3H, OCH3), 3.41 (s, 3H, OCH3), 3.38 (s, 
3H, OCH3), 3.11 (dd, 1H, H-6, J = 17.7 Hz, 3.3 Hz), 2.88 (d, 1H, H-6, J = 17.4 Hz), 
2.63 (m, 1H), 2.39 (m, 1H), 1.96 (m, 1H), 1.86(m, 1H), 1.74 (m, 2H), 1.51 (m, 3H), 
0.81 (s, 3H, H-18). 13C NMR (CDCl3) δ: 155.58 (C-3), 134.63 (C-5), 132.85 (C-10), 
126.68 (C-1), 117.15 (C-4), 114.59 (C-2), 96.70 (OCH2O), 96.01 (OCH2O), 94.66 
(OCH2O), 92.93 (C-17), 82.02 (C-16), 65.9 (C-7), 56.06 (OCH3), 55.75 (OCH2O), 
55.76 (OCH2O), 43.84 (C-14), 43.35 (C-13), 42.04 (C-6), 38.82 (C-9), 37.28 (C-8), 
35.71 (C-12), 30.57 (C-15), 26.1 (C-11), 12.93 (C-18). MS m/z (relative intensity) 
436 M+ (78), 418 (60), 404 (17), 374 (70), 329 (50), 311 (34), 295 (77). 
 
6.9.4 Synthesis of 7O-(3-cyanopropyl)hydroxy-estra-1,3,5(10)-triene-3,16α ,17β-
triol-3,16,17-tris(methoxymethyl) ether (171)  
 
Compound 170 (297 mg, 0.68 mmol) was dissolved in 21 ml of DCM. A mixture of 
acrylonitrile (2.7 ml, 40.7 mmol) and 40% aq. KOH (4.2 ml) was added followed by 
356 mg of 18-crown-6. After stirring overnight at rt water (40 ml) was added. The 
reaction mixture was neutralized with HCl and extracted with DCM (3 x 30 ml). The 
combined organic phases were washed successively with NaHCO3 solution and brine, 
dried over Na2SO4. After removal of solvent crude was purified by flash column 
chromatography with 8:1 DCM/EtOAc to afford 128 mg (33%) of 171 as pale yellow 
sticky liquid. 1H NMR (CDCl3) δ: 7.21 (d, 1H, H-1, J = 8.4 Hz), 6.84 (dd, 1H, H-2, J 
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= 8.4 Hz, 2.4 Hz), 6.75 (d, 1H, H-4, J = 2.4 Hz), 5.13 (s, 2H, OCH2O), 4.75 (ABq, 
2H, OCH2O, Δν =  26.1 Hz, J = -6.3 Hz), 4.68 (s, 2H, OCH2O), 4.15 (m, 1H, H-16), 
3.84 (m, 1H, H-1´) 3.73 (m, 1H, H-7), 3.68 (d, 1H, H-17, J = 6 Hz), 3.59 (m, 1H, H-
1´), 3.47 (s, 3H, OCH3), 3.41 (s, 3H, OCH3), 3.39 (s, 3H, OCH3), 3.05 (d, 1H, H-6, J = 
17.7 Hz), 2.88 (dd, 1H, H-6, J = 17.8 Hz, 3.3 Hz), 2.71 (m, 1H), 2.53 (t, 2H, CH2CN), 
2.34 (m, 1H), 1.96 (m, 2H), 1.74 (m, 2H), 1.51 (m, 3H), 0.79 (s, 3H, H-18). 13C NMR 
(CDCl3) δ: 155.45 (C-3), 134.52 (C-5), 133.48 (C-10), 126.63 (C-1), 117.92 (CN), 
116.85 (C-4), 114.51 (C-2), 96.72 (OCH2O), 96.13 (OCH2O), 94.70 (OCH2O), 92.76 
(C-17), 82.02 (C-16), 74.54 (C-7), 64.2 (C-1´), 56.10 (OCH3), 55.74 (OCH2O), 55.6 
(OCH2O), 43.41 (C-14), 43.24 (C-13), 42.04 (C-6), 37.10 (C-9), 36.19 (C-8), 33.98 
(C-12), 30.90 (C-15), 26.2 (C-11), 19.34 (C-2´), 12.78 (C-18). 
 
6.9.5 Synthesis of 7O-(3-aminopropyl)hydroxy-estra-1,3,5(10)-triene-3,16α ,17β--
triol-3,16,17-tris(methoxymethyl) ether (172)  
 
To a solution of 171 (90 mg, 0.184 mmol) in dry ether (4 ml) cooled to 0 oC was 
added a suspension of LAH (70 mg, 1.84 mmol) in dry ether (4 ml) under argon. The 
mixture was stirred at rt for 1 h, then 10 ml of saturated NaHCO3 solution was added. 
The reaction mixture was extracted with extracted with EtOAc (3 x 10 ml), combined 
organic fractions were washed with brine (10 ml) and dried over Na2SO4. Removal of 
the solvent after filtration provided crude 172 as colorless sticky liquid (140 mg). 1H 
NMR (acetone-d6) δ: 7.21 (d, 1H, H-1, J = 8.7 Hz), 6.80 (dd, 1H, H-2, J = 8.6 Hz, 2.6 
Hz), 6.73 (d, 1H, H-4, J = 2.4 Hz), 5.14 (s, 2H, OCH2O), 4.77 (ABq, 2H, OCH2O, 
Δν = 40 Hz, J = -6.3 Hz), 4.64 (s, 2H, OCH2O), 4.09 (m, 1H, H-16), 3.68 (m, 1H, H-
7), 3.63 (d, 1H, H-17, J = 5.7 Hz), 3.59 (m, 1H, H-1´), 3.42 (s, 3H, OCH3), 3.36 (s, 
3H, OCH3), 3.34 (s, 3H, OCH3), 3.72 (m, 1H, H-1´), 3.07 (d, 1H, H-6, J = 17.7 Hz), 
2.82 (m, 3H, H-3´, H-6), 2.21 (m, 1H), 2.37 (m, 1H), 1.96 (m, 2H), 1.88 (m, 2H), 1.76 
(m, 3H), 1.54 (m, 1H), 0.82 (s, 3H, H-18). 13C NMR (acetone-d6) δ: 156.83 (C-3), 
136.99 (C-5), 134.84 (C-10), 127.52 (C-1), 118.24 (C-4), 115.22 (C-2), 97.57 
(OCH2O), 96.99 (OCH2O), 95.69 (OCH2O), 94.10 (C-17), 83.27 (C-16), 74.35 (C-7), 
67.76 (C-1´), 56.45 (OCH3), 56.07 (OCH2O), 55.95 (OCH2O), 49.05 (C-3´), 45.07 
(C-14), 44.39 (C-13), 43.39 (C-6), 38.74 (C-9), 37.76 (C-8), 34.95 (C-12), 32.82 (C-
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2´), 32.14 (C-15), 27.41 (C-11), 13.66 (C-18). MS m/z (relative intensity) 493 M+ 
(0.8), 488 (12), 472 (5), 418 (43). 
 
6.9.6 Synthesis of 7O-(propyl-3-tert-butylcarbamate)hydroxy-estra-1,3,5(10)-
triene-3,16α ,17β-triol-3,16,17-tris(methoxymethyl) ether (173)  
 
Without further purification 172 was dissolved in dry DCM (4 ml) and added to a 
mixture of (Boc)2O (42 µl, 0.184 mmol) and Amberlyst-15 (15 mg). The mixture was 
stirred at rt for 15 min, then DCM (10 ml) was added and catalyst was removed by 
filtration. After removal of the solvent crude was purified by flash column 
chromatography with 1:1 n-hexane/EtOAc to afford 36 mg (34%) of 173 as colorless 
sticky liquid. 1H NMR (acetone-d6) δ: 7.21 (d, 1H, H-1, J = 8.4 Hz), 6.81 (d, 1H, H-2, 
J = 8.4 Hz), 6.74 (s, 1H, H-4), 5.75 (bs, 1H, NHBoc), 5.13 (s, 2H, OCH2O), 4.79-4.63 
(ABq and d overlapped, 4H, OCH2O), 4.10 (m, 1H, H-16), 3.73 (m, 2H, H-1´, H-7), 
3.67 (d, 1H, H-17, J = 5.4 Hz), 3.41 (s, 3H, OCH3), 3.35 (s, 3H, OCH3), 3.34 (s, 3H, 
OCH3), 3.08 (m, 3H, H-6, H-1´, H-3´), 2.84 (m, 2H, H-6, H-3´), 2.71 (m, 1H), 2.39 
(m, 1H), 1.94 (m, 2H), 1.78 (m, 2H), 1.69 (t, 2H, H-2´, J = 6.4 Hz), 1.39 (s, 9H, Boc), 
0.83 (s, 3H, H-18). 13C NMR (acetone-d6) δ: 157 (CO2CMe3), 156.88 (C-3), 136.81 
(C-5), 134.69 (C-10), 127.59 (C-1), 118.2 (C-4), 115.31 (C-2), 97.53 (OCH2O), 97.02 
(OCH2O), 95.71 (OCH2O), 93.99 (C-17), 83.42 (C-16), 78.5 (CO2CMe3), 74.81 (C-
7), 68.65 (C-1´), 56.48 (OCH3), 56.11 (OCH2O), 55.95 (OCH2O), 45.17 (C-14), 44.44 
(C-13), 43.31 (C-6), 39.86 (C-3´), 38.76 (C-9), 37.80 (C-8), 34.94 (C-12), 32.27 (C-
2´), 31.86 (C-15), 29.27 (CO2CMe3), 27.48 (C-11), 13.71 (C-18). MS m/z (relative 
intensity) 593 M+ (8), 519 (11), 493 (69), 461 (100), 448 (32), 418 (60), 386 (31), 295 
(78). 
6.10 Synthesis of 7-susbtituted 8-isoestradiol 
 
6.10.1 Synthesis of estra-1,3,5(10),7-tetraene-3,17β-diol (175)  
 
At 0 oC NaBH4 (71 mg 1.88 mmol) was suspended in 3 ml of ethanol and a 
suspension of 160 mg (0.59 mmol) of equilin (174) in 4 ml of ethanol was added 
dropwise. The suspension was allowed to warm up to rt and stirred for further 5 h. 
then water was added carefully to quench the reaction and the mixture was 
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concentrated under educed pressure. The residue was partitioned between ethyl 
acetate and water. The aq. phase was extracted several times with EtOAc and 
combined organic phases were washed with brine, dried over Na2SO4. Removal of 
solvent under reduced pressure afforded 174 as white solid in 89% yield (143 mg). the 
compound was enough pure, TLC showed single spot. 1H NMR (CDCl3) δ: 7.10 (d, 
1H, H-1, J = 8.4 Hz), 6.68 (dd, 1H, H-2, J = 8.1 Hz, 2.4 Hz), 6.58 (d, 1H, H-4, J = 2.4 
Hz), 5.38 (m, 1H, H-7), 3.86 (t, 1H, H-17, J = 8.25 Hz), 3.42, 3.38 (m, 1H, 1H, H-6, 
H-9), 3.07 (m, 1H, H-6), 0.66 (s, 3H). 
 
6.10.2 Synthesis of O,O-dibenzyl-estra-1,3,5(10),7-tetraene-3,17β-diol (176) 
 
Under Ar atmosphere 800 mg (19.99 mmol) of sodium hydride (60% in paraffin) was 
washed three times with hexane. Then it was suspended in DMF and a solution of 1.5 
g (5.55 mmol) of 175 in 5 ml of dry THF was added dropwise at room temperature. 
After stirring for 15 min, 1.6 ml of benzyl bromide was added dropwise. And stirring 
continued overnight at rt. Water was added to quench the reaction and the mixture 
was extracted with ether twice. The combined organic fractions were washed with 
water and dried over Na2SO4. After removal of solvent, the oily residue was purified 
on silica gel column with n-hexane/EtOAc (3:1) to produce 1.93 g of 176 as yellow 
amorphous solid (77% yield). 1H NMR (CDCl3) δ: 7.42-7.24 (m, 10H, OCH2Ph), 7.14 
(d, 1H, H-1, J = 8.7 Hz), 6.82 (dd, 1H, H-2, J = 8.7 Hz, 2.7 Hz), 6.71 (d, 1H, H-4, J = 
2.7 Hz), 5.40 (m, 1H, H-7), 5.04 (s, 2H, OCH2Ph), 4.58 (s, 2H, OCH2Ph), 3.62 (t, 1H, 
H-17, J = 8.1 Hz), 3.45, 3.41 (m, 1H, 1H, H-6, H-9), 3.15 (m, 1H, H-6), 0.75 (s, 3H, 
H-18). 13C NMR (CDCl3) δ: 156.9 (C-3), 139.3 (C-8), 137 (C-5), 134.5 (C-10), 130.7 
128.8-127.4 (C-1, OCH2Ph), 114.28, 113.7 113.6 (C-4, C-2, C-7), 88.6 (C-17), 71.8 
(OCH2Ph), 70.06 (OCH2Ph), 50.5 (C-13), 45.42 (C-14), 40.72 (C-9), 38.83 (C-12), 
32.7 (C-6), 30.12 (C-16), 28.11 (C-11), 21.03 (C-15), 12.05 (C-18). 
 
6.10.3 Synthesis of 3O,17O-dibenzyl-8α-estra-1,3,5(10)-triene-3,7,17-triol (177) 
 
Under Ar 0.1 ml (0.2 mmol) of 2 M borane dimethylsulfide complex in THF was 
added to a solution of 176 (64 mg, 0.14 mmol) in dry THF (0.2 ml). After stirring for 
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24 h at rt, 2 ml of a saturated aqueous sodium hydroxide solution was added, followed 
immediately by 2 ml of hydrogen peroxide. After stirring strongly for 24 h the 
mixture was extracted three times with dichloromethane. The combined organic 
layers were washed successively with sodium thiosulphate solution and brine, dried 
over Na2SO4. The crude product was purified by flash chromatography with a mixture 
of n-hexane/EtOAc (7:3), resulting in 43 mg (64% yield) of 177 as an amorphous, 
colourless solid. 1H NMR (CDCl3) δ: 7.34-7.24 (m, 10H, OCH2Ph), 6.93 (d, 1H, H-1, 
J = 8.7 Hz), 6.70 (dd, 1H, H-2, J = 8.6 Hz, H-2, 2.6 Hz), 6.60 (d, 1H, H-4, J = 8.1 Hz), 
4.93 (s, 2H, OCH2Ph), 4.48 (s, 2H, OCH2Ph),  4.38 (m, 1H, H-7 ), 3.34 (t, 1H, H-17, J 
= 8.4 Hz ), 2.96 (dd, 1H, H-6, J = 15.9 Hz, 5.4 Hz ), 2.60 (m, 2H, H-6, H-9), 1.95 (m, 
2H), 1.90 (m, 1H), 1.03 (s, 3H, H-18). 13C NMR (CDCl3) δ: 157.2 (C-3), 139.5, 
137.4, 135.5, 133.9, 129.5, 128.7-127.5 (C-5, C-10, C-1, OCH2Ph), 114.5 (C-4), 
113.6 (C-2), 88.9 (C-17), 71.7 (OCH2Ph), 70.2 (OCH2Ph), 69.19 (C-7), 48.41 (C-13), 
44.68 (C-14), 44.13 (C-8), 42.51 (C-4), 41.54 (C-6), 39.30 (C-12), 30.15 (C-16), 
27.81 (C-11), 25.09 (C-15), 12.98 (C-18). 
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Figure 5. DQFCOSY spectra of 177 
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Figure 6. NOESY spectra of 177 
 
6.10.4 Synthesis of 3O,17O-dibenzyl-7O-(3-cyanopropyl)-8α-estra-1,3,5(10)-
triene-3,7α ,17β-triol ether (179) 
 
A mixture of 4 ml of aq. KOH (w/w 40%) and 2 ml of acrylonitrile was added to a 
solution of 200 mg (0.43 mmol) of 177 in 15 ml of DCM at rt, followed by the 
addition of 18-crown-6 (265 mg). After stirring at rt for 2 days the reaction mixture 
was diluted with H2O and was acidified with aqueous 1 N HCl solution. The mixture 
was extracted with DCM and the organic layer was washed with brine and dried over 
Na2SO4. The organic solvent was evaporated and crude purified on silica gel column 
with dichloromethane/n-hexane (3:1) to yield 63% of 179 (140 mg) as colorless oil. 
1H NMR (CDCl3) δ: 7.42-7.26 (m, 10H, OCH2Ph), 7.03 (d, 1H, H-1, J = 8.4 Hz), 6.80 
(dd, 1H, H-2, J = 8.4 Hz, 2.4 Hz), 6.69 (d, 1H, J = 2.4 Hz), 5.03 (s, 2H, OCH2Ph), 
4.56 (s, 2H, OCH2Ph), 4.14 (m, 1H, H-7), 3.86 (m, 1H, H-1´), 3.59 (m, 1H, H-1), 3.42 
(t, 1H, H-17), 3.15 (dd, 1H, J = 16.6 Hz, 5.4 Hz), 2.7 (m, 2H, H-6, H-9), 2.6 (t, 2H, J 
= 6.45 Hz), 2.28 (m, 1H), 2.15 (m, 1H), 2.03 (m, 3H), 1.06 (s, 3H, H-18). 13C NMR 
(CDCl3) δ: 157.3 (C-3), 139.49, 137.4, 134.82, 133.92, 129.5, 128.7-127.46 (C-5, C-
10, C-1, OCH2Ph), 117 (CN), 114.66 (C-4), 113.65 (C-2), 88.85 (C-17), 71.70 
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(OCH2Ph), 70.22 (OCH2Ph), 63.02 (C-7), 48.21 (C-13), 43.86 (C-14), 42.43 (C-8), 
39.15 (C-9), 36.18 (C-6), 29.88 (C-16, C-12), 27.69 (C-11), 24.72 (C-15), 19.56 (C-
2´), 13.04 (C-18). MS m/z (relative intensity): 521 M+ (50), 468 (28), 450 (75), 359 
(57). 
 
6.10.5 Reduction of 179 with Raney Ni/NaOH 
 
87 mg (0.17 mmol) of 179 was dissolved in THF/ethanol (3:1). 9 g of Raney Ni and 8 
ml of 6% NaOH was added to it. The mixture was refluxed for 3 days. After cooling 
down to rt acetone was added and the reaction mixture was filtered through Celite. 
Solvent was removed under reduced pressure. The residue was partitioned between 
DCM and water. The organic layer was separated and aqueous layer extracted thrice 
with DCM. Combined organic layers were washed with brine, dried over K2CO3. 
Purification of the crude product on silica gel column with n-hex/EtOAc (1:1) gave 
180 and 181. 
180 (9 mg, 12% yield) 1H NMR (CDCl3) δ: 7.33 (m, 5H, OCH2Ph),  6.93 (d, 1H, H-1, 
J = 8.1 Hz ), 6.60 (d, 1H, H-2, J = 7.9 Hz), 6.52 (s, 1H, H-3), 5.35 (bs, <1H, NH2), 
4.54 (s, 2H, OCH2Ph), 4.01 (m, 1H, H-7), 3.79 (m, 3H, H-1´, H-3´), 3.54 (m, 1H, H-
1)´, 3.43 (t, 1H, H-17, J = 8.4 Hz), 3.11 (dd, 1H, H-6, J = 16.05 Hz, 4.8 Hz), 2.62 (m, 
2H, H-6, H-9), 2.4 (m, 1H), 2.24(m, 1H), 1.02 (s, 3H, H-18). 13C NMR (CDCl3) δ: 
154.07 (C-3), 139.47, 135.47, 133.71, 129.59, 128.47, 127.51 (C-5, C-10, C-1, 
OCH2Ph), 115.27 (C-4), 113.86 (C-2), 88.9 (C-17), 71.79 (OCH2Ph), 67.60 (C-7), 
62.55 (C-1´), 48.18 (C-13), 43.80 (C-14), 42.72 (C-8), 42.37 (C-3´), 39.23 (C-9), 
36.03 (C-6), 32.62 (C-2´), 29.89 (C-16, C-12), 27.87 (C-11), 24.74 (C-15), 12.99 (C-
18). 
181 (20 mg, 32% yield) 1H NMR (CDCl3) δ: 7.33 (m, 5H, OCH2Ph), 6.93 (d, 1H, H-
1, J = 8.1 Hz), 6.62 (d, 1H, H-2, J = 7.9 Hz), 6.50 (s, 1H, H-3), 5.35 (bs, 1H), 4.55 (s, 
2H, OCH2Ph), 4.44 (m, 1H, H-7), 3.41 (t, 1H, H-17, J = 8.25 Hz), 3.01 (dd, 1H, H-6, 
J = 15.7 Hz, 4.65 Hz), 2.66 (m, 2H, H-6, H-9), 2.27 (m, 1H), 1.08 (s, 3H). 13C NMR 
(CDCl3) δ:154 (C-3), 139.39, 138.58, 133.55, 129.65, 128.49, 127.55 (C-5, C-10, C-
1, OCH2Ph), 115.14 (C-4), 113.88 (C-2), 88.88 (C-17), 71.82 (OCH2Ph), 69.21 (C-7), 
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48.31 (C-13), 44.64 (C-14), 44.03 (C-8), 42.48 (C-9), 41.13 (C-6), 39.24 (C-16), 
30.04 (C-12), 27.83 (C-11), 25.07 (C-15), 13.02 (C-18). 
 
6.10.6 Synthesis of 7-O-(3-aminopropyl)-8α-estra-1,3,5(10),-triene-3,17β-diol 
(182) (Reduction of 180 with Pd(OH)2-C under H2) 
 
Pd(OH)2/C was added to a solution of 180 (10 mg, 0.02 mmol) in MeOH (3 ml) and 
deionised water (0.5 ml). The mixture was stirred under an atmosphere of hydrogen 
(58 psi) for 24 h at rt. The catalyst was removed by filtration and filtrate was extracted 
with DCM. Combined organic phases were washed with NaHCO3 solution and dried 
over MgSO4. After removal of solvent crude product was purified on silica gel 
column with EtOAc/n-hexane (10:1), to produce 2.8 mg of 182 (35% yield.) as oil. 1H 
NMR (CDCl3) δ: 6.95 (d, 1H, H-1, J = 8.5 Hz), 6.62 (d, 1H, H-2, J = 8.5 Hz), 6.53 (s, 
1H, H-4), 4.8 (bs, 1H), 3.99 (m, 1H, H-7), 3.82 (m, 1H, H-1), 3.77 (m, 2H, H-3´), 
3.64 (t, 1H, H-17, J = 8.7 Hz), 3.54 (m, 1H, H-1´), 3.17 (dd, 1H, H-6, J = 15.75 Hz, 
5.25 Hz ), 2.69 (m, 1H), 2.6 (dd, 1H, H-6, J = 19 Hz, 7.5 Hz), 0.93 (s, 3H, H-18). 13C 
NMR (CDCl3) δ: 154 (C-3), 135.52 (C-5), 133.75 (C-10), 129.68 (C-1), 115.29 (C-4), 
113.88 (C-2), 82.55 (C-17), 67.49 (C-7), 62.47 (C-1´), 48.07 (C-13), 43.83 (C-14), 
42.68 (C-8), 42.12 (C-3´), 38.01 (C-9), 36.09 (C-6), 31.15 (C-2´), 30.48 (C-16), 29.93 
(C-12, C-11), 24.66 (C-15), 12.18 (C-18). 
 
6.11 Selective debenzylation with Raney Ni/ aq. NaOH 
6.11.2 General procedure for selective debenzylation 
 
10 mg of O-benzyl compound was dissolved in 4 ml of 1:1 EtOH/THF. 0.02 ml of aq. 
NaOH (8%) was added followed by slurry of 200 mg of Raney Nickel. The mixture 
was refluxed and monitored by TLC until all the starting materials is consmed. After 
cooling at rt the catalyst was removed by filtration through celite. Filtrate was dried 
over Na2SO4 and after removal of solvent the crude product was purified by flash 
chromatography. 
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6.11.4. 17O-benzyl-estra-1,3,5(10)-triene-3,7α-diol (184) 
 
1H NMR (CDCl3) δ: 7.34- 7.29 (m, 5H), 7.14 (d, 1H, J = 8.4 Hz), 6.60 (d, 1H, J = 8.7 
Hz), 6.54 (s, 1H), 4.57 (s, 2H), 3.49 (t, 1H, J = 7.5 Hz), 2.79 (m, 2H), 2.25 (m, 2H), 
2.19-2.06 (m, 3H), 1.84 (m, 1H), 0.86 (s, 3H). 13C NMR (CDCl3) δ: 153.47, 138.50, 
133.02, 128.47, 127.53, 126.73, 115.44, 112.84, 88.55, 71.88, 50.44, 44.15, 43.61, 
38.81, 38.16, 29.81, 28.21, 27.36, 26.65, 23.33, 12.04. 
 
6.11.5. 3-(4O-benzyl-phenyl)-1O-benzyl-propanol (185) 
 
1H NMR (CDCl3) δ: 7.43-7.26 (m, 10H), 6.98 (d, 2H, J = 8.1 Hz), 6.79 (m, 2H, J = 
8.4 Hz), 4.87 (s, 2H), 4.37 (s, 2H), 3.36 (t, 2H, J = 6.15 Hz), 2.56 (t, 2H, J = 7.65 Hz), 
1.80 (m, 2H). 13C NMR (CDCl3) δ: 157.08, 138.74, 137.34, 134.35, 129.44- 127.48, 
114.78, 72.9, 70.01, 69.48, 31.62, 31.51. 
 
6.11.6. 3-(4-hydroxyphenyl)-1O-benzyl-propanol (186) 
 
1H NMR (CDCl3) δ: 7.35- 7.15 (m, 5H), 7 (d, 1H, J = 8.4 Hz), 6.92 (d, 1H, J = 8.1 Hz 
), 6.79 (d, 1H, J = 8.4 Hz), 6.62 (d, 1H, J = 8.1 Hz), 4.94 (s, 1H), 4.41 (s, 2H), 3.38 (t, 
2H, J = 5.7 Hz), 2.56 (q, 2H), 1.81 (t, 2H, J = 6 Hz). 13C NMR (CDCl3) δ: 153.82, 
138.79, 134.38, 129.76, 128.6, 127.91, 127.77, 115.35, 73.14, 69.69, 31.78, 31.65. 
 
6.11.7 Synthesis of 6-(3-hydroxybutyl)naphthalen-2-ol (188) 
 
To a solution of 1.00 g (4.38 mmol) of 187 in THF (6 ml) was added 17 ml (17 
mmol) of L-selectride (1M solution in THF) and the resulting mixture was refluxed 
for two days. After cooling down to rt saturated NH4Cl solution was added and the 
mixture was extracted with EtOAc. The organic layer was washed successively with 
10% H2O2-solution, sodium thiosulfate solution and brine. After drying over Na2SO4. 
Solvent was evaporated and the crude was purified on silica gel column with 
dichloromethane/n-hexane to yield 83% of 188. 1H and 13C NMR data of 188 was 
consistent with that of reported.161 
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6.11.8 2O-benzyl-6-(3O-(benzyl)butyl)naphthalene (189) 
 
1H NMR (CDCl3) δ: 7.65 (t, 2H, J = 8.55 Hz), 7.49 (d, 3H, J = 9.6 Hz), 7.42- 7.29 (m, 
8H), 7.20 (m, 3H), 5.17 (s, 2H, CH2Ph), 4.52 (ABq, 2H, CH2Ph, J = -11.85 Hz, Δν = 
42 Hz), 3.56 (m, 1H, H-3´), 2.85 (m, 2H, H-1´), 1.99 (m, 1H, H-2´), 1.84 (m, 1H, H-
2´), 1.25 (d, 3H, H-4´, J = 6.3 Hz). 13C NMR (CDCl3) δ: 156.48 (C-2), 137.86, 
137.21, 133.06, 129.44- 126.97 (Ar-C), 126.42 (C-8), 119.17 (C-3), 107.31 (C-1), 
74.28 (CH2Ph), 72.30 (CH2Ph ), 70.55 (C-3´), 38.61 (C-2´), 31.93 (C-1´), 19.85 (C-
4´). 
6.11.9 6-(3O-(benzyl)butyl)naphthalen-2-ol (190) 
 
1H NMR (CDCl3) δ: 7.64 (d, 1H, J = 8.4 Hz), 7.57 (d, 1H, J = 8.7 Hz), 7.49 (s, 1H), 
7.38- 7.34 (m, 3H), 7.33- 7.25 (m, 3H), 7.06 (m, 2H), 4.53 (ABq, 2H, CH2Ph, J = -
11.55 Hz, Δν= 42.09 Hz), 3.57 (m, 1H, H-3´), 2.83 (m, 2H, H-1´), 1.98 (m, 1H, H-2´), 
1.83 (m, 1H, H-2´), 1.25 (d, 3H, H-4´, J = 6.3 Hz). 13C NMR (CDCl3) δ: 153.105 (C-
2), 139.15, 137.7, 133.19, 129.47- 127.71 (Ar-C), 126.49 (C-8), 117.93 (C-3), 109.54 
(C-1), 74.4 (CH2Ph), 70.61 (C-3´), 38.6 (C-2´), 31.97 (C-1´), 19.85 (C-4´). 
 
6.11.10 6-(3O-(benzyl)butyl)-1,2,3,4-tetrahydronaphthalen-2-ol (191) 
 
1H NMR (CDCl3) δ: 7.35 (m, 3H), 6.94 (m, 5H), 4.52 (ABq, 2H, CH2Ph, J = -11.55 
Hz, Δν = 39.6 Hz), 3.52 (m, 1H, H-2´), 3.06 (dd, 1H, J = 16.05 Hz, 4.65 Hz), 3.94- 
2.17 (m, 6H), 2.01 (m, 1H, H-2´), 1.85 (m, 3H), 1.23 (d, 3H, H-4´, J = 6 Hz). 13C 
NMR (CDCl3) δ: 140.35, 135.71, 131.69, 129.69- 127.65 (Ar-C), 126.33 (C-8), 74.41 
(CH2Ph), 70.55 (C-3´), 67.66 (C-2), 38.77 (C-1), 38.34 (C-2´), 31.80 (C-1´), 31.58 
(C-3), 27.20 (C-4), 19.83 (C-4´). 
 
6.11.11 6-butylnaphthalene-2-ol (192) 
 
1H NMR(CDCl3) δ: 7.68 (d, 2H, J = 8.7 Hz), 7.60 (d, 2H, J = 8.7 Hz), 7.54 (s, 1H), 
7.29 (m, 1H),7.11 (d, 1H, J = 2.4 Hz), 7.06 (dd, 1H, J = 2.55 Hz, 8.85 Hz),  2.73 (t, 
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2H, H-1´, J = 7.65 Hz), 1.67 (m, 2H, H-2´), 1.39 (m, 2H, H-3´), 0.94 (t, 3H, H-4´, J = 
7.35 Hz). 13C NMR (CDCl3) δ: 152.95 (C-2), 138.34, 129.48, 128.37, 126.41, 117.81 
(C-3), 109.54 (C-1), 35.80 (C-1´), 33.79 (C-2´), 22.58 (C-3´). 
 
6.11.12 1O-benzyl-3-(4-chlorophenyl)propan-1-ol (195) 
 
1H NMR (CDCl3) δ: 7.33 (m, 5H, Ar-H), 7.22 (d, 2H, J = 8.4 Hz, Ar-H), 7.08 (d, 2H, 
J = 7.8 Hz, Ar-H), 4.49 (s, 2H, CH2Ph), 3.46 (t, 2H, J = 6.6 Hz, H-1), 2.68 (t, 2H, J = 
7.5 Hz, H-3), 1.9 (m, 2H, m, H-2). 
 
6.12 Synthesis of steroid fatty acid ester 
 
6.12.1 General procedure for the synthesis of 17β-monoesters of estradiol 
 
20 mg (0.07 mmol) of estradiol, 1 mg (0.008 mmol) of 4-(N,N-
dimethylamino)pyridine (DMAP) and about 70 mg of [Bmim]Cl were taken in a 
microwave vial and 0.1 ml of pyridine was added to it. Then 2.4 molar equivalent of 
the fatty acid chloride was added to the vial. The mixture was microwave irradiated at 
40 oC with 20 W power for 1 min. After that 71 mg (1.4 mmol) of KOH and 1 ml of 
toluene was added to the vial. The mixture was again microwave irradiated at 80 oC 
for 1 min and then poured into ice-cold water, neutralized with 1 N HCl and extracted 
three times with 7 ml of EtOAc. Combined organic phase was washed successively 
with NaHCO3 solution and brine, and dried over Na2SO4. The crude product was 
purified on a silica gel column with n-hexane/EtOAc eluent. For yields see Table 6.  
Analytical data of estradiol 17β-monooleate (196), Estradiol 17β-monolinoleate (197) 
and estradiol 17β-monostearate (198) are consistent with literature values.117 
Analytical data for estradiol 17β-monopalmitate (199) 
1H NMR (CDCl3) δ: 7.13 (d, 1H, H-1, J = 8.1 Hz), 6.61 (dd, 1H, H-2, J = 8.1 Hz, 2.5 
Hz), 6.56 (d, 1H, H-4, J = 2.4 Hz), 4.69 (t, 1H, H-17, J = 8.4 Hz), 2.30 (t, 2H, H-2´, J 
= 7.5 Hz), 0.88 (t, 3H, H-18´, J = 6.3 Hz), 0.82 (s, 3H, H-18). 13C NMR (CDCl3) δ: 
126.65 (C-1), 112.98 (C-2), 153.86 (C-3), 115.51 (C-4), 132.5 (C-5), 27.80 (C-7), 
 110 
38.79 (C-8), 43.99 (C-9), 138.26 (C-10), 26.43 (C-11), 37.13 (C-12), 43.18 (C-13), 
49.98 (C-14), 23.49 (C-15), 27.41 (C-16), 82.17 (C-17), 12.31 (C-18), 174.54 (C-1´), 
34.85 (C-2´), 25.34 (C-3´), 29.35- 29.89 (C-4´- C-13´), 32.13 (C-14´), 22.89 (C-15´), 
14.31 (C-16´). MS m/z (relative intensity) 510 M+ (12), 282 (50), 259 (25).  
 
6.12.2 General procedure for esterification 
 
0.07 mmol of steroid, 1 mg (0.008 mmol) of DMAP and about 70 mg of [Bmim]Cl 
were taken in a microwave vial and 0.1 ml of pyridine was added. Then 0.105 mmol 
(1.2 molar equivalent per OH or 2.4 fold excess for diesters) of the fatty acid chloride 
was added to the vial. The mixture was microwave irradiated at 40 oC with 20 W 
power for 1 min. After the reaction, the mixture was poured into ice-cold water and 
neutralized with 1 N HCl. The aqueous phase was extracted with EtOAc (3 x 7 ml). 
Combined organic phase was washed successively with NaHCO3 solution and brine 
and dried over Na2SO4. The crude product was purified on silica gel column with n-
hexane/EtOAc eluent. For yields see Table 7. 
 
6.12.3 Estradiol dioleate (200) 
 
Colorless liquid. 1H NMR (CDCl3) δ: 7.27 (d, 1H, H-1, J = 8.2 Hz), 6.83 (dd, 1H, H-
2, J = 8.2 Hz, 2.5 Hz), 6.77 (d, 1H, H-4, J = 2.5 Hz), 5.35 (m, 4H, H- 9´ and H-10´), 
4.7 (dd, 1H, H-17, J = 8.85 Hz, 7.65 Hz), 2.02 (m, 8H, H-8´, H-11´), 0.88 (t, 6H, H-
18´, J = 6.9 Hz), 0.82 (s, 3H, H-18). 13C NMR (CDCl3) δ: 126.55 (C-1), 118.79 (C-2), 
148.72 (C-3), 121.7 (C-4), 138.31 (C-5), 29.97 (C-6), 27.81 (C-7), 38.44 (C-8), 44.2 
(C-9), 137.93 (C-10), 26.26 (C-11), 37.12 (C-12), 43.13 (C-13), 50.07 (C-14), 23.49 
(C-15), 27.25 (C-16), 82.57 (C-17), 12.29 (C-18), 174.10, 172.78 (C-1´), 34.81, 34.63 
(C-2´), 25.33, 25.20 (C-3´), 29.33- 29.9 (C-4´- C-7´ and C-12´-C-15), 130.23, 129.95 
(C-9´, C-10´), 22.88 (C-17´), 14.31 (C-18´). MS m/z (relative intensity) 800 M+(3), 
536 (44), 272 (22), 255 (50), 159 (16), 133 (8).  
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6.12.4 Estradiol dilinoleate (201) 
 
Colorless liquid. 1H NMR (CDCl3) δ: 7.27 (d, peak overlapped with CHCl3 peak, 1H, 
H-1), 6.83 (dd, 1H, H-2, J = 8.4 Hz, 2.4 Hz), 6.77 (d, 1H, H-4, J = 2.4 Hz), 5.35 (m, 
8H, H- 9´ H-10´, H-12´, and H-13´), 4.7 (t, 1H, H-17, J = 8.4 Hz), 2.77 (t, 4H, H-11´, 
J = 5.55 Hz), 2.04 (m, 8H, H-8´, H-14´), 0.89 (t, 6H, H-18´), 0.82 (s, 3H, H-18). 13C 
NMR (CDCl3) δ: 126.56 (C-1), 118.79 (C-2), 148.73 (C-3), 121.7 (C-4), 138.31 (C-
5), 27.82 (C-7), 38.45 (C-8), 44.2 (C-9), 137.94 (C-10), 26.26 (C-11), 37.12 (C-12), 
43.14 (C-13), 50.06 (C-14), 23.49 (C-15), 27.25 (C-16), 82.59 (C-17), 12.3 (C-18), 
174.10, 172.77 (C-1´), 34.81, 34.63 (C-2´), 25.32, 25.20 (C-3´), 29.34- 29.8 (C-6, C-
4´- C-7´ and C-12´-C-15´), 130.43, 130.25 (C-9´, C-13´), 128.23, 128.12 (C-10´, C-
12´), 22.78 (C-17´), 14.28 (C-18´). MS m/z (relative intensity) 796 M+(8), 534 (40), 
272 (48), 255 (100), 159 (37), 133 (17).  
 
6.12.5 Estradiol distearate (202) 
 
1H NMR (CDCl3) δ: 7.27 (d, peak overlapped with CHCl3 peak, 1H, H-1), 6.82 (dd, 
1H, H-2, J = 8.4 Hz, 2.4 Hz), 6.77 (d, 1H, H-4, J = 2.1 Hz), 4.7 (t, 1H, H-17, J = 8.1 
Hz), 2.85 (m, 2H, H-6), 2.52 (t, 2H, J = 7.5 Hz), 2.30 (t, 4H, H-2´, J = 9.3 Hz), 0.88 (t, 
6H, H-18´, J = 6.6 Hz), 0.82 (s, 3H, H-18). 13C NMR (CDCl3) δ: 126.56 (C-1), 118.79 
(C-2), 148.73 (C-3), 121.7 (C-4), 138.32 (C-5), 27.82 (C-7), 38.45 (C-8), 44.21 (C-9), 
137.94 (C-10), 26.27 (C-11), 37.13 (C-12), 43.14 (C-13), 50.07 (C-14), 23.49 (C-15), 
27.25 (C-16), 82.58 (C-17), 12.3 (C-18), 174.17, 172.82 (C-1´), 34.84, 34.65 (C-2´) 
32.13- 29.37 (C-4´- C-16´), 22.9 (C-17´), 14.32 (C-18´). MS m/z (relative intensity) 
804 M+ (very small), 538 (100), 255 (14), 159 (9).  
 
6.12.6 Estradiol dipalmitate (203) 
 
1H NMR (CDCl3) δ: 7.27 (d, peak overlapped with CHCl3 peak, 1H, H-1), 6.83 (dd, 
1H, H-2, J = 8.7 Hz, 2.2 Hz), 6.78 (d, 1H, H-4, J = 2.1 Hz), 4.7 (t, 1H, H-17, J = 8.25 
Hz), 2.52 (t, 2H, J = 7.5 Hz), 2.30 (t, 4H, H-2´, J = 9 Hz), 0.88 (t, 6H, H-18´, J = 6.6 
Hz), 0.82 (s, 3H, H-18). 13C NMR (CDCl3) δ: 126.56 (C-1), 118.81 (C-2), 148.74 (C-
3), 121.7 (C-4), 138.32 (C-5), 27.82 (C-7), 38.45 (C-8), 44.21 (C-9), 137.94 (C-10), 
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26.27 (C-11), 37.13 (C-12), 43.15 (C-13), 50.07 (C-14), 23.50 (C-15), 27.26 (C-16), 
82.58 (C-17), 12.3 (C-18), 174.16, 172.82 (C-1´), 34.84, 34.66 (C-2´), 32.14- 29.36, 
25.36, 25.22, 22.9 (C-4´- C-15´), 14.32 (C-16´). MS m/z (relative intensity) 748 M+ 
(very small), 510 (100), 255 (10), 159 (6).  
 
6.12.7 5-Androsten-3β-ol-17-one oleate (204) 
 
NMR data are identical with that of literature.116 MS m/z (relative intensity) 552 
M+(very small), 270 (31), 255 (14), 145 (8), 121 (23), 107 (11).  
 
6.12.8 4-Androsten-17β-ol–3-one linoleate (205) 
 
NMR data are identical with that of literature.116  MS m/z (relative intensity) 550 M+ 
(9), 270 (93), 255 (47), 145 (30), 121 (63).  
 
6.12.9 5α-Androstane-3β ,17β-diol dioleate (207) 
 
Colorless liquid, 1H NMR (CDCl3) δ: 5.34 (m, 4H, H-9´and 10´), 4.69 (m, 1H, H-3), 
4.59 (t, 1H, H-17, J = 8.4 Hz), 2.25 (q, 4H, H-2´, J = 16.2 Hz, 7.8 Hz), 2.01 (m, 8H, 
H-8´, H-11´), 0.83 (s, 3H, H-19), 0.77 (s, 3H, H-18), 0.88 (t, 6H, H-18´, J = 6.45 Hz). 
13C NMR (CDCl3) δ: 37.62 (C-1), 25.92 (C-2), 73.75 (C-3), 2.73 (C-4), 43.56 (C-5), 
28.38 (C-6), 32.38 (C-7), 37.93 (C-8), 55.19 (C-9), 36.41 (C-10), 21.55 (C-11), 36.22 
(C-12), 45.56 (C-13), 51.62 (C-14), 24.22 (C-15), 30.57 (C-16), 83.02 (C-17), 12.64 
(C-18), 173.62, 173.20 (C-1´), 35.05 (C-2´), 25.83 (C-3´), 28.38-30.57 (C-4´, C-5´, C-
6´, C-7´, C-12´, C-13´, C-14´, C-15´), 130.69, 130.61 (C-9´and C-10´), 27.88 (C-
8´and C-11´), 30.68 (C-16´), 23.42 (C-17´), 14.46 (C-18´and C-19). MS m/z (relative 
intensity) 820 M+ (very small), 539 (16), 265 (21), 257 (46), 163 (14), 95 (18).  
 
 113 
6.12.10 5α-Androstane-3β ,17β-diol dilinoleate (208) 
 
Colorless liquid, 1H NMR (CDCl3) δ: 5.35 (m, 8H, H-9´, 10´, 12´, 13´), 4.54 (m, 1H, 
H-3), 4.52 (q, 1H, H-17, J = 9 Hz, 7.8 Hz), 2.77 (t, 4H, H-11´, J = 5.85 Hz), 2.26 (m, 
4H, H-2´), 2.04 (m, 8H, H-8´, H-11´), 0.77 (s, 3H, H-18), 0.83 (s, 3H, H-19), 0.89 (t, 
6H, H-18´, J = 6.9 Hz). 13C NMR (CDCl3) δ: 37.14 (C-1), 27.41 (C-2), 73.54 (C-3), 
34.81 (C-4), 42.9 (C-5), 34.26 (C-7), 35.77 (C-8), 54.39 (C-9), 35.49 (C-10), 20.88 
(C-11), 37.14 (C-12), 44.86 (C-13), 50.91 (C-14), 23.76 (C-15), 31.73 (C-16), 82.77 
(C-17), 12.43 (C-18), 174.11, 173.62 (C-1´), 34.96 (C-2´), 25.31 (C-3´), 27.79-29.55 
(C-6, C-4´, C-5´, C-6´, C-7´, C-15´), 130.43, 130.27 (C-9´and C-10´), 128.25, 128.13, 
(C-12´and C-13´), 27.7 (C-8´and C-14´), 25.84 (C-11´), 29.80 (C-16´), 22.78 (C-17´), 
14.27 (C-18´and C-19). MS m/z (relative intensity) 816 M+ (1), 537 (1.5), 257 (11.5).  
 
6.12.11 4-Androsten-17β-ol–3-one oleate (210) 
 
Colorless liquid, 1H NMR (CDCl3) δ: 5.73 (s, 1H, H-4), 5.34 (m, 2H, H-9´and H-10´), 
4.61(q, 1H, H-17, J = 9.15 Hz, 7.65 Hz), 2.29 (t, 2H, H-2´, J = 7.55 Hz), 2.00 (m, 4H, 
H-8´and H-11´), 1.19 (s, 3H, H-19), 0.88 (t, 3H, H-18´, J = 6.75 Hz), 0.84 (s, 3H, H-
18). 13C NMR (CDCl3) δ: 35.63 (C-1), 34.76 (C-2), 199.58 (C-3), 124.16 (C-4), 
171.08 (C-5), 32.94 (C-6), 32.10 (C-7), 35.63 (C-8), 53.93 (C-9), 38.81 (C-10), 20.75 
(C-11), 36.86 (C-12), 42.72 (C-13), 50.47 (C-14), 23.69 (C-15), 27.71 (C-16), 82.36 
(C-17), 12.26 (C-18), 17.6 (C-19), 174.03 (C-1´), 34.12 (C-2´), 25.3 (C-3´), 29.30-
29.96 (C-4´, C-5´, C-6´, C-7´, C-12´, C-13´, C-14´, C-15´), 130.20, 129.94 (C-9´and 
C-10´), 27.37, 27.42 (C-8´and C-11´), 31.70 (C-16´), 22.87 (C-17´), 14.31 (C-18´). 
MS m/z (relative intensity) 552 M+ (14), 271 (38), 147 (6).  
 
6.12.12 4-Androsten-17β-ol–3-one linoleate (211) 
 
Colorless liquid, 1H NMR (CDCl3) δ: 5.73 (s, 1H, H-4), 0.84 (s, 3H, H-18), 1.19 (s, 
3H, H-19), 5.35 (m, 4H, H-9´, H-10´, H-12´and H-13´), 4.6 (q, 1H, H-17, J = 9.3 Hz, 
7.5 Hz), 2.77 (t, 2H, H-11´, J = 5.55 Hz), 2.29 (t, 2H, H-2´, J = 7.5 Hz), 2.03 (m, 4H, 
H-8´and H-14´), 0.89 (t, 3H, H-18´, J = 6.9 Hz). 13C NMR (CDCl3) δ: 35.61 (C-1), 
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34.74 (C-2), 199.65 (C-3), 124.15 (C-4), 171.15 (C-5), 32.93 (C-6), 31.7 (C-7), 35.9 
(C-8), 53.91 (C-9), 38.8 (C-10), 20.73 (C-11), 36.84 (C-12), 42.7 (C-13), 50.45 (C-
14), 23.68 (C-15), 27.71 (C-16), 82.36 (C-17), 12.25 (C-18), 17.59 (C-19), 174.03 (C-
1´), 34.1 (C-2´), 25.28 (C-3´), 130.42, 130.22 (C-9´and C-13´), 128.25, 128.1 (C-
10´and C-12´) 25.82 (C-11´), 14.25 (C-18´). MS m/z (relative intensity) 550 M+ (20), 
271 (37), 253 (8.5), 147 (8).  
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